

Curriculum Vitae
Almut G. Winterstein, RPh, PhD, FISPE

University of Florida, College of Pharmacy
PO Box 100496
Gainesville, FL 32610-0496

Phone: +1 (352) 273-6268

Fax: +1 (352) 273-6270

email: almut@ufl.edu

Present Position: Distinguished Professor, Department of Pharmaceutical Outcomes and Policy
Dr. Robert and Barbara Crisafi Chair for Medication Safety
College of Pharmacy
Director, Center for Drug Evaluation and Safety (CoDES)
University of Florida

Short bio

Almut Winterstein is Distinguished Professor and the Dr. Robert and Barbara Crisafi Chair for Medication Safety in the Department of Pharmaceutical Outcomes and Policy, Affiliate Distinguished Professor in Epidemiology, and the founding Director of the Center for Drug Evaluation and Safety at the University of Florida. Since 2019, she also serves as director of the Consortium for Medical Marijuana Clinical Outcomes Research, a state-funded consortium of 9 universities in Florida. Dr. Winterstein's research interests center on the post-marketing evaluation of medications in pediatrics and pregnancy, infectious disease and psychiatry and the evaluation of policy surrounding medication use using real-world data. As expert in drug safety, she has chaired the Food and Drug Administration's Drug Safety and Risk Management Advisory Committee from 2012-2018. Recognizing her contributions in pharmacoepidemiology, Dr. Winterstein was inducted as a fellow of the International Society of Pharmacoepidemiology in 2013 and served as president of the society from 2019-2020. In 2022, she was inducted in the Academy of Science, Engineering and Medicine in Florida. She received her pharmacy degree from Friedrich Wilhelm University in Bonn, Germany and her PhD in Pharmacoepidemiology from Humboldt University in Berlin. Dr. Winterstein has chaired more than two dozen PhD committees and received the UF-wide Dissertation Advisor/Mentoring award for her excellence in graduate training.

Almut Winterstein ist Distinguished Professor in dem Institut für Pharmazeutische Ergebnisforschung und Politik (Pharmaceutical Outcomes and Policy), außerordentlicher Professor in Epidemiologie, und Gründungsdirektor des Centers for Drug Evaluation and Safety (CoDES). In 2017 erhielt sie die Dr. Robert and Barbara Crisafi Stiftungsprofessur in Arzneimittelsicherheit angesichts ihrer Forschung in Sicherheitsbedenken und dem sicheren Gebrauch von Arzneimitteln. Sie hat Pharmazie an der Friedrich-Wilhelm-Universität in Bonn studiert und im Themenschwerpunkt der Pharmakoepidemiologie an der Humboldt Universität in Berlin promoviert. Dr. Wintersteins Forschungsinteressen liegen in der Bewertung von Arzneimittelsicherheit und -Effektivität nach der Zulassung, mit besonderem Fokus auf Arzneimittel in der Pädiatrie, Schwangerschaft,

Infektionserkrankungen, Psychiatrie, und den jeweiligen gesetzlichen Regelungen des Arzneimittelgebrauchs in „Real-world“ Populationen.

Von 2012-2018 was sie als Expertin in Arzneimittelsicherheit die Vorsitzende des Drug Safety and Risk Management Advisory Committees der amerikanischen Food and Drug Administration. Sie ist Fellow der International Society of Pharmacoepidemiology und war Präsidentin der Gesellschaft von 2019-2020. Seit 2019 ist sie ebenfalls Direktorin des Consortium for Medical Marijuana Clinical Outcomes Research, eine staatlich-geförderte Forschungsgemeinschaft von neun Universitäten in Florida. Seit 2022 ist sie ein Mitglied der Academy of Science, Engineering and Medicine in Florida. Dr. Winterstein hat mehr als zwei Dutzend Promotionen begleitet und wurde mit dem Dissertation Advisor/Mentoring Award ausgezeichnet.

EDUCATION

Dr.rer.nat (Doctor of Philosophy) Magna cum laude	Pharmacoepidemiology / Social Pharmacy, Humboldt University, Charité, Berlin, Germany	1995-1999
Staatsexamen (pharmacy degree)	College of Pharmacy, Friedrich Wilhelm University, Bonn, Germany	1986-1990
Internship	Praktikum in Pharmacy, Römer Apotheke, Bad Münstereifel and Goldkopf Apotheke, Cologne, Germany	1990-1991
	License as Pharmacist	1991

POST-DOCTORAL TRAINING

Research fellow in the DuBow Family Center for Research in Pharmaceutical Care, University of Florida, Gainesville, USA	1999-2000
--	-----------

PROFESSIONAL POSITIONS

Distinguished Professor, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida	2021 – present
Director, Consortium for Medical Marijuana Clinical Outcomes Research	2019 - present
Director, Center for Drug Evaluation and Safety (CoDES)	2019 - present
Chair, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida	2016 – 2022
Professor, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida	2012 – 2021

Graduate Program Director, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida	2011 – 2015
Special Government Employee, FDA/CDER Drug Safety and Risk Management Advisory Board	2009 – present
Director, FDA/CDER & UF Graduate training program in Pharmaceutical Outcomes and Policy Research, University of Florida	2009 – 2012
Associate Professor with tenure, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida	2008 – 2012
Assistant Professor, Department of Pharmaceutical Outcomes and Policy (POP), College of Pharmacy, University of Florida	2003 – 2008
Clinical Assistant Professor, Department of Pharmacy Health Care Administration, College of Pharmacy, University of Florida	2000 – 2003
Scientist at the DuBow Family Center for Research in Pharmaceutical Care, University of Florida, Gainesville, Florida	1999 - 2000
Independent contract work for Glaxo Wellcome, Hamburg, Germany; Merck KgAA, Darmstadt, Germany; German Pharmaceutical Association	1996 – 1999
Development work in Mutumba hospital, Burundi	May 1991
Practicing pharmacist in Römer Apotheke, Bad Münstereifel, Germany	1991 – 1997

ACADEMIC APPOINTMENTS

Graduate Faculty, PhD program in Epidemiology, College of Public Health and Health Professions and College of Medicine, UF	2009 – present
Affiliate Associate Professor, Department of Epidemiology and Biostatistics, College of Public Health and Health Professions, UF	2010 – present
Affiliate Assistant Professor, Department of Epidemiology and Biostatistics, College of Public Health and Health Professions, University of Florida	2007 – 2010
Affiliate Assistant Professor, Department of Health Services and Research, Management and Policy, College of Public Health and Health Professions	2005 - 2006
Core faculty, Institute on Aging, University of Florida	2001 – 2004
Graduate faculty, Master of Public Health Program, College of Health Professions and Public Health and College of Medicine, University of Florida	2001 – 2006
Graduate faculty, Ph.D. Program in Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida	2000 – present

REPORT ON RESEARCH AND SCHOLARSHIP

Throughout my academic career I have participated in >50 extramurally funded projects. I have led the majority of these as PI, co-PI or PI of a subcontract, totaling more than \$20 million of support from AHRQ, CMS, FDA, NIH,

CDC, the state of Florida and professional associations/foundations. Key methodological emphasis areas have included (a) population-based pharmacoepidemiologic studies on drug effectiveness and safety, (b) contributions to pharmacoepidemiologic methods development especially in the area of measurement, (c) assessment of the quality of medication use and related policy and programs aimed at improving quality, and (d) development of clinical decision-support tools to improve medication use.

BIBLIOGRAPHY

H-Index 39, i10 Index 132, citations 11,094 (Google Scholar)

[My bibliography in NCBI](#)

[Bibliography in Google Scholar](#)

Original Articles

Senior or corresponding author; * trainee (including faculty career awardees)

1. Goodin AJ, Tran PT, McKee S, Sajdeya R, Jyot J, Cook RL, Wang Y, **Winterstein AG**. Proceedings of the 2023 Cannabis Clinical Outcomes Research Conference. *Med Cannabis Cannabinoids*. 2023 Sep 29;6(1):97-101. doi: [10.1159/000533943](#). PMID: [37900895](#); PMCID: PMC10601943.
2. Wang Y*, Smolinski NE, Thai TN, Sarayani A, Ewig C, Rasmussen SA, **Winterstein AG**. Common teratogenic medication exposures-a population-based study of pregnancies in the United States. *Am J Obstet Gynecol MFM*. 2023 Dec 6;6(1):101245. doi: [10.1016/j.ajogmf.2023.101245](#). Epub ahead of print. PMID: [38061552](#).
3. Wang Y*, Jiao T, Muschett MR, Brown JD, Guo SJ, Kulshreshtha A, Zhang Y, **Winterstein AG**, Shao H. Associations Between Postdischarge Care and Cognitive Impairment-Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia in Adults With Diabetes. *Diabetes Care*. 2023 Dec 4;dca230013. doi: [10.2337/dca23-0013](#). Epub ahead of print. PMID: [38048487](#).
4. **Winterstein AG**, Ehrenstein V, Brown JS, Stürmer T, Smith MY. A Road Map for Peer Review of Real-World Evidence Studies on Safety and Effectiveness of Treatments. *Diabetes Care*. 2023 Aug 1;46(8):1448-1454. doi: [10.2337/dc22-2037](#). PMID: [37471605](#); PMCID: PMC10369122.
5. Wei YJ, **Winterstein AG**, Schmidt S, Fillingim RB, Daniels MJ, Solberg L, DeKosky ST. Pain intensity, physical function, and depressive symptoms associated with discontinuing long-term opioid therapy in older adults with Alzheimer's disease and related dementias. *Alzheimers Dement*. 2023 Oct 19. doi: [10.1002/alz.13489](#). Epub ahead of print. PMID: [37855270](#).
6. Thai TN, **Winterstein AG**. Core concepts in pharmacoepidemiology: Measurement of medication exposure in routinely collected healthcare data for causal inference studies in pharmacoepidemiology. *Pharmacoepidemiol Drug Saf*. 2023 Sep 26. doi: [10.1002/pds.5683](#). Epub ahead of print. PMID: [37752827](#).
7. Sarayani A*, Brown JD, Hampf C, Donahoo WT, **Winterstein AG**. Adaptability of High Dimensional Propensity Score Procedure in the Transition from ICD-9 to ICD-10 in the US Healthcare System. *Clin Epidemiol*. 2023 May 29;15:645-660. doi: [10.2147/CLEP.S405165](#). PMID: [37274833](#); PMCID: PMC10237200.
8. Wang Y*, Cavallari LH, Brown JD, Thomas CD, **Winterstein AG**. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US. *JAMA Netw Open*. 2023 Apr 3;6(4):e238585. doi: [10.1001/jamanetworkopen.2023.8585](#). PMID: [37067798](#).
9. Nduaguba SO*, Smolinski NE, Thai TN, Bird ST, Rasmussen SA, **Winterstein AG**. Validation of an ICD-9-Based Algorithm to Identify Stillbirth Episodes from Medicaid Claims Data. *Drug Saf*. 2023 May;46(5):457-465. doi: [10.1007/s40264-023-01287-3](#). Epub 2023 Apr 12. PMID: [37043168](#).

10. Sajdeya R*, Mardini MT, Tighe PJ, Ison RL, Bai C, Jugl S, Hanzhi G, Zandbiglari K, Adiba FI, **Winterstein AG**, Pearson TA, Cook RL, Rouhizadeh M. Developing and validating a natural language processing algorithm to extract preoperative cannabis use status documentation from unstructured narrative clinical notes. *J Am Med Inform Assoc*. 2023 May 13;ocad080. doi: [10.1093/jamia/ocad080](https://doi.org/10.1093/jamia/ocad080). Epub ahead of print. PMID: [37178155](https://pubmed.ncbi.nlm.nih.gov/37178155/).
11. Sajdeya R*, Fechtel HJ, Spandau G, Goodin AJ, Brown JD, Jugl S, Smolinski NE, **Winterstein AG**, Cook RL, Wang Y. Protocol of a Combined Cohort and Cross-Sectional Study of Persons Receiving Medical Cannabis in Florida, USA: The Medical Marijuana and Me (M3) Study. *Med Cannabis Cannabinoids*. 2023 May 9;6(1):46-57. doi: [10.1159/000530052](https://doi.org/10.1159/000530052). PMID: [37261066](https://pubmed.ncbi.nlm.nih.gov/37261066/).
12. Sarayani A*, Donahoo WT, Hampp C, Brown JD, **Winterstein AG**. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy. *Ann Intern Med*. 2023 Apr;176(4):443-454. doi: [10.7326/M22-1743](https://doi.org/10.7326/M22-1743). PMID: [36940443](https://pubmed.ncbi.nlm.nih.gov/36940443/).
 - Altmetric score 269
13. Albogami Y*, Zhu Y, Wang X, **Winterstein AG**. Concordance of neonatal critical condition data between secondary databases: Florida and Texas birth certificate Linkage with medicaid analytic extract. *BMC Med Res Methodol*. 2023 Feb 20;23(1):47. doi: [10.1186/s12874-023-01860-5](https://doi.org/10.1186/s12874-023-01860-5). PMID: [36803103](https://pubmed.ncbi.nlm.nih.gov/36803103/).
14. Wang X*, Zimmermann EM, Goodin AJ, Brown J, **Winterstein AG**. Risk of preterm delivery and small for gestational age among women with inflammatory bowel disease using TNF-alpha inhibitors during pregnancy. *Am J Obstet Gynecol*. 2023 Apr;228(4):474-476. doi: [10.1016/j.ajog.2022.12.303](https://doi.org/10.1016/j.ajog.2022.12.303). Epub 2022 Dec 21. PMID: [36565900](https://pubmed.ncbi.nlm.nih.gov/36565900/).
15. Nduaguba SO*, Tran PT, Choi Y, **Winterstein AG**. Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019. *PLoS One*. 2023 Feb 16;18(2):e0281555. doi: [10.1371/journal.pone.0281555](https://doi.org/10.1371/journal.pone.0281555). PMID: [36795639](https://pubmed.ncbi.nlm.nih.gov/36795639/).
16. Sarayani A*, **Winterstein A**, Cristofolletti R, Vozmediano V, Schmidt S, Brown J. Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes. *Contraception*. 2023 Apr;120:109953. doi: [10.1016/j.contraception.2023.109953](https://doi.org/10.1016/j.contraception.2023.109953). Epub 2023 Jan 11. PMID: [36641095](https://pubmed.ncbi.nlm.nih.gov/36641095/).
17. Thai TN*, Rasmussen SA, Smolinski NE, Nduaguba S, Zhu Y, Bateman BT, Huybrechts KF, Hernandez-Diaz S, **Winterstein AG**. Impact of Maternal Continuous Enrollment on Stillbirth Gestational Age Distributions and Maternal Characteristics in Medicaid Enrollees. *Am J Epidemiol*. 2023 Feb 24;192(3):497-502. doi: [10.1093/aje/kwac206](https://doi.org/10.1093/aje/kwac206). Epub ahead of print. PMID: [36482740](https://pubmed.ncbi.nlm.nih.gov/36482740/).
18. Smith SM*, **Winterstein AG**, Gurka MJ, Walsh MG, Keshwani S, Libby AM, Hogan WR, Pepine CJ, Cooper-DeHoff RM. Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network. *J Am Heart Assoc*. 2023 Jan 3;12(1):e026652. doi: [10.1161/JAHA.122.026652](https://doi.org/10.1161/JAHA.122.026652). PMID: [36565195](https://pubmed.ncbi.nlm.nih.gov/36565195/).
19. Sarayani A*, Hampp C, Brown JD, Donahoo WT, **Winterstein AG**. Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. *Drug Saf*. 2022 Dec;45(12):1517-1527. doi: [10.1007/s40264-022-01244-6](https://doi.org/10.1007/s40264-022-01244-6). Epub 2022 Nov 1. PMID: [36318419](https://pubmed.ncbi.nlm.nih.gov/36318419/).
20. Zhu Y, Thai TN, Hernandez-Diaz S, Bateman BT, **Winterstein AG**, Straub L, Franklin JM, Gray KJ, Wyss R, Mogun H, Vine S, Taylor LG, Ouellet-Hellstrom R, Ma Y, Qiang Y, Hua W, Huybrechts KF. Development and Validation of Algorithms to Estimate Live Birth Gestational Age in Medicaid Analytic eXtract Data. *Epidemiology*. 2023 Jan 1;34(1):69-79. doi: [10.1097/EDE.0000000000001559](https://doi.org/10.1097/EDE.0000000000001559). PMID: [36455247](https://pubmed.ncbi.nlm.nih.gov/36455247/).
21. Smolinski NE*, Sajdeya R, Cook R, Wang Y, **Winterstein AG**, Goodin A. Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference. *Med Cannabis Cannabinoids*. 2022 Oct 17;5(1):138-141. doi: [10.1159/000527080](https://doi.org/10.1159/000527080). PMID: [36467782](https://pubmed.ncbi.nlm.nih.gov/36467782/).

22. Tran PT*, Antonelli PJ, **Winterstein AG**. Quinolone Ear Drops and Achilles Tendon Rupture. Clin Infect Dis. 2023 Feb 8;76(3):e1360-e1368. doi: 10.1093/cid/ciac709. Epub ahead of print. PMID: [36065683](#).
23. Wei YJ, Chen C, Cheng TD, Schmidt SO, Fillingim RB, **Winterstein AG**. Association of injury after prescription opioid initiation with risk for opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study. PLoS Med. 2022 Sep 22;19(9):e1004101. doi: [10.1371/journal.pmed.1004101](#). PMID: [36136971](#); PMCID: PMC9498946.
 - Altmetric score 14
24. **Winterstein AG**, Thai TN, Nduguba S, Smolinski NE, Wang X, Sahin L, Krefting I, Gelperin K, Bird ST, Rasmussen SA. Risk of fetal/neonatal death or neonatal intensive care unit admission associated with gadolinium magnetic resonance imaging exposure during pregnancy. Am J Obstet Gynecol. 2023 Apr;228(4):465.e1-465.e11. doi: [10.1016/j.ajog.2022.10.005](#). PMID: [36241080](#).
 - Altmetric score 29
25. Tran PT*, Nduguba SO, Diaby V, Choi Y, **Winterstein AG**. RSV testing practice and positivity by patient demographics in the United States: integrated analyses of MarketScan and NREVSS databases. BMC Infect Dis. 2022 Aug 8;22(1):681. doi: [10.1186/s12879-022-07659-x](#). PMID: [35941563](#).
26. Smolinski NE*, Antonelli PJ, **Winterstein AG**. Watchful Waiting for Acute Otitis Media. Pediatrics. 2022 Jul 1;150(1):e2021055613. doi: [10.1542/peds.2021-055613](#). PMID: [35726560](#).
27. Cicali B, Da Silva L, Sarayani A, Lingineni K, Pressly M, Kim S, Wendl T, Hoechel J, Vozmediano V, **Winterstein AG**, Brown JD, Schmidt S, Cristoforetti R. Development of a Translational Exposure-Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug Products. Clin Pharmacol Ther. 2022 Oct;112(4):909-916 doi: [10.1002/cpt.2690](#). PMID: [35723889](#).
 - Altmetric score 13
28. Chen C*, Tighe PJ, Lo-Ciganic WH, **Winterstein AG**, Wei YJ. Perioperative Use of Gabapentinoids and Risk for Postoperative Long-Term Opioid Use in Older Adults Undergoing Total Knee or Hip Arthroplasty. J Arthroplasty. 2022 Nov;37(11):2149-2157.e3. doi: [10.1016/j.arth.2022.05.018](#). PMID: [35577053](#)
29. Wei YJ*, Chen C, Lewis MO, Schmidt SO, Winterstein AG. Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study. PLoS Med. 2022 Mar 15;19(3):e1003947. doi: [10.1371/journal.pmed.1003947](#). PMID: [35290389](#).
30. Thomas CD, Franchi F, Keeley EC, Rossi JS, Winget M, Anderson RD, Dempsey AL, Gong Y, Gower MN, Kerensky RA, Kulick N, Malave JG, McDonough CW, Mulrenin IR, Starostik P, Beitelshees AL, Johnson JA, Stouffer GA, **Winterstein AG**, Angiolillo DJ, Lee CR, Cavallari LH. Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation. Clin Pharmacol Ther. 2022 Jul;112(1):146-155. doi: [10.1002/cpt.2612](#). PMID: [35429163](#).
31. Tang H, Kimmel SE, Smith SM, Cusi K, Shi W, Gurka M, **Winterstein AG**, Guo J. Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care. 2022 Apr 1;45(4):1007-1012. doi: [10.2337/dc21-1722](#). PMID: [35349656](#).
32. Lo-Ciganic WH, Hincapie-Castillo J, Wang T, Ge Y, Jones BL, Huang JL, Chang CY, Wilson DL, Lee JK, Reisfield GM, Kwok CK, Delcher C, Nguyen KA, Zhou L, Shorr RI, Guo J, Marcum ZA, Harle CA, Park H, **Winterstein A**, Yang S, Huang PL, Adkins L, Gellad WF. Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: Group-based multi-trajectory models. Addiction. 2022 Feb 28. doi: 10.1111/add.15857. Epub ahead of print. PMID: [35224799](#).
33. Chen C*, **Winterstein AG**, Lo-Ciganic WH, Tighe PJ, Wei YJ. Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with

chronic noncancer pain: A population-based cohort study. PLoS Med. 2022 Mar 1;19(3):e1003921. doi: 10.1371/journal.pmed.1003921. PMID: [35231025](#).

- Altmetric score 16

34. Beitelshes AL, Thomas CD, Empey PE, Stouffer GA, Angiolillo DJ, Franchi F, Tuteja S, Limdi NA, Lee JC, Duarte JD, Kreutz RP, Skaar TC, Coons JC, Giri J, McDonough CW, Rowland R, Stevenson JM, Thai T, Vesely MR, Wellen JT, Johnson JA, **Winterstein AG**, Cavallari LH, Lee CR. Implementing Genomics in Practice (IGNITE) Network Pharmacogenetics Working Group. CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. J Am Heart Assoc. 2022 Feb 15;11(4):e024159. doi: 10.1161/JAHA.121.024159. PMID: [35156424](#).
35. Huo T, Li Q, Cardel MI, Bussing R, **Winterstein AG**, Lemas DJ, Xu H, Woodard J, Mistry K, Scholle S, Muller KE, Shenkman EA. Enhancing Quality Measurement With Clinical Information: A Use Case of Body Mass Index Change Among Children Taking Second Generation Antipsychotics. Acad Pediatr. 2022 Apr;22(3S):S140-S149. doi: 10.1016/j.acap.2021.11.012. PMID: [35339240](#).
36. Chen C*, Lo-Ciganic WH, **Winterstein AG**, Tighe P, Wei YJ. Concurrent Use of Prescription Opioids and Gabapentinoids in Older Adults. Am J Prev Med. 2022 Apr;62(4):519-528. doi: [10.1016/j.amepre.2021.08.024](#). PMID: [34802816](#)
37. Sarayani A*, Albogami Y, Thai TN, Smolinski NE, Patel P, Wang Y, Nduaguba S, Rasmussen SA, **Winterstein AG**. Prenatal Exposure to Teratogenic Medications in the Era of Risk Evaluation and Mitigation Strategies. Am J Obstet Gynecol. 2022 Aug;227(2):263.e1-263.e38. doi: 10.1016/j.ajog.2022.01.004. PMID: 35032444
 - Altmetric score 32
38. Wei YJ, Chen C, **Winterstein AG**. Discontinuation of Long-Term Opioid Therapy in Patients With Versus Without Dementia. Am J Prev Med. 2022 Feb;62(2):270-274. doi: [10.1016/j.amepre.2021.07.020](#). PMID: [34702606](#)
39. **Winterstein AG**, Antonelli PJ. Triangulation of pharmacoepidemiology and laboratory science to tackle otic quinolone safety. Basic Clin Pharmacol Toxicol. 2022 Jan;130 Suppl 1:75-80. doi: [10.1111/bcpt.13668](#). PMID: [34611995](#).
40. Pottegård A, Morin L, Hallas J, Gerhard T, **Winterstein AG**, Perez-Gutthann S, Tadrous M. Where to Begin? Thirty must-read papers for newcomers to pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):257-259. doi: [10.1002/pds.5382](#). PMID: [34738294](#).
41. Sajdeya R*, Shavers A, Jean-Jacques J, Costales B, Jugl S, Crump C, Wang Y, Manfio L, Pipitone RN, Rosenthal MS, **Winterstein AG**, Cook RL. Practice Patterns and Training Needs Among Physicians Certifying Patients for Medical Marijuana in Florida. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211042790. doi: [10.1177/21501327211042790](#). PMID: [34452585](#)
42. Albogami Y*, Wei YJ, **Winterstein AG**. Generalizability and accuracy of IBM MarketScan health risk assessment instrument data for augmentation of commercial claims data. Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):100-104. doi: [10.1002/pds.5371](#). PMID: [34657354](#).
43. Jugl* S, Okpeku A, Costales B, Morris EJ, Alipour-Haris G, Hincapie-Castillo JM, Stetten NE, Sajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y, Adkins L, **Winterstein AG**, Goodin A. A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. Med Cannabis Cannabinoids. 2021 Feb 25;4(1):21-42. doi: [10.1159/000515069](#). PMID: [34676348](#)
44. Choi Y*, Meissner HC, Hampp C, Park H, **Winterstein AG**. Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines. Eur J Pediatr. 2021 Aug 7:1–5. doi: [10.1007/s00431-021-04233-6](#). PMID: [34365543](#).

45. Tang H, Kimmel SE, Hernandez I, Brooks MM, Cusi K, Smith SM, Shi W, **Winterstein AG**, Magnani JW, Guo J. Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. *Diabetes Obes Metab*. 2022 Jan;24(1):154-159. doi: 10.1111/dom.14540. PMID: [34472689](#).
46. Vouri SM*, Morris EJ, Usmani SA, Reise R, Jiang X, Pepine CJ, Manini TM, Malone DC, **Winterstein AG**. Evaluation of the Key Prescription Sequence Symmetry Analysis Assumption using the Calcium Channel Blocker - Loop Diuretic Prescribing Cascade. *Pharmacoepidemiol Drug Saf*. 2022 Jan;31(1):72-81. doi: [10.1002/pds.5362](#). PMID: [34553438](#).
47. Song HJ, Blake KV, Wilson DL, **Winterstein AG**, Park H. Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey. *J Asthma Allergy*. 2021 Jul 28;14:929-941. doi: [10.2147/JAA.S316278](#). PMID: [34349523](#); PMCID: PMC8326771.
48. DeRemer CE, Vouri SM, Guo J, Donahoo WT, **Winterstein AG**, Shao H. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study. *J Diabetes Complications*. 2021 Sep;35(9):107972. doi: [10.1016/j.jdiacomp.2021.107972](#). PMID: [34247911](#).
49. Wang CY, Berlin JA, Gertz B, Davis K, Li J, Dreyer NA, Zhou W, Seeger JD, Santanello N, **Winterstein AG**. Uncontrolled Extensions of Clinical Trials and the Use of External Controls - scoping opportunities and methods. *Clin Pharmacol Ther*. 2022 Jan;111(1):187-199. doi: [10.1002/cpt.2346](#). PMID: [34165790](#).
50. Lo Re V 3rd, Klungel OH, Chan KA, Panozzo CA, Zhou W, **Winterstein AG**. Global covid-19 vaccine rollout and safety surveillance-how to keep pace. *BMJ*. 2021 Jun 18;373:n1416. doi: [10.1136/bmj.n1416](#). PMID: [34144957](#)
 - Altmetric 25
51. Jenny Wei YJ*, Chen C, Fillingim RB, DeKosky ST, Schmidt S, Pahor M, Solberg L, **Winterstein AG**. Uncontrolled Pain and Risk for Depression and Behavioral Symptoms in Residents With Dementia. *J Am Med Dir Assoc*. 2021 Oct;22(10):2079-2086.e5. doi: [10.1016/j.jamda.2021.05.010](#). PMID: [34089652](#)
52. Vouri SM*, Jiang X, Morris EJ, Brumback BA, **Winterstein AG**. Use of negative controls in a prescription sequence symmetry analysis to reduce time-varying bias. *Pharmacoepidemiol Drug Saf*. 2021 Sep;30(9):1192-1199. doi: 10.1002/pds.5293. PMID: 33993606.
53. Tran PT*, Antonelli PJ, Hincapie-Castillo JM, **Winterstein AG**. Association of US Food and Drug Administration Removal of Indications for Use of Oral Quinolones With Prescribing Trends. *JAMA Intern Med*. 2021 Jun 1;181(6):808-816. doi: [10.1001/jamainternmed.2021.1154](#). PMID: [33871571](#)
 - Altmetric 32
54. Wei YJ*, Schmidt S, Chen C, Fillingim RB, Reid MC, DeKosky S, Solberg L, Pahor M, Brumback B, **Winterstein AG**. Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia. *Alzheimers Res Ther*. 2021 Apr 12;13(1):78. doi: [10.1186/s13195-021-00818-3](#). PMID: [33883028](#).
55. Albogami Y*, Cusi K, Daniels MJ, Wei YJ, **Winterstein AG**. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. *Diabetes Care*. 2021 Jun;44(6):1344-1352. doi: [10.2337/dc20-1794](#). Epub 2021 Apr 19. PMID: [33875487](#)
 - Altmetric 29
56. Jeon N*, Park H, Segal R, Brumback B, **Winterstein AG**. Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients? *Eur J Clin Pharmacol*. 2021 Sep; 77(9):1409-1417. doi: [10.1007/s00228-021-03121-0](#). PMID: [33772627](#).
57. Ginsburg GS, Cavallari LH, Chakraborty H, Cooper-DeHoff RM, Dexter PR, Eadon MT, Ferket BS, Horowitz CR, Johnson JA, Kannry J, Kucher N, Madden EB, Orlando LA, Parker W, Peterson J, Pratt VM, Rakhra-Burris TK, Ramos MA, Skaar TC, Sperber N, Steen-Burrell KA, Van Driest SL, Voora D, Wiisanen K,

Winterstein AG, Volpi S; IGNITE PTN. Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. *Genet Med*. 2021 Jul;23(7):1185-1191. doi: [10.1038/s41436-021-01118-9](https://doi.org/10.1038/s41436-021-01118-9). PMID: [33782552](https://pubmed.ncbi.nlm.nih.gov/33782552/).

- Altmetric 12

58. Li Y*, Delcher C, Reisfield GM, Wei YJ, Brown JD, **Winterstein AG**. Utilization patterns of skeletal muscle relaxants among commercially insured adults in the United States from 2006 to 2018. *Pain Med*. 2021 Oct;22(10):2153-2161. doi: [10.1093/pm/pnab088](https://doi.org/10.1093/pm/pnab088). PMID: [33690860](https://pubmed.ncbi.nlm.nih.gov/33690860/).
59. Albogami Y*, Sarayani A, Hincapie-Castillo JM, **Winterstein AG**. Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015. *Drug Saf*. 2021 Apr;44(4):447-454. doi: [10.1007/s40264-021-01053-3](https://doi.org/10.1007/s40264-021-01053-3). PMID: [33683646](https://pubmed.ncbi.nlm.nih.gov/33683646/).
 - Altmetric 16
60. Yang L, Gabriel N, Hernandez I, **Winterstein AG**, Guo J. Using Machine Learning to Identify Diabetes Patients with Canagliflozin Prescriptions at High-risk of Lower Extremity Amputation Using Real-world Data. *Pharmacoepidemiol Drug Saf*. 2021 May;30(5):644-651. doi: [10.1002/pds.5206](https://doi.org/10.1002/pds.5206). PMID: [33606340](https://pubmed.ncbi.nlm.nih.gov/33606340/).
61. Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Anne Tang L, Aquilante CL, Beitelshes AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, P Lipori G, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, **Winterstein AG**, Van Driest SL, Cavallari LH, Peterson JF; IGNITE Pharmacogenetics Working Group. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. *Clin Pharmacol Ther*. 2021 Jul;110(1):179-188. doi: [10.1002/cpt.2161](https://doi.org/10.1002/cpt.2161). Epub 2021 Feb 16. PMID: [33428770](https://pubmed.ncbi.nlm.nih.gov/33428770/).
62. Costales B, van Boemmel-Wegmann S, **Winterstein A**, Segal R. Clinical Conditions and Prescription Drug Utilization among Early Medical Marijuana Registrants in Florida. *J Psychoactive Drugs*. 2021 Jul-Aug;53(3):185-194. doi: [10.1080/02791072.2020.1864069](https://doi.org/10.1080/02791072.2020.1864069). PMID: [33393877](https://pubmed.ncbi.nlm.nih.gov/33393877/).
63. Song HJ, Blake KV, Wilson DL, **Winterstein AG**, Park H. Medical Costs and Productivity Loss Due to Mild, Moderate, and Severe Asthma in the United States. *J Asthma Allergy*. 2020 Oct 29;13:545-555. doi: [10.2147/JAA.S272681](https://doi.org/10.2147/JAA.S272681). PMID: [33149626](https://pubmed.ncbi.nlm.nih.gov/33149626/).
64. Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshes AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, **Winterstein AG**, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL; IGNITE Pharmacogenetics Working Group. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. *JAMA Netw Open*. 2020 Dec 1;3(12):e2029411. doi: [10.1001/jamanetworkopen.2020.29411](https://doi.org/10.1001/jamanetworkopen.2020.29411). PMID: [33315113](https://pubmed.ncbi.nlm.nih.gov/33315113/)
65. Sarayani A*, Brown JD, Goodin AJ, Squires P, Pham P, Cicali B, Henriksen C, Schmidt S, **Winterstein AG**. A Pharmacoepidemiologic Approach to Evaluate Real-world Effectiveness of Hormonal Contraceptives in the Presence of Drug-drug Interactions. *Epidemiology*. 2021 Mar 1;32(2):268-276. doi: [10.1097/EDE.0000000000001302](https://doi.org/10.1097/EDE.0000000000001302). PMID: [33196560](https://pubmed.ncbi.nlm.nih.gov/33196560/)
66. Choi Y*, Meissner HC, Hampf C, Park H, Brumback B, **Winterstein AG**. Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization. *J Pediatric Infect Dis Soc*. 2021 Apr 3;10(3):317-325. doi: [10.1093/jpids/piaa107](https://doi.org/10.1093/jpids/piaa107). Online ahead of print. PMID: [32978942](https://pubmed.ncbi.nlm.nih.gov/32978942/)
67. Li Y*, Delcher C, Wei YJ, Reisfield GM, Brown JD, Tighe PJ, **Winterstein AG**. Risk of opioid overdose associated with concomitant use of opioids and skeletal muscle relaxants: a population-based cohort study. *Clin Pharmacol Ther*. 2020 Jul;108(1):81-89. doi: [10.1002/cpt.1807](https://doi.org/10.1002/cpt.1807). PubMed PMID: [32022906](https://pubmed.ncbi.nlm.nih.gov/32022906/)
 - Recognized with a commentary in CPT: <https://doi.org/10.1002/cpt.1807>
68. Osborne V*, Serdarevic M, Striley CW, Nixon SJ, **Winterstein AG**, Cottler LB. Age of First Use of Prescription Opioids and Prescription Opioid Non-Medical Use among Older Adolescents. *Subst Use*

- Misuse. 2020;55(14):2420-2427. doi: [10.1080/10826084.2020.1823420](https://doi.org/10.1080/10826084.2020.1823420). Epub 2020 Oct 15. PMID: [33059498](https://pubmed.ncbi.nlm.nih.gov/33059498/).
69. Seeger JD, Davis KJ, Iannacone MR, Zhou W, Dreyer N, **Winterstein AG**, Santanello N, Gertz B, Berlin JA. Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials. *Pharmacoepidemiol Drug Saf*. 2020 Nov;29(11):1382-1392. doi: [10.1002/pds.5141](https://doi.org/10.1002/pds.5141). PMID: [32964514](https://pubmed.ncbi.nlm.nih.gov/32964514/).
 70. Sarayani A*, Wang X, Thai T, Albogami Y, Jeon N, **Winterstein AG**. Impact of the transition from ICD–9–CM to ICD–10–CM on the identification of pregnancy episodes in U.S. health insurance claims data. *J Clin Epidemiology* 2020;12:1129-1138. doi: [10.2147/CLEP.S269400](https://doi.org/10.2147/CLEP.S269400). PMID: [33116906](https://pubmed.ncbi.nlm.nih.gov/33116906/)
 71. Zhu Y*, Hampp C, Wang X, Albogami Y, Wei Y-J, Brumback BA, Roussos-Ross D, **Winterstein AG**. Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract-Quantifying the misclassification of maternal drug exposure during pregnancy. *Pharmacoepidemiol Drug Saf* 2020 Nov;29(11):1414-1422. doi:[10.1002/pds.5126](https://doi.org/10.1002/pds.5126) PMID: [32909348](https://pubmed.ncbi.nlm.nih.gov/32909348/)
 72. Vouri SM*, Thai TN, **Winterstein AG**. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. *Res Social Adm Pharm*. 2021 Jan;17(1):2012-2017. doi: [10.1016/j.sapharm.2020.04.031](https://doi.org/10.1016/j.sapharm.2020.04.031) PMID: [32409150](https://pubmed.ncbi.nlm.nih.gov/32409150/)
 - Altmetric score: 112
 73. Wei YJ*, Solberg L, Chen C, Fillingim RB, Pahor M, DeKosky S, **Winterstein AG**. Agreement of Minimum Data Set 3.0 depression and behavioral symptoms with clinical diagnosis in a nursing home. *Aging Ment Health*. 2021; Oct;25(10):1897-1902. doi: [10.1080/13607863.2020.1758921](https://doi.org/10.1080/13607863.2020.1758921). PMID: [32447973](https://pubmed.ncbi.nlm.nih.gov/32447973/)
 74. Thai TN*, Sarayani A, Wang X, Albogami Y, Rasmussen SA, **Winterstein AG**. Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: A retrospective cohort study. *Pharmacoepidemiol Drug Saf*. 2020 Jun;29(6):716-724. doi:[10.1002/pds.5017](https://doi.org/10.1002/pds.5017). PMID: [32347619](https://pubmed.ncbi.nlm.nih.gov/32347619/).
 - Altmetric: 10
 75. **Winterstein AG**, Li Y, Gerhard T, Linden S, Shuster JJ. Medication Use for ADHD and the Risk of Driving Citations and Crashes Among Teenage Drivers: A Population-Based Cohort Study. *J Atten Disord*. 2021 Sep;25(11):1511-1518. doi: [10.1177/1087054720915768](https://doi.org/10.1177/1087054720915768). PMID: [32338114](https://pubmed.ncbi.nlm.nih.gov/32338114/).
 76. Brown B, Costales B, van Boemmel-Wegmann S, Goodin A, Segal S, **Winterstein AG**. Characteristics of older adults who were early adopters of medical cannabis in the Florida medical marijuana use registry. *JCM* 2020; Apr 18;9(4). pii: E1166. doi: [10.3390/jcm9041166](https://doi.org/10.3390/jcm9041166). PMID [32325769](https://pubmed.ncbi.nlm.nih.gov/32325769/)
 77. **Winterstein AG**, Bussing R, Goodin A, Xu D, Keenan M, Turner K, Meyyur V, Duseja R, Campbell K. Development and Validation of an Administrative Claims-based Measure for All-cause 30-day Risk-standardized Readmissions after Discharge from Inpatient Psychiatric Facilities. *Med Care*. 2020 Mar;58(3):225-233. doi: [10.1097/MLR.0000000000001275](https://doi.org/10.1097/MLR.0000000000001275). PMID: [32106165](https://pubmed.ncbi.nlm.nih.gov/32106165/).
 78. Nguyen T*, Liu X, Abuhashem W, Bussing R, **Winterstein AG**. Quality of Evidence Supporting Major Psychotropic Drug-Drug Interaction Warnings: A Systematic Literature Review. *Pharmacotherapy*. 2020 May;40(5):455-468. doi: [10.1002/phar.2382](https://doi.org/10.1002/phar.2382). PMID: [32107798](https://pubmed.ncbi.nlm.nih.gov/32107798/)
 79. Smith SM, Gurka MJ, **Winterstein AG**, Handberg E, Pepine CJ, Cooper-DeHoff RM. Redefining Resistant Hypertension: A Comparison of Cardiovascular Risk Associated With the 2018 Versus 2008 American Heart Association Definitions for Resistant Hypertension. *Circ Cardiovasc Qual Outcomes* 2020 Feb;13:e005979. doi: [10.1161/CIRCOUTCOMES.119.005979](https://doi.org/10.1161/CIRCOUTCOMES.119.005979). PMID: [32008359](https://pubmed.ncbi.nlm.nih.gov/32008359/)
 80. Vouri SM*, Jiang X, Manini TM, Solberg LM, Pepine C, Malone DC, **Winterstein AG**. Magnitude of and Characteristics Associated with the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics. *JAMA Netw Open*. 2019; Dec 2;2(12):e1918425. PMID: [31880802](https://pubmed.ncbi.nlm.nih.gov/31880802/) doi: [10.1001/jamanetworkopen.2019.18425](https://doi.org/10.1001/jamanetworkopen.2019.18425).

- Altmetric 64
81. Muñoz MA*, Dal Pan GJ, Wei YJ, Delcher C, Xiao, H, Kortepeter CM, **Winterstein AG**. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. *Drug Saf.* 2020 Apr;43(4):329-338. PMID: [31912439](#) doi: [10.1007/s40264-019-00897-0](#).
 - Altmetric score: 10
 82. Tran PT*, **Winterstein AG**, Wang X, Rhew K, Antonelli PJ. Appropriateness of Otic Quinolone Use among Privately Insured US Patients. *Otolaryngol Head Neck Surg.* 2020 Jan;162(1):102-102. PMID: [31743076](#) doi: [10.1177/0194599819889607](#)
 83. Choi Y*, Park H, Hampp C, Brumback B, Meissner HC, Li Y, Roussos-Ross D, Zhu Y, Henriksen C, **Winterstein AG**. Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women. *Pharmacoepidemiol Drug Saf.* 2020 Jan;29(1):30-38 doi: [10.1002/pds.4923](#). PMID: [31737976](#)
 84. El Rouby N*, Alrwisan A, Langae T, Lipori G, Angiolillo DJ, Franchi F, Riva A, Elsey A, Johnson JA, Cavallari LH, **Winterstein AG**. Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention (PCI). *Clin Transl Sci.* 2020 May;13(3):473-481. doi: [10.1111/cts.12729](#). PMID: [31758664](#)
 85. Talevi A, Morales JF, Hather G, Podichetty JT, Kim S, Bloomingdale PC, Kim S, Burton J, Brown JD, **Winterstein AG**, Schmidt S, White JK, Conrado DJ. Machine Learning in Drug Discovery and Development Part 1: A Primer. *CPT Pharmacometrics Syst Pharmacol.* 2020 Mar;9(3):129-142. doi: [10.1002/psp4.12491](#). PMID: [31905263](#)
 86. Wei YJ, Chen C, Fillingim R, Schmidt SO, **Winterstein AG**. Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study. *PLoS Med.* 2019 Nov 5;16(11):e1002941. doi: [10.1371/journal.pmed.1002941](#). PMID: [31689302](#)
 - Altmetric score 30
 87. Alrwisan AA*, Wei YJ, Brumback BA, Antonelli PJ, **Winterstein AG**. Concomitant Use of Quinolones and Stimulants and the Risk of Adverse Cardiovascular Symptoms: A Retrospective Cohort Study. *Pharmacotherapy.* 2019 Dec;39(12):1167-1178. doi:[https://doi.org/10.1002/phar.2343](#) PMID: [31674031](#).
 - Altmetric score 31
 88. Sarayani A*, Albogami Y, Elkhider M, Hincapie-Castillo JM, Brumback BA, **Winterstein AG**. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate. *BMJ Qual Saf.* 2020 Aug;29(8):636-644. doi: [10.1136/bmjqs-2019-010098](#). PMID: [31649165](#).
 - Altmetric score 11
 - Accompanying editorial at doi: [10.1136/bmjqs-2019-010588](#)
 89. Osborne V, Striley CW, Nixon SJ, **Winterstein AG**, Cottler LB. Sex differences in peer and parental risk factors for non-medical use of prescription opioids in youth. *Am J Drug Alcohol Abuse.* 2019 Oct 11:1-13. doi: [10.1080/00952990.2019.1671436](#). PMID: [31603348](#)
 90. Pottegård A, Klungel O, **Winterstein A**, Huybrechts K, Hallas J, Schneeweiss S, Evans S, Bate A, Pont L, Trifirò G, Smith M, Bourke A. The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. *Pharmacoepidemiol Drug Saf.* 2019 Dec;28(12):1640-1641. doi: [10.1002/pds.4911](#). PMID: [31642154](#)
 91. Wei YJ, Chen C, Schmidt SO, LoCiganic WH, **Winterstein AG**. Trends in prior receipt of prescription opioid or adjuvant analgesics among patients with incident opioid use disorder or opioid-related overdose from 2006 to 2016. *Drug Alcohol Depend.* 2019 Sep 27;204:107600. doi: [10.1016/j.drugalcdep.2019.107600](#) PMID: [31586806](#)

92. Muñoz MA*, Delcher C, Dal Pan GJ, Kortepeter CM, Wu E, Jenny Wei YJ, Xiao H, **Winterstein AG**. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration. *Pharmacotherapy*. 2019 Nov;39(11):1042-1052. doi: [10.1002/phar.2325](https://doi.org/10.1002/phar.2325). PMID: [31479525](https://pubmed.ncbi.nlm.nih.gov/31479525/)
93. Dave C*, Goodin A, Zhu Y, **Winterstein A**, Wang X, Alrwisan A, Hartzema A. Prevalence of Maternal Risk Factors related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015. *Pharmacotherapy*. 2019 Oct;39(10):1005-1011. PMID: [31361913](https://pubmed.ncbi.nlm.nih.gov/31361913/) doi: [10.1002/phar.2315](https://doi.org/10.1002/phar.2315)
94. Wei YJ*, Solberg L, Chen C, Fillingim RB, Pahor M, DeKosky S, **Winterstein AG**. Pain Assessments in MDS 3.0: Agreement with Vital Sign Pain Records of Nursing Home Residents. *J Am Geriatr Soc* 2019 Nov;67(11):2421-2422. PMID: [31403708](https://pubmed.ncbi.nlm.nih.gov/31403708/) doi: [10.1111/jgs.16122](https://doi.org/10.1111/jgs.16122).
95. Brown J, **Winterstein AG**. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. *J Clin Med* 2019 Jul;8(7). PMID:[31288397](https://pubmed.ncbi.nlm.nih.gov/31288397/) doi: [10.3390/jcm8070989](https://doi.org/10.3390/jcm8070989).
 - Altmetric score 37
96. Dawwas GK*, Dietrich E, Winchester D, **Winterstein AG**, Segal R, Park H. Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis. *Pharmacotherapy*. 2019 Sep;39(9):912-920. PMID: [31332815](https://pubmed.ncbi.nlm.nih.gov/31332815/) doi: [10.1002/phar.2311](https://doi.org/10.1002/phar.2311).
97. Hincapie-Castillo JM*, Staley B, Henriksen C, Saidi A, Lipori GP, **Winterstein AG**. Development of a predictive model for drug-associated QT prolongation in the inpatient setting using electronic health record data. *Am J Health Syst Pharm* 2019 Jul 2;76(14):1059-1070. PMID: [31185072](https://pubmed.ncbi.nlm.nih.gov/31185072/) doi:[10.1093/ajhp/zxz100](https://doi.org/10.1093/ajhp/zxz100)
98. Knox CA*, Hampp C, Palmsten K, Zhu Y, Setoguchi S, Brumback B, Segal R, **Winterstein AG**. Validation of mother-infant linkage using Medicaid Case ID variable within the Medicaid Analytic eXtract (MAX) database. *Pharmaoepidem Drug Saf* 2019 Sep;28(9):1222-1230. PMID: [31286606](https://pubmed.ncbi.nlm.nih.gov/31286606/) doi: [10.1002/pds.4843](https://doi.org/10.1002/pds.4843)
99. Li Y*, Delcher C, Brown JD, Wei Y-J, Reisfield GM, **Winterstein AG**. Impact of Schedule IV controlled substance classification on carisoprodol utilization in the United States: an interrupted time series analysis. *Drug Alcohol Dependence* 2019(Jul);202:172-177. PMID: [31352307](https://pubmed.ncbi.nlm.nih.gov/31352307/) doi: [10.1016/j.drugalcdep.2019.05.025](https://doi.org/10.1016/j.drugalcdep.2019.05.025).
100. Jeon N*, Staley B, Henriksen C, Lipori GP, **Winterstein AG**. Development and validation of an automated algorithm for identifying patients at higher risk for drug-induced acute kidney injury. *Am J Health-Sys Pharm* 2019; 76(10): 654–666 doi: [10.1093/ajhp/zxz043](https://doi.org/10.1093/ajhp/zxz043) PMID: [31361856](https://pubmed.ncbi.nlm.nih.gov/31361856/)
101. Schmidt S, Kim S, Vozmediano V, Cristofolletti R, **Winterstein AG**, Brown JD. Pharmacometrics, PBPK, QSP – What’s Next? – Joining Mechanistic and Epidemiological Approaches. *CPT Pharmacometric Sys Pharmacol* 2019 Jun;8(6):352-355 PMID: [31179639](https://pubmed.ncbi.nlm.nih.gov/31179639/) doi: [10.1002/psp4.12425](https://doi.org/10.1002/psp4.12425)
102. Chen C*, **Winterstein AG**, Fillingim R, Wei Y-J. Body weight, frailty and chronic pain in older adults: a cross-sectional study. *BMC Geriatrics* 2019;19(1):143. PMID: [31126233](https://pubmed.ncbi.nlm.nih.gov/31126233/) doi: [10.1186/s12877-019-1149-4](https://doi.org/10.1186/s12877-019-1149-4)
103. Wang X*, **Winterstein AG**, Alrwisan A, Antonelli PJ. Risk for Tympanic Membrane Perforation after Quinolone Ear Drops for Acute Otitis Externa. *Clin Infect Dis*. 2020 Mar 3;70(6):1103-1109. doi: [10.1093/cid/ciz345](https://doi.org/10.1093/cid/ciz345). PMID: [31044229](https://pubmed.ncbi.nlm.nih.gov/31044229/)
 - Altmetric score 116
104. Smith SM*, Pepine CJ, Gurka M, **Winterstein AG**, DeHoff RM. Incidence, Prevalence and Predictors of Treatment-Resistant Hypertension with Intensive Blood Pressure Lowering. *J Clin Hyp* 2019;21:825–834. PMID: [31066177](https://pubmed.ncbi.nlm.nih.gov/31066177/) doi: [10.1111/jch.13550](https://doi.org/10.1111/jch.13550)
105. Wang Z, Brumback B, Alrwisan A, **Winterstein AG**. Model-based standardization using outcome model with random effects. *Statistics in Medicine* 2019 Aug 15;38(18):3378-3394 PMID: [31150151](https://pubmed.ncbi.nlm.nih.gov/31150151/) doi:[10.1002/sim.8182](https://doi.org/10.1002/sim.8182)
106. Choi Y*, Staley B, Soria-Saucedo R, Henriksen C, Rosenberg A, **Winterstein AG**. Common inpatient hypoglycemia phenotypes identified from an automated electronic health record-based prediction model. *Am J Health Syst Pharm*. 2019;25;76(3):166-174. PMID: [30689749](https://pubmed.ncbi.nlm.nih.gov/30689749/) doi: [10.1093/ajhp/zxy017](https://doi.org/10.1093/ajhp/zxy017)

107. Baker C, Feinstein JA, Ma X, Bolen S, Dawson NV, Golchin N, Horace A, Kleinman LC, Meropol SB, Pestana Knight EM, **Winterstein AG**, Bakaki PM. Variation of the prevalence of pediatric polypharmacy: A scoping review. *Pharmacoepidemiol Drug Saf* 2019; ;28(3):275-287 PMID: [30724414](#) doi: [10.1002/pds.4719](#)
108. Li Y*, Staley B, Henriksen C, Xu D, Lipori G, **Winterstein AG**. Development and validation of a dynamic inpatient risk prediction model for clinically significant hypokalemia using electronic health record data. *Am J Health Syst Pharm*. 2019;76(5):301-311. PMID: [30698650](#) doi: [10.1093/ajhp/zxy051](#)
109. Munoz M*, Jeon N, Staley B, **Winterstein AG**. Predicting medication-associated altered mental status in hospitalized patients: Development and validation of a risk model. *Am J Health Sys Pharm* 2019 Jun 18;76(13):953-963. PMID:[31361885](#) doi:[10.1093/ajhp/zxz119](#)
110. Bakaki PM*, Staley J, Liu R, Dawson N, Golchin N, Horace A, Johnson H, Waldron J, **Winterstein A**, Kleinman LC, Bolen SD. A transdisciplinary team approach to scoping reviews: the case of pediatric polypharmacy. *BMC Med Res Methodol*. 2018;18(1):102. PMID: [30286720](#) doi: [10.1186/s12874-018-0560-4](#).
111. Bakaki PM*, Horace A, Dawson N, **Winterstein A**, Waldron J, Staley J, Pestana Knight EM, Meropol SB, Liu R, Johnson H, Golchin N, Feinstein JA, Bolen SD, Kleinman LC. Defining pediatric polypharmacy: A scoping review. *PLoS One*. 2018 Nov 29;13(11):e0208047. PMID: [30496322](#); doi: [10.1371/journal.pone.0208047](#)
112. Wei Y-J, **Winterstein AG**. Performance of Centers for Medicare and Medicaid Services' Opioid Overutilization Criteria for Classifying Beneficiaries with Opioid Use Disorder or Overdose. *JAMA* 2019;12;321(6):609-611. PMID: [30747958](#) doi: [10.1001/jama.2018.20404](#) IF (2019): 52
 - Altmetric score 39
113. Osborne V*, Striley C, Nixon SJ, **Winterstein AG**, Cottler L. Sex Differences in Patterns of Prescription Opioid Non-Medical Use among 10-18 Year Olds in the US. *Addict Behav* 2019;89:163-171. PMID: [30316142](#); doi: [10.1016/j.addbeh.2018.10.009](#)
114. **Winterstein AG**, Jeon N, Staley B, Xu D, Henriksen C, Lipori GP. Development and validation of an automated algorithm for identifying patients at high risk for drug-induced hypoglycemia. *Am J Health Syst Pharm* 2018;75(21):1714-1728 PMID: [30279185](#); doi: [10.2146/ajhp180071](#)
 - Altmetric score 12
115. Lesko L, Vozmediano V, Brown J, **Winterstein A**, Zhao P, Lippert J, Hoechel J, Chaturvedula A, White A, Schmidt S. Establishing a multidisciplinary framework to study drug-drug interactions of hormonal contraceptives: an invitation to collaborate. *CPT Pharmacometrics Syst Pharmacol*. 2018 Nov;7(11):706-708. PMID: [30260082](#); doi: [10.1002/psp4.12357](#)
116. Wang X*, **Winterstein AG**, Antonelli PJ. Use of Systemic Antibiotics for Acute Otitis Externa: Impact of A Clinical Practice Guideline. *Otol Neurotol*. 2018;39(9):1088-1094. PMID: [3012461](#); doi: [10.1097/MAO.0000000000001955](#)
117. Dave CV, **Winterstein AG**, Park H, Cook RL, Hartzema AG. Comparative risk of lipophilic and hydrophilic statins on incident depression: a retrospective cohort study. *J Affect Disord*. 2018 Oct 1;238:542-546. PMID: [29936394](#); doi: [10.1016/j.jad.2018.06.021](#)
118. Soria-Saucedo R*, Liu X, Hincapie-Castillo J, Zambrano D, Bussing R, **Winterstein AG**. Prevalence, time trends and utilization patterns of psychotropic polypharmacy: Evidence from children and adolescent Medicaid beneficiaries, 1999-2010. *Psychiatr Serv*. 2018 Aug 1;69(8):919-926. PMID: [29879872](#); doi: [10.1176/appi.ps.201700260](#)
119. Wei Y-J, Zhu Y, Liu W, Bussing R. **Winterstein AG**. Prevalence of and factors associated with long-term concurrent use of stimulants and opioids among adults with Attention- Deficit/Hyperactivity Disorder. *JAMA Netw Open* 2018;;1(4):e181152. doi: [10.1001/jamanetworkopen.2018.1152](#). PMID: [30646105](#)
120. Choi YY*, Staley B, Henriksen C, Xu D, Lipori G, Brumback B, **Winterstein AG**. A dynamic risk model for inpatient falls. *Am J Health Syst Pharm*. 2018;75(17):1293-1303. PMID: [30037814](#); doi: [10.2146/ajhp180013](#).

121. Alrwisan A*, Antonelli PJ, **Winterstein AG**. Azithromycin and Sensorineural Hearing Loss in Adults: A Retrospective Cohort Study. *Otol Neurotol*. 2018;39(8):957-963. PMID: [29965935](#); doi: [10.1097/MAO.0000000000001887](#)
122. Liu W*, Antonelli PJ, Dahm P, Gerhard T, Delayne JAC, Segal R, Crystal S, **Winterstein AG**. Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: population-based cohort study. *Pharmacoepidemiol Drug Saf*. 2018;27(6):587-595. PMID:[29512263](#); doi: [10.1002/pds.4405](#)
123. Xu D*, Daniels M, **Winterstein AG**. A Bayesian Nonparametric Approach to Causal Inference on Quantiles. *Biometrics* 2018;74(3):986-996 PMID: [29478267](#); DOI: [10.1111/biom.12863](#)
124. Li Y*, Henriksen C, **Winterstein AG**. Internal validation of Medicaid Analytic eXtract data capture for comprehensive managed care plan enrollees from 2007 to 2010. *Pharmacoepidemiol Drug Saf*. 2018;27(10):1067-1076. PMID: [29210142](#); doi: [10.1002/pds.4365](#)
125. Liu X*, Carney PR, Bussing R, Segal R, Cottler LB, **Winterstein AG**. Stimulants Do Not Increase the Risk of Seizure-related Hospitalizations in Children with Epilepsy. *J Child Adolesc Psychopharm* 2018 Mar;28(2):111-116 PMID: [29028437](#); doi: [10.1089/cap.2017.0110](#)
 - Altmetric score 11
126. **Winterstein AG**, Choi YY, Meissner C. Association of age with risk for Hospitalization for Respiratory Syncytial Virus in Preterm Infants with Chronic Lung Disease. *JAMA Ped* 2018; Feb 1;172(2):154-160 PMID: [29204660](#)
 - Selected as paper of the months by the Respiratory Syncytial Virus Consortium in Europe
 - Altmetric score 13
127. Liu X*, Barnicoat M, Zhu Y, Hatton R, Bussing R, **Winterstein AG**. Consistency of psychotropic drug–drug interactions listed in drug monographs. *JAPHA* 2017;57(6):698-703. PMID:28844584
128. **Winterstein AG**, Soria Saucedo R, Gerhard T, Correll CU, Olfson M. Differential risk of increasing psychotropics polypharmacy use in children diagnosed with ADHD as preschoolers. *J Clin Psychiatry* 2017; 78(7):e744-e781 PMID: [28686819](#) doi: [10.4088/JCP.16m10884](#)
 - Altmetric score 30
 - Picked up by US News
129. Yan L*, Liu X, Zhu Y, Liu W, **Winterstein AG**. Determinants of pharmacological treatment initiation and persistence in publicly insured adults with attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol* 2017;37(5):546-554. PMID:[28787373](#) doi: [10.1097/JCP.0000000000000759](#)
130. Wei Y-J, Liu X, Rao N, Bussing R, **Winterstein AG**. Physical health outcomes in preschoolers with prior authorization for antipsychotics. *J Child Adolesc Psychopharmacol*. 2017 Nov;27(9):833-839. PMID [28708433](#); doi: [10.1089/cap.2017.0006](#)
131. Liu X*, Carney PR, Bussing R, Segal R, Cottler LB, **Winterstein AG**. Trends in antiepileptic drug use in children and adolescents with epilepsy. *Ped Neurology* 2017;74:32-40 PMID [28676250](#) doi:[10.1016/j.pediatrneurol.2017.05.016](#)
132. Cavallari LH, Lee C, Beitelshes A, Cooper-DeHoff R, Duarte J, Voora D, Kimmel S, McDonough C, Gong Y, Dave C, Pratt V, Alestock T, Anderson R, Alsip J, Ardati A, Brott B, Brown L, Chumnumwat S, Clare-Salzler M, Coons J, Denny J, Dillon C, Elsey A, Hamadeh I, Harada S, Hillegass W, Hines L, Horenstein R, Howell L, Jeng L, Kelemen M, Lee YM, Magvanjav O, Montasser M, Nelson D, Nutescu E, Nwaba D, Pakyz R, Palmer K, Peterson J, Pollin T, Quinn A, Robinson S, Schub J, Skaar T, Smith D, Sriramoju V, Starostik P, Stys T, Stevenson J, Varunok N, Vesely M, Wake D, Weck K, Weitzel K, Wilke R, Willig J, Zhao R, Kreutz R, Stouffer G, Empey P, Limdi N, Shuldiner A, **Winterstein AG**, Johnson JA. Multi-site Investigation of Outcomes with Implementation of *CYP2C19* Genotype-Guided Antiplatelet Therapy after Percutaneous Coronary Intervention. *JACC* 2018;11(2):181-191.PMID: [29102571](#) doi: [10.1016/j.jcin.2017.07.022](#)

- Altmetric: 44
 - Accompanying editorial: Sibbing D, Gross L. CYP2C19 Genotyping in Percutaneous Coronary Intervention-Treated Patients: Ready for Prime Time? JACC 2017
133. Jeon N*, Sorokina R, Henriksen C, Staley B, Lipori G, **Winterstein AG**. Measurement of selected preventable adverse drug events in hospital electronic health records. Toward developing a complexity score. Am J Health-Sys Pharm. 2017 Nov 15;74(22):1865-1877. PMID 29118045
 134. Jeon N*, Staley B, Klinker KP, Hincapie-Castillo J, **Winterstein AG**. Acute kidney injury risk associated with piperacillin-tazobactam compared with cefepime during vancomycin therapy in hospitalized patients: cohort study stratified by baseline kidney function. Int J Antimicrob Agents 2017; 50(1):63-67. PMID:28522340
 135. **Winterstein AG**, Staley B, Henriksen C, Xu D, Lipori G, Jeon N, Choi YY, Li Y, Hincapie-Castillo J, Soria-Saucedo R, Brumback B, Johns T. Development and validation of a Complexity-Score to rank hospitalized patients at risk for preventable adverse drug events. Am J Health-Sys Pharm 2017 Dec 1;74(23):1970-1984. PMID 29167139; doi: [10.2146/ajhp160995](https://doi.org/10.2146/ajhp160995)
 - Altmetric score 10
 136. Jeon N*, Staley B, Johns T, Lipori G, Brumback B, Segal R, **Winterstein AG**. Identifying and Characterizing Preventable Adverse Drug Events for Pharmacist Intervention in Hospitals: Results of a Literature Review and an ASHP Member Survey. Am J Health-Sys Pharm. 2017;74(21):1774-1783 PMID 29070499
 - Altmetric score 13
 137. Wang X*, Zhu Y, Dave CV, Alrwisan AA, Voils SA, **Winterstein AG**. Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in Florida. Pharmacother 2017; 37(7):806-813 PMID 28500694
 138. Hincapie-Castillo JM*, Liu X, Bussing R, **Winterstein AG**. Prevalence of psychotherapy surrounding initiation of psychotropic medication polypharmacy in the Medicaid-insured population, 1999-2010. Psychiatric Services 2017;68(11):1120-1126 PMID 28669287
 139. Cavallari LH, Weitzel KW, Elsey AR, Liu X, Mosley SA, Smith DM, Staley BJ, **Winterstein AG**, Mathews CA, Franchi F, Rollini F, Angiolillo DJ, Starostik P, Clare-Salzler MJ, Nelson DR, Johnson JA. Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics. 2017 Apr;18(5):421-426 PMID: 28346068
 140. Alrwisan A*, Antonelli PJ, **Winterstein AG**. Quinolone Ear Drops After Tympanostomy Tubes and the Risk of Eardrum Perforation: A Retrospective Cohort Study. Clin Inf Dis. 2017 (Feb); 64(8):1052-1058 PMID: [28329128](https://pubmed.ncbi.nlm.nih.gov/28329128/) doi: [10.1093/cid/cix032](https://doi.org/10.1093/cid/cix032)
 - Altmetric: 528; Noteworthy for news coverage: <https://oxfordjournals.altmetric.com/details/18288345/news>
 141. Zhu Y*, Liu W, Li Y, Wang X, **Winterstein AG**. Prevalence of Attention Deficit / Hyperactivity Disorder in Publicly Insured Adults. J Att Dis. 2017;22(2):182-190 PMID: 28363250
 142. Liu X*, Kubilis P, Bussing R, **Winterstein AG**. Development of a refill pattern method to measure polypharmacy in administrative claims databases. Pharmacoepidemiol Drug Saf. 2017 (Dec);25(12):1407-1413 PMID: 27528378
 143. Alrwisan A*, **Winterstein AG**, Antonelli JP. Epidemiology of Persistent Tympanic Membrane Perforation Subsequent to Tympanostomy Tubes Assessed with Real World Data. Otol Neurotol 2016 (Oct);37(9):1376-80 PMID: 27636392
 144. Hu X*, Harman J, **Winterstein AG**, Zhong Y, Wheeler AL, Taylor TN, Plankey M, Rubtsova A, Cropsey K, Cohen MH, Adimora AA, Milam J, Adedimeji A, Cook RL. Utilization of alcohol treatment among HIV-positive women with hazardous Drinking. J Sub Abuse Treatment 2016 May;64:55-61 PMID: 26961420

145. Xu D*, Daniels MJ, **Winterstein AG**. Sequential BART for imputation of missing covariates. *Biostatistics*. 2016 Jul;17(3):589-602. doi:[10.1111/biom.12863](https://doi.org/10.1111/biom.12863) PMID: [26980459](https://pubmed.ncbi.nlm.nih.gov/26980459/)
146. Linden S*, Bussing R, Kubilis P, Gerhard T, Segal R, Shuster J, **Winterstein AG**. Risk of suicidal events with atomoxetine compared to stimulants treatment: a cohort study. *Pediatrics* 2016 May;137(5):e20153199. PMID: [27244795](https://pubmed.ncbi.nlm.nih.gov/27244795/); doi:[10.1542/peds.2015-3199](https://doi.org/10.1542/peds.2015-3199)
 - Altmetric score: 43
147. Chen CY*, Bussing R, Hartzema AG, Shuster J, Segal R, **Winterstein AG**. Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides. *Pharmacoepidemiol Drug Saf* 2016 Jun;(6):678-86. PMID: [26597624](https://pubmed.ncbi.nlm.nih.gov/26597624/); doi:[10.1002/pds.3894](https://doi.org/10.1002/pds.3894)
148. Liu X*, Shah V, Kubilis P, Xu D, Bussing R, **Winterstein AG**. Psychotropic treatment pattern in Medicaid pediatric patients with concomitant ADHD and ODD/CD. *J Attention Dis* 2015 Aug PMID: [26269095](https://pubmed.ncbi.nlm.nih.gov/26269095/); doi: [10.1177/1087054715596574](https://doi.org/10.1177/1087054715596574)
149. Knox C*, Hampp C, Willy M, **Winterstein AG**, Pan GD. Patient understanding of drug risks: an evaluation of medication guide assessments. *Pharmacoepidemiol Drug Saf*. 2015 Mar 23;24(5):518-525 PMID: [25808393](https://pubmed.ncbi.nlm.nih.gov/25808393/); doi: [10.1002/pds.376](https://doi.org/10.1002/pds.376)
150. Ali AK*, Hartzema AG, **Winterstein AG**, Segal R, Lu X, Hendeles L. Application of Multicategory Exposure Marginal Structural Models to Investigate the Association between Long-Acting Beta-Agonists and Prescribing of Oral Corticosteroids for Asthma Exacerbations in the Clinical Practice Research Datalink. *Value Health*. 2015 Mar;18(2):260-70. doi: [10.1016/j.jval.2014.11.007](https://doi.org/10.1016/j.jval.2014.11.007) PMID: [25773561](https://pubmed.ncbi.nlm.nih.gov/25773561/).
151. **Winterstein AG**, Johns TE, Campbell KN, Libby J, Pannel B. Development of a medication safety survey for small rural hospitals. *J Pat Safety* 2015 Feb; Dec;13(4):249-254. PMID: [25719815](https://pubmed.ncbi.nlm.nih.gov/25719815/)
152. Eworuke E*, Zeng QY, **Winterstein AG**. Clinical and socio-demographic factors associated with attention deficit/hyperactivity disorder in patients with cystic fibrosis. *Psychosomatics* 2015 Sep-Oct;56(5):495-503. doi: [10.1016/j.psych.2014.09.001](https://doi.org/10.1016/j.psych.2014.09.001) PMID: [25620567](https://pubmed.ncbi.nlm.nih.gov/25620567/)
153. Liu X*, Kubilis P, Xu D, Bussing R, **Winterstein AG**. Psychotropic Drug Utilization in Children with Concurrent Attention-Deficit/Hyperactivity Disorder and Anxiety. *J Anxiety Dis* 2014;28:530-536 doi: [10.1016/j.janxdis.2014.06.005](https://doi.org/10.1016/j.janxdis.2014.06.005) PMID: [24981018](https://pubmed.ncbi.nlm.nih.gov/24981018/)
154. **Winterstein AG**, Kubilis P, Bird S, Cooper-DeHoff R, Nichols G, Delaney JAC. Misclassification in Assessment of Diabetogenic Risk using Electronic Health Records. *Pharmacoepi Drug Saf* 2014 Aug;23(8):875-81 doi: [10.1002/pds.3656](https://doi.org/10.1002/pds.3656) PMID: [24923707](https://pubmed.ncbi.nlm.nih.gov/24923707/)
155. Bussing R, Narwaney KJ, **Winterstein AG**, Newton DA, Debar L, Boscarino JA, Toh S, Pawloski P, Nordin JD, Herrinton LJ, Mason D, Daley MF. Pharmacotherapy for Incident Attention-Deficit/Hyperactivity Disorder: Practice Patterns and Quality Metrics. *Current Med Res Opin* 2014 Aug;30(8):1687-99 doi: [10.1185/03007995.2014.905461](https://doi.org/10.1185/03007995.2014.905461) PMID: [24635013](https://pubmed.ncbi.nlm.nih.gov/24635013/)
156. Knox CA*, Delaney JAC, **Winterstein AG**. Anti-diabetic drug utilization of pregnant diabetic women in US managed care. *BMC Pregnancy Childbirth*. 2014 Jan;14:28 PMID: [24438493](https://pubmed.ncbi.nlm.nih.gov/24438493/)
157. Toh S, Avorn J, D'Agostino RB Sr, Gurwitz JH, Psaty BM, Rothman KJ, Saag KG, Sturkenboom MC, Vandenbroucke JP, **Winterstein AG**, Strom BL. Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. *Pharmacoepidemiol Drug Saf*. 2013;22(10):1036-45 PMID: [23922322](https://pubmed.ncbi.nlm.nih.gov/23922322/)
158. DeHoff R, Delaney JAC, Bird S, Nichols G, **Winterstein AG**. Antihypertensive Drug Class Interactions and Risk for Incident Diabetes; a Nested Case Control Study. *JAMA* 2013 Jun 10;2(3):e000125 PMID: [2375271](https://pubmed.ncbi.nlm.nih.gov/2375271/); doi: [10.1161/JAHA.113.000125](https://doi.org/10.1161/JAHA.113.000125)

159. Birnbaum ML, Saito E, Gerhard T, **Winterstein A**, Olfson M, Kane JM, Correll CU. Pharmacoeconomics of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications. *Curr Psychiatry Rep*. 2013 Aug;15(8):382. PMID: 23881713.
160. **Winterstein AG**, Knox C, Kubilis P, Hampp C. Accuracy of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Late-Preterm Infants - A cohort study. *JAMA Pediatrics* 2013 Dec 1;167(12):1118-24 PMID: 24126903
 - Altmetric: 23
 - Noteworthy for news coverage: <https://jamanetwork.altmetric.com/details/1827270#score>
161. **Winterstein AG**. Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies. *Curr Psychiatry Rep*. 2013 Aug;15(8):379. PMID: 23913135
162. Delaney JA, Lehmann N, Jöckel K-H, Elmariah S, Psaty BM, Mahabadi A, Budoff M, Kronmal RA, Nasir K, O'Brien KD, Möhlenkamp S, Moebus S, Dragano NO, **Winterstein A**, Erbel R, Kälisch H. Associations between Aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. *Atherosclerosis* 2013;229:310-316. PubMed PMID: 23880181
163. Toteja N, Gallego JA, Saito E, Gerhard T, **Winterstein A**, Olfson M, Correll CU. Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. *Int J Neuropsychopharmacology* 2013 May 14:1-11 PMID: 23673334
164. **Winterstein AG**, Liu W, Xu D, Antonelli PJ. Sensorineural hearing loss associated with neomycin eardrops and non-intact tympanic membranes. *Otol Head Neck Surg* 2013 Feb;148(2):277-83 PMID: 23264116
165. **Winterstein AG**, Eworuke E, Xu D, Schuler P. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. *Pediatr Pulmonol* 2013 Sep;48(9):874-84 PMID: 23139089
166. Gerhard T*, Delaney JAC, Cooper-DeHoff RM, Shuster J, Brumback BA, Johnson JA, Pepine CJ, **Winterstein AG**. Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. *BMC Med Res Methodology* 2012 Aug;12:119 PMID: 22866767
167. **Winterstein AG**, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M. Cardiovascular safety of central nervous system stimulants in children and adolescents. *BMJ* 2012;345:e4627 PMID: 22809800 doi:[10.1136/bmj.e4627](https://doi.org/10.1136/bmj.e4627)
 - Altmetric score: 38
168. Hampp C*, Asal N, Lipowski EE, Kauf T, Kubilis P, **Winterstein AG**. Validity of Laboratory Based Surveillance to Detect Respiratory Syncytial Virus Seasons. *Am J Epidemiol* 2013 Apr 15;177(8):841-51 PMID: 23479344
169. **Winterstein AG**, Hincapie-Castillo J, Xu, D, Liu W, Antonelli PJ. Otological neomycin in children with non-intact tympanic membranes. *Laryngoscope* 2012 Nov;122(11):2529-32 PMID: 22965584
170. Eworuke E*, Hampp C, Saidi A, **Winterstein AG**. An algorithm to identify premature infants in administrative claims data. *Pharmacoeconomics Drug Saf* 2012 Jun;21:640-50 PMID: 22504840
171. Olfson M, Huang C, Gerhard T, **Winterstein AG**, Crystal S, Allison PD, Marcus SC. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psych* 2012;51:147-56. PMID:22265361
172. **Winterstein AG**, Hampp C, Saidi A. Effectiveness of palivizumab prophylaxis in infants and children in Florida. *Pharmacoeconomics Drug Saf* 2012;21:53-60. PMID:21919115
173. Kimberlin CL, Jamison AN, Linden S, **Winterstein AG**. Patient counseling practices in U.S. pharmacies. Effects of having pharmacists hand the medication to the patient and state regulations on pharmacist counseling. *J Am Pharm Assoc* 2011;51(14):527-34

174. **Winterstein AG**. Rosiglitazone and the risk of adverse cardiovascular outcomes. Point/Counterpoint in Clin Pharmacol Ther 2011;89(6):776-778
175. Guervil DJ, Rosenberg AF, **Winterstein AG**, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011;45:861-8
176. Snyder AM, Klinker K, Orrick JJ, Janelle J, **Winterstein AG**. An in-depth analysis of medication errors in hospitalized patients with HIV. Ann Pharmacother 2011;45(4):459-68
177. Hampp C*, Kauf T, Saidi A, **Winterstein AG**. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications. Arch Ped Adolesc Med 2011;165:498-505. PMID: 21300647
178. **Winterstein AG**, Linden S, Lee AE, Fernandez EM, Kimberlin CL. Evaluation of Consumer Medication Information Dispensed in Retail Pharmacies. Arch Intern Med 2010;170:1317-24 PMID: [20696955](#) doi:[10.1001/archinternmed.2010.263](#)
179. Shuster J, **Winterstein AG**, Hatton RC, Hendeles L. Reply to discussion: Empirical versus natural weighting in random effects meta-analysis. Statistics in Medicine May 2010;29:1272-1281
180. Rosenwasser R*, **Winterstein AG**, Rosenberg AF, Rosenberg EI, Antonelli PJ. Perioperative Medication Errors in Otolaryngology. Laryngoscope 2010;120:1214-1219
181. Antonelli PJ, **Winterstein AG**, Schultz GS. Topical dexamethasone and tympanic membrane perforation healing in otitis media: a short-term study. Otol Neurotol 2010;3:519-23
182. Hampp C*, Saidi A, **Winterstein AG**. Palivizumab Utilization and Compliance: Trends in Respiratory Syncytial Virus Prophylaxis in Florida. J Pediatr 2010; 156: 953-9
183. Gerhard T, **Winterstein AG**, Olfson M, Huang C, Saidi A, Crystal S. Pre-Existing Cardiovascular Conditions and Pharmacological Treatment of Adult ADHD. Pharmacopei Drug Saf 2010;19:457-65
184. He J*, Beaver T, **Winterstein AG**. Projecting the effect of nesiritide on dialysis and hospital mortality in cardiac surgery patients. Value in Health 2010;13(5):643-8
185. Ejaz AA, Martin TD, Johnson RJ, **Winterstein AG**, Klodell CT et al. Prophylactic Nesiritide Does Not Prevent Dialysis or All Cause Mortality in Patients undergoing High-Risk Cardiac Surgery. Journal of Thoracic and Cardiovascular Surgery 2009;138:959-64
186. **Winterstein AG**, Gerhard TG, Shuster J, Saidi A. Cardiac Safety of Methylphenidate versus Amphetamine Salts in the Treatment of Attention Deficit/Hyperactivity Disorder. Pediatrics;2009:e75-80
187. Chen CY*, Gerhard T, **Winterstein AG**. Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:187-95
188. Beaver TM, **Winterstein A**, Hess PJ Jr, Martin TD, Arnaoutakis GJ, Peng YG, Ejaz AA. Nesiritide following maze and mitral valve surgery. J Card Surg 2008;23(5):431-6
189. Kimberlin CL, **Winterstein AG**. Validity and reliability of measurement instruments used in research. Am J Health Syst Pharm 2008;65(23):2276-84
190. Bush SE, Hatton RC, **Winterstein AG**, Thomson MR, Woo GW. Effects of concomitant amiodarone and haloperidol on Q-Tc interval prolongation. American J Health Syst Pharm 2008;65:2232-6
191. Onyenwenyi AJ*, **Winterstein AG**, Hatton RC. An evaluation of the effects of gatifloxacin on glucose homeostatis. Pharmacy World Science 2008;30:544-549
192. Graham SD*, Hartzema AG, Sketris IS, **Winterstein A**. Effect of an Academic Detailing Intervention on the Utilization Rate of Cyclo-Oxygenase-2 Inhibitors. Ann Pharmacother 2008;42(6):749-56

193. Gerhard T*, Zineh I, Winterstein AG, **Hartzema AG**. Uncertain Economic Impact of Nesiritide in Advanced Decompensated Heart Failure. *Pharmacotherapy* 2008;28:1e-2e
194. **Winterstein AG**, Gerhard T, Shuster J, Zito JM, Johnson M, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. *Pediatrics* 2007;120(6):e1494-501
195. **Winterstein AG**, Gerhard T, Shuster J, Zito JM, Johnson M, Liu H, Saidi A. Utilization of pharmacological treatment in youths with attention-deficit/hyperactivity disorder in Florida Medicaid 1995-2004. *Ann Pharmacother* 2008;42:24-31
196. Thomsen LA*, **Winterstein AG**, Sondergaard B, Haugbolle LS, Melander A. A systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. *Ann Pharmacother* 2007;41:1411-1426
197. Hatton RC, **Winterstein AG**, McKelvey RP, Shuster J, Henderson L. Efficacy and safety of oral phenylephrine: a systematic review and meta-analysis. *Ann Pharmacother* 2007;41(3):381-90
198. Hartzema AG, **Winterstein AG**, Johns T, De Leon J, Baily W, McDonald K, Pannell R. Planning for Pharmacy Health Information technology (pHIT) in Critical Access Hospitals. *America J Health-Syst Pharm* 2007;64:315-21
199. Shuster J, **Winterstein AG**. Interrupted time series was accurate in showing improvement in medication errors. *J Clin Epidem* 2006;59:957-963
200. Beaver TM, **Winterstein AG**, Shuster JJ, Gerhard T, Martin T, Alexander JA, Johnson RJ, Ejaz A, Hartzema AG. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. *Clin Cardiol* 2006;29:18-24
201. **Winterstein AG**, Hartzema AG, Johns JE, DeLeon JM, McDonald K, Henshaw Z, Pannell R. Medication Safety Infrastructure in critical access hospitals in Florida. *American Journal of Health Systems Pharmacy* 2006; 63(5):442-450
202. Pasanen AL*, Edwards E, Annis LG, Guyer LK, **Winterstein AG**. The Influence of Age on Knowledge and Medication Usage by Persons Attending Rural North Florida Clinics. *Florida Public Health Review* 2006;3:8-15
203. Gerhard T*, Zineh I, **Winterstein AG**, Hartzema AG. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. *Pharmacother* 2006;26(1):34-43
204. **Winterstein AG**, Hartzema AG. Pharmacy-specific quality indicators for asthma therapy. *Research in Social and Administrative Pharmacy*. 2005;1:430-445
205. Smith WD*, **Winterstein AG**, Johns TE, Rosenberg EI, Sauer BC. Causes of Hyper- and Hypoglycemia in adult medical and surgical patients. *Am J Health Syst Pharm* 2005;62 714-719
206. **Winterstein AG**, Johns TE, Rosenberg EI, Hatton RC, Gonzalez-Rothi R. Nature and causes of clinically significant medication errors in hospitals: Results of a unique multidisciplinary prospective data collection method. *Am J Health Syst Pharm*. 2004 Sep 15;61(18):1908-16
207. Kanjanarat P*, **Winterstein AG**, Johns TE, Gonzalez-Rothi R, Hatton RC, Segal R, The nature of preventable adverse drug events in hospitals: a literature review. *Am J Health-Syst Pharm* 2003;60:1750-9
208. **Winterstein AG**, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. *Am J Health-Syst Pharm* 2002;59:1742-9
209. Brushwood DB, **Winterstein AG**. Manufacturer Warnings of System-Related Medication Errors. *American Journal of Health-Systems Pharmacy* 2002;59:1110-1112

210. Björkman IK, Fastbom J, Schmidt IK, Bernsten CB, Caramona M, Crealey G, Frøkjær B, Grünberger E, Gustafsson T, Henman M, Herborg H, Hughes C, McElnay JC, Magner M, van Mil F, Schaeffer S, Silva S, Søndergaard B, Sturgess I, Tromp D, Vivero L, **Winterstein A**, Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Drug-drug interactions in the elderly. *Ann Pharmacother* 2002;36(11):1675-1681
211. **Winterstein AG**, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. *Annals of Pharmacotherapy* 2002;36:1238-1248
212. Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjar B, Grundberger E, Gustafsson T, Henman M, Herborg H, Hughes C, McElnay J, Magner M, van Mil F, Schaefer M, Silva S, Sondergaard B, Sturgess I, Tromp D, Vivero L, **Winterstein A** on behalf of the Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care – a multi-center study in seven European countries. *Drugs & Aging* 2001;18(1):63-77
213. **Winterstein AG**, Jopp R, Schaefer M. Aeltere multimorbide Patienten werden in Apotheken gut betreut – Ergebnisse der OMA Studie Teil 1. [Pharmaceutical Care for elderly multimorbide patients – results of the OMA study, part 1] *Pharm Ztg* 2001;146(11): 833 - 841
214. **Winterstein AG**, Jopp R, Schaefer M. Gesundheitsbezogene Lebensqualität als wichtiges Zielkriterium [Health-related quality of life as important health outcome] *Pharm Ztg*. 2001;146 (12):936 - 942
215. **Winterstein AG**, Jopp R, Schaefer M. Patienten profitieren von der Pharmazeutischen Betreuung [Patient benefit of pharmaceutical care] *Pharm Ztg*. 2001;146 (13):1024-1033
216. Schaefer M., Bergmann KC., Schulz M., Mühlbauer K., **Müller-Jaeger A.**, Kahmen U.: Pharmazeutische Betreuung – Arzt und Apotheker auf dem Weg in die Zukunft. [Pharmaceutical Care – physician and pharmacist on their way to future], *Münch Med Wschr*. 1998; 140(23): 343-345.
217. **Müller-Jaeger A**, Pharmaceutical care – nutzbringende Innovation für die Gesundheitsversorgung, [Pharmaceutical Care: beneficial innovation in health care] *Apothekenpraxis* (1998)
218. Belgardt C, Krishnan HS, **Müller-Jaeger A**, Räuscher E. Qualität der Pharmakotherapie sichern. [Assure quality of pharmacotherapy] *Pharm Ztg*. 1997; 142(3): 152-154
219. Belgardt C, Krishnan HS, **Müller-Jaeger A**, Räuscher E. Social pharmacy goes west. *Pharm Ztg*. 1997; 142 (1/2): 38-40
220. **Müller-Jaeger A**. Erkennen wie uns andere sehen. [Recognize how others see us.] *Pharm Ztg*. 1997; 142(7): 527-531
221. Van Mil JWF, **Müller-Jaeger A**, Schaefer M, Tromp Th. Pharmazeutische Betreuung: Fortschritte und Erfahrungen in den Niederlanden. [Pharmaceutical Care: progress and experiences in the Netherlands] *Pharm Ztg*. 1997;142(25): 2543-49
222. **Müller-Jaeger A**, Schaefer M. Pharmaceutical Care in der Praxis: Startschuss für Pilotprojekt in Berlin. [Pharmaceutical Care in practice: go-ahead for a pilot project in Berlin] *Pharm Ztg*. 1996; 141(30): 2739-2748
223. Schaefer M, **Müller-Jaeger A**, Belgardt C. Berlin startet bundesweit erste Studie. [Pharmaceutical Care-Berlin starts first national study] *Pharm Ztg*. 1996; 33(141): 44-45

Letters to the Editor / Editorials / Commentaries

224. **Winterstein AG**, Rasmussen SA. Trade-offs in safety study design decisions on teratogenic gadolinium effects. *Am J Obstet Gynecol*. 2023 Aug 5:S0002-9378(23)00535-5. doi: 10.1016/j.ajog.2023.08.003. Epub ahead of print. PMID: 37544348.

225. Jugl S*, Winterstein AG. Ectopic Pregnancy Risk and Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2023 Jul 25;330(4):378. doi: [10.1001/jama.2023.8888](https://doi.org/10.1001/jama.2023.8888). PMID: [37490092](https://pubmed.ncbi.nlm.nih.gov/37490092/).
226. Albogami Y*, Cusi K, Daniels MJ, Wei YJ, **Winterstein AG**. Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352. Diabetes Care. 2021 Aug;44(8):e167. doi: [10.2337/dci21-0024](https://doi.org/10.2337/dci21-0024). Epub 2021 Jul 20. PMID: [34285101](https://pubmed.ncbi.nlm.nih.gov/34285101/)
227. Goodin AJ, Winterstein AG, Cook RC, Wang Y, Brown JD. Introducing Commentary Series: "Evidence in Context". Med Cannabis Cannabinoids. 2021 Feb 23;4(1):61-62. doi: [10.1159/000512684](https://doi.org/10.1159/000512684). PMID: [34676350](https://pubmed.ncbi.nlm.nih.gov/34676350/)
228. Sarayani A*, Jugl S, **Winterstein AG**. Letter by Sarayani et al Regarding Article, "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque". Circulation. 2021 Jun 22;143(25):e1031-e1032. doi: [10.1161/CIRCULATIONAHA.120.052678](https://doi.org/10.1161/CIRCULATIONAHA.120.052678). PMID: [34152796](https://pubmed.ncbi.nlm.nih.gov/34152796/)
229. **Winterstein AG**, Girman CJ, Pottegård A. Randomization versus Real-World Evidence. N Engl J Med. 2020 Jul 23;383(4):e21. doi: [10.1056/NEJMc2020020](https://doi.org/10.1056/NEJMc2020020). PMID: [32706549](https://pubmed.ncbi.nlm.nih.gov/32706549/)
230. Alipour Haris G, Sarayani A, **Winterstein AG**. **Letter Regarding Article, "Marijuana Use Among Young Adults (18-44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey Analysis"**. Stroke. 2020 May;51(5):e91 doi: [10.1161/STROKEAHA.120.029273](https://doi.org/10.1161/STROKEAHA.120.029273). PubMed PMID: [32252600](https://pubmed.ncbi.nlm.nih.gov/32252600/)
231. Smith SM, Winterstein AG, Pepine CJ, Cooper-DeHoff RM. **Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus: A Point of Clarification**. Hypertension 2020 Feb 3;75:e2-e5. doi: [10.1161/HYPERTENSIONAHA.119.14447](https://doi.org/10.1161/HYPERTENSIONAHA.119.14447). PubMed PMID: [32008437](https://pubmed.ncbi.nlm.nih.gov/32008437/)
232. Rhew K, Reams VZ, Brown JD, **Winterstein AG**. Commentary on: **Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence**. Ann Med. 2019 Feb;51(1):97-98. doi: [10.1080/07853890.2019.1581941](https://doi.org/10.1080/07853890.2019.1581941). PMID: [30801227](https://pubmed.ncbi.nlm.nih.gov/30801227/)
233. Sarayani A,* Winterstein AG. **Immeasurable Time Bias In Exposure to Ivacaftor**. Health Aff (Millwood). 2019 Feb;38(2):328. PMID: [30715971](https://pubmed.ncbi.nlm.nih.gov/30715971/); doi: [10.1377/hlthaff.2018.05175](https://doi.org/10.1377/hlthaff.2018.05175)
234. Hincapie-Castillo J*, Wei Y-J, **Winterstein AG**. **Clinical utility and perils of prescription drug monitoring program-based alert systems**. PAIN 2018 Apr;159(4):804-805 PMID: [29557901](https://pubmed.ncbi.nlm.nih.gov/29557901/); doi: [10.1097/j.pain.0000000000001157](https://doi.org/10.1097/j.pain.0000000000001157)
235. Meissner HC, Brady MT, Byington CL, Kimberlin DW, Liberthal AS, Maldonado YA, Ralston SL, Winterstein AG. **Re: Severe RSV Disease in Preterm Infants Born at 29 to 35 Weeks Gestation in the United States**. Pediatrics 2014 Pediatrics. 2014 Dec;134(6):e1782-3 PMID: [25452650](https://pubmed.ncbi.nlm.nih.gov/25452650/).
236. Winterstein AG, Liu W, Antonelli P. **Negative Results Do Not Imply Absence of Ototoxicity with Middle Ear Application of Neomycin**. Otol Head Neck Surg 2014 Jul;151:369 PMID: [25057051](https://pubmed.ncbi.nlm.nih.gov/25057051/)
237. Winterstein AG, Knox C, Kubilis P. **Methods to estimate gestational age can significantly affect study results-reply**. JAMA Pediatr. 2014 Apr 1;168(4):388-9. PMID: [24710586](https://pubmed.ncbi.nlm.nih.gov/24710586/)
238. Toh S, Avorn J, D'Agostino RB Sr, Gurwitz JH, Psaty BM, Rothman KJ, Saag KG, Sturkenboom MC, Vandenbroucke JP, Winterstein AG, Strom BL RE: **Drug risk assessment and data reuse**. Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):109-10 PMID: [24395550](https://pubmed.ncbi.nlm.nih.gov/24395550/)
239. Winterstein AG, Antonelli PJ. Response to Letter to the Editor Regarding **Sensorineural Hearing Loss Associated with Neomycin Eardrops and Nonintact Tympanic Membranes**. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1061-1062. PMID: [23690083](https://pubmed.ncbi.nlm.nih.gov/23690083/)

240. Hampp C,* Kauf TL, Saidi AS, Winterstein AG. **Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid-Reply.** ArchPediatr Adolesc Med. 2012 Oct 1;166(10):968-70 PMID: 23027563
241. Bussing R, Winterstein AG. **Polypharmacy in attention deficit hyperactivity disorder treatment: current status, challenges, and next steps.** Curr Psychiatry Rep 2012 Oct;14(5):447-9 PMID: 22684300
242. Winterstein AG. **Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use.** Evid Based Ment Health 2012 May;15:43 PMID: 22334580
243. Winterstein AG. **ADHD treatment – supply or demand?** Pharmcoepi Drug Saf 2012;21:450-1 PMID: 22290762
244. Winterstein AG, Heckbert S, Schambelan M. **Intensive glucose lowering and cardiovascular outcomes.** Letter to the editor. NEJM 2011;364:2263
245. Hampp C*, Kauf T, Winterstein AG. **Small Budget Impact is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis.** Value Health 2010;13(5):684
246. Hampp C*, Winterstein AG. **Response to: Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.** (letter to the editor) Southern Med J 2008;101(2):212-3
247. Winterstein AG, Vermeulen LC. A toolkit for practice-based research. (Editorial) Am J Health Sys Pharm 2008;65:1607

Book Chapters

Winterstein AG. Pharmacoepidemiology. In Andresen E, DeFries Bouldin E. Public Health Foundations – Concepts and Practices. Jossey-Bass, San Francisco, CA, 2010. Pages 161-176

Weiner ID, Winterstein AG. Drug-induced Nephrotoxicity, in Hartzema AG, Tilson H, Chan A. Pharmacoepidemiology – An Introduction. 4th edition. Harvey Whitney Publishing, Cincinnati, OH 2008, 907-932

Winterstein AG, Pharmakooekonomie [Pharmaco-economics] (chapter 7), in Weinzierl S (ed.) Praxis der Arzneimittelinformation [Practice of Drug Information], Govi Verlag, Eschborn, 2002 201-227

Doctoral Thesis

Winterstein AG, **Basics and methods of outcomes evaluation in Pharmaceutical Care – an experimental study to improve drug therapy outcomes in an elderly multimorbid population.** Dissertation, Humboldt University Berlin, 1999

- magna cum laude

Reports

Consortium for Medical Marijuana Clinical Outcomes Research. **Annual report 2022.** February 2022 (72 pages)

Consortium for Medical Marijuana Clinical Outcomes Research. **Annual report 2021.** February 2022 (63 pages)

Winterstein AG, Thai T, Nduaguba S, Smolinski N, Rasmussen S. **Safety of gadolinium-enhanced MRI exposure during pregnancy on adverse fetal outcomes.** Research report to the Food and Drug Administration. April 2021. (53 pages)

Consortium for Medical Marijuana Clinical Outcomes Research. **Annual report 2020.** February 2021 (52 pages)

Consortium for Medical Marijuana Clinical Outcomes Research. **Annual report 2019.** February 2020 (44 pages)

Winterstein AG, Liu X, Jean N, Hall MC, Keenan M, McKay P, Staley B, Smuk K, Stanback B, Turner K, Wright S, Yang T-H, Bussing R, Campbell C. **Medication reconciliation on admission, Version 1.1** – Methodology and testing report to the Centers for Medicare and Medicaid Services. July 2017 (54 pages)

Winterstein AG, Bussing R, Keenan M, Pace K, Turner K, Xu D, Yang T-H, Zambrano D, Campbell K. **Inpatient psychiatric facility all-cause unplanned readmission measure. Version 1.0.** Technical report to the Centers for Medicare and Medicaid Services. December 2015 (58 pages)

Winterstein AG, Liu X, Hincapie-Castillo J, Bussing R. **Psychotropic polypharmacy in Florida Medicaid.** Report to the Agency for Healthcare Administration, 2015 (39 pages)

Winterstein AG, Kubilis P. **Age-related effects of RSV risk in children with chronic lung disease.** Report to the Agency for Healthcare Administration, 2015 (10 pages)

Winterstein AG, Zhu Y, Li Y, Liu W. **ADD/ADHD treatment patterns in adult Medicaid beneficiaries.** Report to the Agency for Healthcare Administration, 2015 (56 pages)

Winterstein AG, Delaney JA, Kubilis P, Crystal S, Gerhard T. **Imbalanced confounder associations between exposure versus outcome can compromise propensity score-based adjustments – examination of a real-life example in pediatric psychopharmacology** Report to the Agency for Healthcare Research and Quality (AHRQ) DEcIDE Network, 2013 (31 pages)

Mini-Sentinel Data Reuse Committee. **Re-use of mini-sentinel data following rapid assessments of potential safety signals using customizable modular programs.** Mini-Sentinel Coordinating Center. November 30, 2012 (16 pages)

Winterstein AG, Oda E, Xu D, Schuler P. **Risk of Respiratory Syncytial Virus (RSV) Infections and Effects on Disease Prognosis in Children with Cystic Fibrosis.** Report to the Agency for Healthcare Administration, Division of Medicaid. June 2011 (75 pages)

Winterstein AG, Hampp C, Kubilis PS. **Effectiveness of palivizumab in older premature infants.** Report to the Agency for Healthcare Administration, Division of Medicaid. June 2010 (15 pages)

Hampp C*, Winterstein AG. **Utility of current surveillance systems to detect respiratory Syncytial virus seasons and implications for Immunoprophylaxis.** Report to the Agency for Healthcare Administration, Division of Medicaid. June 2010 (92 pages)

Hampp C*, Winterstein AG. **RSV Seasonality and Numbers Needed to Treat with Palivizumab in Florida Medicaid.** Report to the Agency for Healthcare Administration, Division of Medicaid. March 2009 (11 Pages)

Kimberlin C, Winterstein AG. **Expert and Consumer Evaluation of Consumer Medication Information – 2008.** Report to the Center for Drug Evaluation and Research at the Food and Drug Information. February 2008 (32 pages)

Winterstein AG, Saidi A, Hampp C. **Palivizumab utilization, effectiveness and cost among Florida Medicaid recipients.** Report to the Agency for Healthcare Administration, Division of Medicaid. July 2008 (84 pages)

Winterstein AG, Gerhard T, Shuster J, Saidi A. **Utilization and Safety of Central Nervous System Stimulants in Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Florida Medicaid Beneficiaries 1995-2004.** Report to the Agency for Healthcare Administration, Division of Medicaid. 2006 (29 pages)

Frank R, Segal R, Winterstein AG, Hartzema AG, Chorba L. **Evaluation of the DiabetikSmart Program – clinical effectiveness of phase II.** Report to the Agency for Healthcare Administration, Division of Medicaid. 2006 (30 pages)

Frank R, Segal R, Hartzema AG, Winterstein AG, Taylor MD, Snedecor S, Chorba L. **Evaluation of the DiabetikSmart Program – Clinical effectiveness and projection of long-term cost savings.** Report to the Agency for Healthcare Administration, Division of Medicaid. 2005 (87 pages)

Winterstein AG, Taylor MD, Hartzema AG, Segal R. **The economic impact of glycemic control measured by glycosylated hemoglobin – a systematic review of diabetes outcomes studies.** Report to the Agency for Healthcare Administration, Division of Medicaid. 2004 (31 pages)

Nationally endorsed performance measures (developed and validated for the Centers for Medicare and Medicaid Services in collaboration with Health Services Advisory Group)

NQF 3313 Medication reconciliation on admission to inpatient psychiatric facilities

NQF 3205 Medication continuation following inpatient psychiatric discharge

NQF 2860 Thirty-day all-cause unplanned readmission following psychiatric hospitalization in an inpatient psychiatric facility

NQF 1879 Adherence to Antipsychotic Medications for Individuals with Schizophrenia

NQF 1880 Adherence to Mood Stabilizers for Individuals with Bipolar Disorder

NQF 0543 Adherence to Statin Therapy for Individuals with Coronary Artery Disease

NQF 0545 Adherence to Statins for Individuals with Diabetes Mellitus

NQF 0555 Lack of monthly INR monitoring for Individuals on Warfarin

NQF 0556 INR for Individuals Taking Warfarin and Interacting Anti-infective Medications

NQF 2362 Glycemic control – Hyperglycemia

NQF 2363 Glycemic control – Hypoglycemia

NQF 2379 Adherence to antiplatelet therapy after stent implementation

NQF 2468 Adherence to oral diabetes agents for individuals with diabetes mellitus

NQF 2732 INR monitoring for individuals on warfarin after hospital discharge

Presentations

National and International Invited Presentations

1. Building research and training capacity in postmarketing evaluation of drugs and policy. University of Arkansas Medical Sciences, Little Rock, AR. October 13, 2023
2. Measuring contraceptive failure in real-world data. Workshop on streamlining development of contraceptive products with exposure bracketing. Bill and Melinda Gates Foundation, December 5-6, 2023, Washington, DC

3. Why design trumps analysis – pharmacoepidemiology in the era of big data and AI. 11th BPE Festival, Bordeaux, France, May 24-26, 2023
4. Introduction of RWD and RWE and advancing utilization of RWD and RWE in clinical pharmacology and translational research – academia perspective. ASCPT Preconference on Advancing the utilization of RWD and RWE in clinical pharmacology and translational research. ASCPT Annual Meeting, Atlanta, GA, March 21, 2023.
5. The role of time in bias and what to do about it: pharmacoepidemiologic case studies in medications & pregnancy. University of Illinois in Chicago Center for Pharmacoepidemiology and Pharmacoeconomic Research Health Outcomes Seminar Series, April 21, 2022
6. RCT versus RWE: Good versus Evil or Yin and Yang? 67th Biometric Colloquium. International Biometrics Society. Münster, Germany and converted to a Virtual Meeting due to COVID-19. March 14-17, 2021
7. The art and science of risk evaluation and mitigation – FDA’s REMS program. Division of Pharmaceutical Outcomes and Policy Research Seminar, University of North Carolina at Chapel Hill, September 16, 2020
8. Bolstering your impact. Lecture in short course “The pharmacoepidemiologist toolbox to professional empowerment” presented at the 35th International Conference of Pharmacoepidemiology. Virtual Conference, starting September 16th, 2020
9. Comparative Effectiveness of Risk Mitigation Strategies for Prescription Drugs – evidence gaps, public health impact and lessons learned from patient safety and implementation science. FDA CACSE seminar. Silver Spring, MD. December 12, 2019
10. Opportunities and limitations of EHR data for use in pharmacoepidemiologic studies – alternatives or supplements to claims data. Lecture in advanced pharmacoepidemiology course: EHR data for pharmacoepidemiologic research: successful applications and lessons learned. ISPE’s 12th Asian Conference on Pharmacoepidemiology. Kyoto, Japan. October 11-13, 2019
11. Data science and pharmacoepidemiology in RWE: what can we learn from each other and where must we differ? Symposium at the 12th Asian Conference on Pharmacoepidemiology. Kyoto, Japan. October 11-13, 2019
12. Marrying laboratory and data science to evaluate otic quinolone safety. 12th Global Gator Symposium on New Developments in Clinical Pharmacy and Clinical Pharmacology. Reims, France, Germany, June 28, 2019
13. Prioritizing patients for pharmacist intervention: development and implementation of automated electronic health record-based prediction models for adverse drug events. (co-presented with Ben Staley) American Society of Health-System Pharmacists Summer Meetings, Informatics Institute, Denver, CO, June 5, 2018
14. Effective research grant writing. Short course at the International Conference of Pharmacoepidemiology. Montreal, CA, August 26-30, 2017; Prague, Czech Republic, August 22-26, 2018, Philadelphia, August 24-28, 2019
15. Risk evaluation and mitigation approaches of marketed drugs. Friday Talk – Pharma MBA Program. Goethe University, Frankfurt, June 23, 2017
16. Development and implementation of an EHR-based real-time prediction model for drug-induced hypoglycemia in hospitalized patients. 11th Global Gator Symposium on New Developments in Clinical Pharmacy and Clinical Pharmacology. Düsseldorf, Germany, June 17, 2017

17. Forschungsansätze in der Arzneimittelsicherheit – sind randomisierte Studien genug? [Research approaches in drug safety – are randomized studies sufficient?] Goethe University Frankfurt, July 21, 2016.
18. Cohort Study Design. Lecture in short course “Introduction to Pharmacoepidemiology” at the International Conference of Pharmacoepidemiology. Virtual August 2021, April 14, 2021, Sep 16, 2020, August 23, 2019, Philadelphia, USA; April 7, 2019, Rome, Italy; August 22, Prague, Czech Republic; April 21, 2018, Toronto, Canada; August 26, 2017 Montreal, CA; April 1, 2017 London, UK; August 25, 2016. Dublin, Ireland; April 10, 2016. Baltimore, USA; August 23, 2015. Boston, USA; October 24, 2014. Taipei, Taiwan; April 11, 2013. Munich, Germany; April 21, 2012. Miami, FL; April 9, 2011. Florence, Italy
19. Data linkages to obtain information on driving conditions in a study evaluating exposure to ADHD medications and motor-vehicle accidents. FDA Public Workshop on Methodological considerations to address unmeasured health factors in pharmacoepidemiology studies that rely on electronic healthcare databases to evaluate the safety of regulated pharmaceutical products in the post-approval setting, May 4, 2015, Silver Spring, MD
20. Under the magnifying glass: what do we really know about rural healthcare? 48th ASHP Midyear Clinical Meeting. December 8-12, 2013, Orlando, USA
21. Cardiac safety of central nervous system stimulants in children with ADHD. 4th World Congress on ADHD, June 6-9, 2013. Milan, Italy
22. Methodological challenges in a study on cardiac risk of central nervous system stimulants. Research seminar at the Department for Pharmaceutical Health Services Research at the University of Maryland, Baltimore. March 4, 2013.
23. CMS Medication Measures Special Innovation Project: Glycemic Control Measure. Joint presentation with Kyle Campbell, FMQAI via Webinar to the Federal Interagency Work Group on Glycemic Control. January 29, 2013
24. Cardiovascular safety of central nervous system stimulants in children and adolescents: a population-based cohort study. Plenary session at the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain
25. Avoiding Adverse Medication Events. Centers for Medicare and Medicaid Grand Rounds. Jointly presented with Drs. Kyle Campbell and Dan Budnitz. April 26, 2012. Baltimore, MD
26. What does pharmacy do in pharmacoepidemiology? Clinical and Translational Research and Education Meeting, Washington DC, April 5-7, 2010. Clin Trans Science 2010;3:S1
27. Developing a rigorous MUE program: applying the principles of descriptive research. (with Erstad BL, Wall GC, Coley KC, Miller MJ). 44th ASHP Midyear Clinical Meeting. Las Vegas, NV; December 6-10, 2009.
28. Cardiac risk of stimulants. 2nd International Congress on ADHD. May 21-24, 2009, Vienna
29. Expert and Consumer Evaluations of Written Consumer Medication Information. 2008 Final Report. Joint Meeting of the FDA Risk Communication and the Drug Safety and Risk Management Advisory Committee. February 26-27, 2009, Washington, DC
30. Applying Analytical Research Principles in Medication-Use Evaluation - Cohort Study Design and Confounding. 43rd ASHP Midyear Clinical Meeting, December 7-11, 2008, Orlando, FL
31. Applying Analytical Research Principles in Medication-Use Evaluation - Data Analysis. 43rd ASHP Midyear Clinical Meeting, December 7-11, 2008, Orlando, FL

32. Expert and Consumer Evaluations of Written Consumer Medication Information. FDA Scientific Rounds. November 5, 2008, Silver Springs, MD
33. Analyzing your data – didactic review of analytical strategies. American Society of Health-System Pharmacists (ASHP) 2007 Midyear Clinical Meeting. December 2-6, 2007, Las Vegas, NV.
34. Epidemiologic methods. American Society of Health-System Pharmacists (ASHP) 2007 Midyear Clinical Meeting. December 2-6, 2007, Las Vegas, NV.
35. The economic impact of preventable drug-related morbidity. Pharmaceutical Care Network Europe 5th Working Conference. February 21-24, 2007. Gothenburg, Sweden
36. Approaches to the economic evaluation of pharmaceutical care services. Workshop (co-chair Dr. Birthe Sondergaard) at the Pharmaceutical Care Network Europe 5th Working Conference. February 21-24, 2007. Gothenburg, Sweden
37. Making sense of research findings: data manipulation and presentation. American Society of Health System Pharmacists (ASHP) 2006 Midyear Clinical Meeting and Exhibition. December 3-7, 2006. Anaheim, CA
38. Making sense of research findings: Data manipulation and presentation. Lecture at the 40th Midyear Clinical Meeting of the American Society of Health Systems Pharmacist. December 4-8, 2005. Las Vegas.
39. Medication Safety at the University of Florida teaching hospitals: systematic use of data to guide quality improvement. Secumed - German network unit-dose 3rd German Unit-Dose Symposium, May 5-6, 2006. Neuss, Germany
40. Relationship between glycemic control and the incidence of diabetes-related complications in Florida Medicaid recipients. The 2005 National Medicaid Summit, Park City, Utah, September 29 - October 1, 2005
41. Evaluation of secondary stroke prevention with ACE-Inhibitors. 65th International Congress of The International Pharmaceutical federation (FIP). Cairo, Egypt, September 2-8, 2005
42. Epidemiology of Medication Errors. 33rd European Symposium in Clinical Pharmacy. European Society of Clinical Pharmacy. October 20-23, 2004. Prague, Czech Republic.
43. The added value of pharmaceutical services. ISA Press conference, May 26, 2003 Berlin, Germany
44. Pharmacoeconomic evaluations of medications and medication use. Bavarian Pharmaceutical Association Clinical Pharmacy Congress May 2002, Munich (podium presentation and workshop chair)
45. Screening tools for medication errors in hospitals. Joint Annual Meeting of the Association for Applied Human Pharmacology and the American College of Clinical Pharmacology. January 2002, Garmisch-Partenkirchen, Germany
46. Detection and prevention of adverse drug events through pharmaceutical care. 40-hour short course at the Central University of Venezuela, Caracas, Venezuela, November 2001
47. Translating evidence into practice, 60th Congress of the International Pharmaceutical Federation, Vienna, August 2000 (workshop chair)
48. How to think about quality of life as a clinical measure? American Pharmaceutical Association, Advanced Practice Institute 2000, Gainesville, USA, July 2000

49. How to think about quality of life as a clinical measure? Lecture at the American Pharmaceutical Association, Advanced Practice Institute, Gainesville, USA. July 1999
50. Assessing drug-related problems from the patient's perspective. Workshop chair (with JWF van Mil) at the 1st International Working Conference on Outcome Measurement in Pharmaceutical Care, PCNE (Pharmaceutical Care Network Europe), January 1999. Hillerod, Denmark
51. Pharmaceutical Care for hypertensive patients with regard to psychological aspects of enhancing patient compliance. Lecture and workshop at the 3rd National Pharmaceutical Care Symposium, November 1998. Berlin, Germany
52. Pharmaceutical care for hypertensive patients. Lecture at the 5th International Management Congress for Pharmacies, November 1998, Tenerife, Canaries Islands
53. Managing Pharmaceutical care and pharmacists' intervention. Workshop chair at the 58th World Conference of the International Federation of Pharmacists, Continuing Professional Development, September 1998, The Hague, The Netherlands
54. Pharmaceutical Care for multimorbid elder patients – the OMA-study. Lecture at the „Berliner Ärztekongress“ (congress of general physicians), May 1998, Berlin, Germany
55. Pharmaceutical Care for hypertensive patients. Lecture at the Annual Congress of the National Pharmacy Association, January 1998, Davos, Switzerland.
56. Pharmaceutical Care and drug-related morbidity for elderly patients. Lecture at the 2nd National Pharmaceutical Care Symposium, November 1997, Frankfurt, Germany
57. Elements and methods of Pharmaceutical Care. Lecture at the Congress of the National Pharmacy Association, September 1997, Westerland, Germany
58. Introduction into Pharmaceutical Care. Lecture at the Symposium of the German Pharmaceutical Society, October 1996, Berlin, Germany
59. Patient recruitment and work with study pharmacists in a Pharmaceutical Care study for elderly patients. Lecture at the Interpharm congress, Symposium of the German Pharmaceutical Society, October 1996, Leipzig, Germany

Local invited presentations

60. The Consortium for Medical Marijuana Clinical Outcomes Research – Research Progress Update 2023. Healthcare Regulations Subcommittee, Florida House of Representatives, December 13, 2023. Tallahassee, FL
61. How do we know that drugs are safe? – Accelerating evidence on medication safety. ASEMFL Annual Meeting, November 4th, 2023, Orlando, FL
62. Efficacy & Effectiveness of cannabis & cannabinoids in qualified conditions – A status update. Florida Medical Association Council on Medical Education, Science & Public Health, May 9th, 2022 (virtual)
63. Drugs and vaccines are safe – or are they. Distinguished Professor Lecture Series – UF Faculty Senate, January 20, 2022, Gainesville, FL
64. The Consortium for Medical Marijuana Clinical Outcomes Research. House of Representatives Professions and Public Health Subcommittee. Tallahassee, FL, November 3, 2021.

65. Prediction & evaluation of drug effects: : opportunities and limitations of AI. Learning Health System and AI Symposium. UF Clinical Translational Science Institute. Virtual, February 12, 2021.
66. Toward closing the medical marijuana research gap. UF Eye Opener Discoverer Breakfast. Gainesville, FL, March 11, 2020
67. Data science and pharmacoepidemiologic methods in RWE: what can we learn from each other and where must we differ? 2020 Pharmaceutical Outcomes and Policy Annual Seminar: Real-world evidence: Can it be used in the real world. Gainesville, Florida, March 7-8, 2020
68. Strengths and challenges of pharmacoepidemiology in evaluating real-world outcomes. University of Florida, Lake Nona Leadership Council Meeting, March 19-20, 2018
69. Medical Marijuana. Psychiatry Grand Rounds. University of Florida. Gainesville, FL. January 27, 2017
70. Regulatory and clinical context of off label prescribing and psychotropic polypharmacy. Florida Medicaid Drug Therapy Management Program for Behavioral Health: Integration, Collaboration, and Improved Outcomes: Expanding the Pharmacist's Role. University of South Florida. Tampa, May 21, 2016
71. Appropriateness of age thresholds for RSV prophylaxis in premature infants with chronic lung disease. UF Research Colloquium. Agency for Healthcare Administration, Tallahassee, FL, May 28, 2015
72. The face of quality: Medication Errors. FMQAI Engaging Partnerships for Patients Florida Summit. Orlando, FL, July 21, 2011
73. Epidemiology of respiratory syncytial virus. Florida Medicaid Drug Utilization Board. Tampa, FL, February 12, 2011
74. Utilization, effectiveness and cost-effectiveness of palivizumab in Florida Medicaid. Annual Florida Medicaid Research Conference. University of Florida Center for Medicaid Issues and the Uninsured. Tallahassee, FL. September 16, 2010
75. Medication errors. Pharmacy Law and Management Conference. August 29-30, 2009. Orlando, FL
76. Written drug information for patients. Pharmacy Law and Management Conference. August 29-30, 2009. Orlando, FL
77. Epidemiology of medication errors. Florida Society for Health-System Pharmacists. October 17, 2006. Gainesville, FL
78. Blood glucose management in acute and critical care. Florida Society of Health-System Pharmacy 40th Annual Meeting. August 4-6, 2006, Orlando, FL
79. Evidence-based Quality Improvement. National Advisory Board Meeting, College of Pharmacy at the University of Florida, April 21, 2006. Gainesville, Florida
80. Medication Error and Decision Support Systems. Florida Society of Hospital Pharmacy First Health Information Technology Conference. March 18, 2006. Orlando, FL
81. Quality Improvement at Shands at UF. University of Florida, College of Pharmacy, Pharmacy Practice Seminar. February 9, 2006. Gainesville, FL
82. Evidence-based Quality Improvement. Lecture to UF&Shands clinical practice committee members and QA staff, April 2005, Gainesville, FL

83. Cost-effectiveness of Disease Management Programs for Medicaid Diabetes Type II Patients. 4th Annual Florida Medicaid Research Conference. University of Florida Center for Medicaid Issues and the Uninsured. Tallahassee, FL. March 11, 2005.
84. The epidemiology of medication errors. 39th Annual Meeting of the Florida Society of Health Systems Pharmacists, Kissimmee, FL, August 5-7, 2005. *Adverse Drug Events and Medication Errors in the Elderly, Lecture for the Department of Anesthesiology, College of Medicine, University of Florida, January 2003
85. Investment in Health Information Infrastructure: Pharmacy and Pharmacists. Governor's Health Information Infrastructure Advisory Board Workshop. November 19, 2004. Orlando, FL.
86. Medication Errors. Florida Society of Health Systems Pharmacy - North Central Florida Section Continuous Education program. October 27, 2004. Gainesville, FL.
87. Epidemiology of medication errors and preventable adverse drug events: introduction of a study in acute care. Seminar Series of the Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy at the University of Florida. December 2001
88. Prevalence, nature and etiology of medication errors. Invited presentation, Medical Grand Rounds, College of Medicine at the University of Florida; May 2001

Peer-reviewed Abstracts & Symposia

* identifies trainee (including work within career awards, e.g., NIH K awardees)
identifies senior author

89. **Winterstein AG**, Wang Y, Smolinski NE, Thai TN, Ewig C, Rasmussen S. No time to lose: Prenatal exposure to teratogenic medications and new abortion laws in the United States. Society for Birth Defects Research 63rd Annual Meeting, Charleston, SC. June 23-28, 2023. Birth Defects Research. 2023;115(8):856.
 - Finalist for innovator award
90. Wang Y*, Smolinski NE, Ewig C, Thai TN, **Winterstein AG**. Utilization of antihypertensives before, during, and after pregnancy. Society for Birth Defects Research 63rd Annual Meeting, Charleston, SC. June 23-28, 2023. Birth Defects Research. 2023;115(8):858.
91. Thai TN*, Maro JC, Brown J, Schmidt S, Rasmussen SA, **Winterstein AG**. In utero antiemetic combination during the first trimester and adverse circulatory outcomes: A signal identification analysis. Society for Birth Defects Research 63rd Annual Meeting, Charleston, SC. June 23-28, 2023. Birth Defects Research. 2023;115(8):868.
92. Ewig C*, Muschett M, Smolinski NE, Thai TN, Rasmussen SA, **Winterstein A**. Secular Trends and Determinants of Hepatitis C Virus Testing during Pregnancy. Society for Birth Defects Research 63rd Annual Meeting, Charleston, SC. June 23-28, 2023. Birth Defects Research. 2023;115(8):873.
93. Smolinski NE*, Sarayani A, Thai TN, Jugl S, Ewig C, **Winterstein AG**. Prenatal exposure to valproic acid in the United States. Society for Birth Defects Research 63rd Annual Meeting, Charleston, SC. June 23-28, 2023. Birth Defects Research. 2023;115(8):880.

94. Smolinski NE*, **Winterstein AG**, Antonelli PJ. Measurement of acute otitis media complications and recurrence in observational studies. 22nd International Symposium on Recent Advances in Otitis Media, Milwaukee, WI. June 21-23, 2023. (featured poster)
95. Osborne V, Layton D, Goodin A, **Winterstein A**, Bate A, Cohet C, Kurz X, Pont L, Money D, Klungel O, Pinheiro S, Seeger J, Chan KA, Edlavitch S, Tilson H, Brown J. Shaping the Future of Pharmacoepidemiology. Symposium at the 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark.
96. **Winterstein A**, Ehrenstein V, Brown J, Stürmer T, Smith M. How can we mitigate publication of poorly conducted RWE studies? Hot topic session at the 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark.
97. Vouri S*, Wang G, Morris E, Solberg L, Daniels M, Pepine C, Mannini T, Malone D, **Winterstein A**. Evaluation of fall-related injuries following a potential calcium channel blocker – loop diuretic prescribing cascade. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):12-13
98. Thai T*, Brown J, Schmidt S, Maro J, Rasmussen S, **Winterstein A**. Evaluating the safety of antiemetic combination use on pregnancy loss. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):19 (podium presentation)
99. Sarayani A*, Hampf C, Donahoo WT, Brown J, **Winterstein A**. Association between phentermine and risk of major adverse cardiovascular events: A suite of self-controlled and comparative cohort studies to conquer confounding. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):65 (podium presentation)
100. Sarayani A*, Brown J, Hampf C, Donahoo WT, **Winterstein A**. Adaptability of high dimensional propensity score procedure in the transition from ICD-9 to ICD-10 in the US healthcare system. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):86 (podium presentation)
101. Sarayani A*, Cicali B, Schmidt S, Brown J, **Winterstein A**. A translational approach to study drug-drug interaction with hormonal contraceptives: From Pharmacoepidemiology to mechanistic modeling. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):108 (podium presentation)
102. Smolinski N*, Wang Y, Thai T, Sarayani A, Ewig C, Rasmussen S, **Winterstein A**. Prenatal exposure to teratogenic drugs: Contrasts between publicly and privately insured persons. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):148
103. Wang Y*, Smolinski N, Thai T, Sarayani A, Ewig C, Rasmussen S, **Winterstein A**. Targets for quality improvement? Top 10 teratogenic drugs used during pregnancy in the US. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):150
104. Aydogan TMI*, Smolinski N, Thai T, Jugl S, Sarayani A, Ewig C, **Winterstein A**. A comprehensive review on the teratogenic risks for twelve drugs with risk evaluation and mitigation strategy (REMS) to prevent prenatal exposure. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):151

105. Wang Y*, Brown J, Cavallari L, **Winterstein A**. Initial choice and switching of P2Y12 inhibitors among patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):170
106. Guo SJ, Li Y, Bian J, Lackland DT, Kimmel S, Schatz DA, **Winterstein A**. Differences in heart failure hospitalization risk following initiating SGLT2 inhibitors versus DPP4 inhibitors across race/ethnicity and rural/urban areas. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):196
107. Thai T*, **Winterstein A**, Suarez E, Stojanovic D, Liedtka J, Anderson AF, Zhang D, Zhao Y, Munoz M, Liu W, Dashevsky I, Menzin T, Messenger-Jones E, Siranosian E, Maro J. Design considerations for using the tree-based scan statistic in surveillance of maternal outcomes following medication use during pregnancy. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):252
108. Ewig C*, Smolinski N, Wang Y, Thai T, Sarayani A, Jugl S, Rasmussen S, **Winterstein A**. Utilization of biologics before, during and after pregnancy among patients with autoimmune conditions. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):263
109. Vouri SM, Wang G, Morris E, Solberg L, Daniels M, Pepine C, Mannini T, Malone D, **Winterstein A**. Evaluation of downstream use of medication treatment for overactive bladder following potential calcium channel blocker—Loop diuretic prescribing cascade. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):380
110. Ndai AM, Morris E, **Winterstein A**, Vouri SM. Evaluating provider and pharmacy discordance in potential calcium channel blocker—Loop diuretic prescribing cascades. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):389
111. **Winterstein A**, Tran P, Nduaguba SO, Shih R. Incidence of RSV lower respiratory tract infections among infants considering effects of palivizumab immunoprophylaxis. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):413-414
112. Morris E, Wang C-Y, Antonelli J, **Winterstein A**, Hallas J, Vouri JM. Use of a rate-based sequence symmetry analysis to assess recurring adverse drug events. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):528-529
113. Vouri SM, Tran P, Deravi M, Grieser E, **Winterstein A**. An epidemiological evaluation of topical ophthalmologic prescriptions across age spectrums using US claims database: 2005 to 2019. 38th International Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):445-446
114. Osborne V, Layton D, Goodin A, **Winterstein A**, Bate A, Cohet C, Kurz X, Pont L, Money D, Klungel OH, Pinheiro S, Seeger J, Chan KA, Brown J. Updated core competencies in Pharmacoepidemiology to inform contemporary curricula and training for academia, government, and industry. 38th International

Conference on Pharmacoepidemiology, August 26–28, 2022, Copenhagen, Denmark. *Pharmacoepidem Drug Saf*; 2022;31(Suppl. 2):564-656

115. Nduaguba SO*, Tran PT, **Winterstein AG**. Correction of Diagnostic Coding-based RSV Incidence using NREVSS Data. Society for Epidemiologic Research Conference. June 14-17, 2022. https://epiresearch.org/abstract-search/?abst_id=130023
116. Thai T*, Smolinski NE, Nduaguba S, Zhu Y, Straub L, Bateman BT, Hernandez-Diaz S, Huybrechts KF, Rasmussen SA, **Winterstein AG**. Development and validation of an algorithm to predict stillbirth gestational age in Medicaid billing records. Society for Epidemiologic Research Conference. June 14-17, 2022. https://epiresearch.org/abstract-search/?abst_id=132300
117. Tran P*, Daniels M, Happe LE, Goodin AJ, **Winterstein AG**. Correction for Unmeasured Confounding Using a Negative Control Outcome: a Case Study of Oral Quinolones and Tendon Rupture Society for Epidemiologic Research Conference. June 14-17, 2022. https://epiresearch.org/abstract-search/?abst_id=127974
118. Vouri SM, Morris E, Wang H, Jiao T, Solberg L, Pepine C, Daniels M, Manini T, Malone D, **Winterstein A**. Quantifying Incidence and Risk of Excessive Loop Diuretic Use relative to Dihydropyridine Calcium Channel Blocker Dose: a Prescribing Cascade Evaluation. American Geriatrics Society Annual Meeting 2022 – Orlando, FL (Presidential Poster Session)
119. Djabali EJ, Smolinski NE, Al-Bahou J, Pomputius A, Antonelli PJ, **Winterstein AG**. Antibiotic Treatment for Pediatric Acute Otitis Media and the Prevention of Serious Complications: A Meta-analysis. *Pediatrics*. 2022;149(1 Meeting Abstracts February 2022):143.
120. Wei Y-J, **Winterstein AG**. Uncontrolled pain and risk for depression and behavioral symptoms in patients with dementia. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. *Pharmacoepidem Drug Saf* 2021;30(S1):20 (podium presentation)
121. Nduaguba S*, Tran P, Diaby V, Choi YY, **Winterstein A**. Seasonal respiratory syncytial virus medically-attended reinfections among infants and young children. Presented at the 39th Annual Meeting, Online Meeting and Hosted from Geneva, May 24-29, 2021.
122. Tran P*, Nduaguba S, Diaby V, Choi YY, **Winterstein AG**. Evaluation of RSV testing practice and positivity by patient demographics in the United State. Presented at the 39th Annual Meeting, Online Meeting and Hosted from Geneva, May 24-29, 2021.
123. Sarayani A*, Brown JD, Schmidt S, **Winterstein AG**. Real-World Evidence on Potential Drug-Drug Interaction Between Topiramate and Oral Hormonal Contraceptives Among Patients with Migraines. *Clinical Pharmacology in Drug Development* 2021;10(S1):28–29 (ACCP Annual Meeting 2021/poster and podium)
 - Received ACCP Student and Trainee Abstract award
124. Sarayani A*, Brown JD, Schmidt S, **Winterstein AG**. Effective prevention of prenatal exposure to topiramate in the presence of potential drug-drug interactions with oral hormonal contraceptives: insight from a real-world retrospective cohort study. *Pharmacoepidemiology and Drug Safety* 2021;30(Suppl. 1):407–408 (ISPE Midyear 2021/podium)
125. Sarayani A*, Brown JD, Goodin AJ, Cicali B, Henriksen C, Schmidt S, **Winterstein AG**. Effect of enzyme-inducing antiepileptic drugs on failure of oral low-dose hormonal contraceptives. *Pharmacoepidemiology and Drug Safety* 2020;29(Suppl 3):638 (poster – accepted as a podium for ISPE Midyear 2020)

130. Sarayani A*, Donahoo WT, Hampf C, Brown JD, **Winterstein AG**. Regulatory approval of phentermine/topiramate for obesity management and off label use of topiramate: a fairytale for drug repurposing and a maze for risk mitigation. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):34-35 (podium presentation)
131. Zhu Y, Thai T, Hernandez-Diaz S, Bateman BT, Straub L, Gray K, **Winterstein AG**, Taylor LG, Quillet-Hellstrom RP, Ma Y, Qiang Y, Hua W, Huybrechts KF. Balance of unmeasured covariates after propensity score matching based on measurable covariates in perinatal pharmacoepidemiologic studies. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):59-60 (podium presentation)
132. Thai T*, Nduaguba S, Smolinski NE, Wang X, Sahin L, Gelperin K, Bird ST, Kreftin I, Rasmussen S, **Winterstein AG**. Effects of gadolinium-enhanced MRI exposure during pregnancy on neonatal intensive care unit admission. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):63-64 (podium presentation)
133. Thai T*, Rasmussen SA, Smolinski NE, Nduaguba S, Zhu Y, Bateman BT, Huybrechts KF, Hernandez-Diaz S, **Winterstein AG**. Implication of maternal continuous enrollment on stillbirth gestational age distributions and maternal characteristics in Medicaid enrollees. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):66-67 (podium presentation)
134. Zhu Y, Thai T, Bateman BT, Hernandez-Diaz S, Straub L, Franklin J, Gray K, **Winterstein AG**, Taylor LG, Ouellet-Hellstrom RP, Ma Y, Qiang Y, Hua W, Huybrechts KF. Validating an optimized live birth gestational age algorithm in a nationwide Medicaid sample and quantifying the misclassification of exposure due to estimated gestational age. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):69 (podium presentation)
135. Smolinski NE*, Sarayani A, **Winterstein AG**. Gender differences in valproic acid use for approved indications in the United States (2017-2018) – an opportunity for risk mitigation? 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):113-114 (podium presentation)
136. Song HY, Blake K, Wilson DL, **Winterstein AG**, Park H. Assessment of health-related quality of life in adults with asthma by asthma severity. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):146-147
137. Albogami Y, **Winterstein AG**. Misclassification of obesity in claims data – Are assumptions about non-differential misclassification warranted? 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):146-147. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):274
138. Tang H, Kimmel S, Hernandez I, Magnani JW, Brooks MM, **Winterstein AG**, Guo J. Novel glucose-lowering agents and cardiorenal benefits: Absence of racial/ethnic diversity in clinical trials. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. Pharmacoepidem Drug Saf 2021;30(S1):281

139. Sarayani A*, **Winterstein AG**, Cicali B, Schmidt S, Brown JD. Oral contraceptive failures in the presence of a drug-drug interaction – does progestin type matter? 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. *Pharmacoepidem Drug Saf* 2021;30(S1):286
 - Drug-drug interaction special interest group spotlight poster award
140. Sarayani A*, Albogami Y, Wang X, Thai T, Smolinski NE, Patel P, Nduaguba S, Rasmussen SA, **Winterstein AG**. Prenatal exposure to teratogenic medications in the era of risk evaluation and mitigation strategies (REMS). 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. *Pharmacoepidem Drug Saf* 2021;30(S1):307
141. Jugl S*, Chen S, Antonelli PJ, **Winterstein AG**. Risk of intracranial meningioma requiring surgical intervention among recent hormonal contraceptives users. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. *Pharmacoepidem Drug Saf* 2021;30(S1):329
142. Wei Y-J, Chen C, **Winterstein AG**, Lewis M. Trajectories of prescription opioid dose and risk of opioid-related adverse events among older adults. 37th Internal Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, August 2021. *Pharmacoepidem Drug Saf* 2021;30(S1):371
143. Deremer CE, Guo J, Vouri SM, Haller MJ, Donahoo WT, **Winterstein AG**, Shao H. Comparing Cardiovascular Benefits between GLP-1RA and SGLT2i as an Add-On to Metformin among U.S. Adults with Type 2 Diabetes (T2D). American Diabetes Association annual clinical conference on diabetes - virtual meeting, June 25th, 2021
144. Yang L, Gabriel N, Hernandez I, **Winterstein AG**, Kimmel S, Guo J. Machine Learning to Identify Diabetes Patients Initiating SGLT2i at High-risk of Acute Kidney Injury. American Diabetes Association annual clinical conference on diabetes - virtual meeting, June 25th, 2021
145. Li P, Guan D, Guo J, **Winterstein AG**, Zhang P, Shao H. Trends in Racial and Ethnic Difference in Glucose-Lowering Medication (GLM) Use, Out of Pocket (OOP) Payment, and HbA1c Control in U.S. Adults with Diabetes, 2005-2018. American Diabetes Association annual clinical conference on diabetes - virtual meeting, June 25th, 2021.
146. Sajdeya R, Jean-Jacques J, Shavers A, Wang Y, Pipitone RN, Rosenthal M, **Winterstein AG**, Cook RL. Information sources and training needs on medical marijuana – preliminary results from a state-wide provider survey. 2020 Virtual Scientific Meeting of the Research Society on Marijuana. July 24th, 2020. *Cannabis* 2021;4(1):13
147. Goodin AJ, Hincapie-Castillo JM, Maguire M, Okpeku A, Min J and **AG Winterstein**. Enhancing Prediction of All-Cause 30-Day Inpatient Psychiatric Facility Readmissions Using Electronic Health Record-Derived Data. Academy Health 2021 Annual Research Meeting. Poster. Washington, DC (virtual). June 14-17, 2021
148. Yang L, Gabriel N, Hernandez I, **Winterstein AG**, Kimmel S, Guo J. Machine Learning to Identify Diabetes Patients Initiating SGLT2i at High-risk of Acute Kidney Injury. Virtual Poster Presentation at 2021 American Diabetes Association's 81st Scientific Sessions (Online meeting), June 25-29, 2021.
149. **Winterstein AG**, Heatherington A. Promise and challenge of real-world data for inferences on drug safety and efficacy. Symposium chair and presenter of “Role of pharmacoepidemiology and quantitative pharmacology in developing valid RWE”. Symposium at the American Society of Clinical Pharmacology (ASCPT) and Therapeutics Annual Meeting. Planned to be held in Houston, TX, March 18-21, 2021 and converted to virtual meeting due to COVID-19. (symposium)

150. Thai T*, Sarayani A, Albogami Y, Wang X, Nduaguba S, Patel P, **Winterstein A**. Pregnancy outcomes among women exposed to potentially harmful drugs. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):12 (oral presentation)
151. Wang X*, Zimmerman E, Brown J, Goodin AJ, **Winterstein A**. Risk of preterm delivery and small for gestational age among women with inflammatory bowel disease using TNF alpha inhibitors during pregnancy. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):23
154. Tran PT*, Antonelli PJ, Hincapie-Castillo JM, **Winterstein AG**. Impact of the food and drug administration safety warnings and removal of indications for use of oral quinolones. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):151 (podium presentation)
158. Jugl S*, Goodin A, Henriksen C, **Winterstein AG**, Brown J. Discontinuation and switching rates among women of childbearing age taking oral hormonal contraceptives: a retrospective cohort study in the United States. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):269
159. Chen C*, **Winterstein AG**, Lo-Ciganic WH, Tighe PJ, Wei YJ. Prescription gabapentinoid use and opioid-related adverse events in Medicare older adults. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):296
162. Wang C-Y, Gretenkord J, Seeger JD, Davis KJ, Iannacone MR, Zhou W, Dreyer N, **Winterstein AG**, Santanello N, Gertz B, Berlin JA. Frequency and characteristics of uncontrolled long-term extensions to randomized controlled trials. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):373
169. Vouri SM, Jiang X, Brumback B, **Winterstein AG**. Use of negative controls in a prescription sequence symmetry analysis used to mitigate time-varying bias. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):390
170. Albogami Y*, Daniels MJ, Wei Y-J, Cusi K, **Winterstein AG**. Machine learning methods to predict unmeasured confounders in claims data: a real-world application. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):413
171. Albogami Y*, **Winterstein AG**. Plasmode simulation of multiple imputation performance using internal validation data to adjust for unmeasured confounders. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):414
174. Zhou W, **Winterstein A**, Wang S, Burcu M, Ritchey ME, Gardarsdottir H. ISPE RWE task force: current status and future directions. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. Pharmacoepidem Drug Saf 2020;29(Suppl 3):423 (symposium)

177. Rhew K, Tran PT, Wang X, **Winterstein AG**, Antonelli PJ. Risk of tympanic membrane perforation with combination quinolone and steroid otic therapy for acute otitis. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. *Pharmacoepidem Drug Saf* 2020;29(Suppl 3):499
178. Albogami Y*, Wei Y-J, Daniels MJ, Cusi K, **Winterstein AG**. Real-world evidence of inhaled corticosteroids and type ii diabetes manifestation. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. *Pharmacoepidem Drug Saf* 2020;29(Suppl 3):595
179. Thai T*, Wang X, Pham P, Winterstein A. Effect modification of inflammatory bowel disease on thromboembolism risk of combined oral contraceptive. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. *Pharmacoepidem Drug Saf* 2020;29(Suppl 3):603 (oral presentation)
180. Pham P*, Albogami Y, Cicali B, Squires P, Sarayani A, Thai T, Reams V, Rhew K, Gooddin A, Schmidt S, **Winterstein AG**, Brown J. Risk of thromboembolic events associated with concomitant use of oral hormonal contraceptives and selective serotonin reuptake inhibitors. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. *Pharmacoepidem Drug Saf* 2020;29(Suppl 3):613 (oral presentation)
181. Sarayani A*, Brown JD, Goodin AJ, Cicali B, Henriksen C, Schmidt S, **Winterstein AG**. Effect of enzyme-inducing antiepileptic drugs on failure of oral low-dose hormonal contraceptives. presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. *Pharmacoepidem Drug Saf* 2020;29(Suppl 3):638
182. Vouri SM, Smith SM, Jiang X, Morris EJ, Usmani SA, Manini T, Solberg LM, Pepine C, **Winterstein AG**. Evaluation of the hydralazine – anxiousness – benzodiazepine prescribing cascade among older adults. *J Am Geriatric Soc*. 2020;68(S1):S223. Scheduled for presentation at the American Geriatric Society Annual Meeting in April 2020, which was canceled due to COVID-19.
183. Vouri SM, Smith SM, Jiang X, Morris EJ, Usmani SA, Manini T, Solberg LM, Pepine C, **Winterstein AG**. Evaluation of the non-dihydropyridine calcium channel blocker – edema – loop diuretic prescribing cascades among older adults. *J Am Geriatric Soc*. 2020;68(S1):S223. Scheduled for presentation at the American Geriatric Society Annual Meeting in April 2020, which was canceled due to COVID-19.
184. **Winterstein AG**, Antonelli PJ, Pottgard A, Stage TB, Schmidt S, Brown J. Joining mechanistic and epidemiological approaches to enhance causal inference of drug effects. Symposium chair and presenter of “Opportunities and barriers of joint approaches to enhance causal inference on drug effects”. Symposium accepted for presentation at the 7th Pharmacy Science World Conference 2020. Montreal, CA, May 22-27, 2020. The conference was converted into a virtual conference held October 4-6, 2020 due to COVID-19. (symposium)
185. Tran PT*, Antonelli PJ, Hincapie-Castillo JM, **Winterstein AG**. Risk of tympanic membrane perforation with combination quinolone and steroid otic therapy for acute otitis. 35th Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 24-28, 2019, Philadelphia, USA. *Pharmacoepi Drug Saf* 2019; 28(Suppl. 2):152-153 (podium presentation)
186. Choi Y*, Meissner C, Hampp C, Park H, Brumback B, **Winterstein AG**. Utilization pattern of chronic lung disease treatment prior to the start of Respiratory Syncytial Virus season”. 35th Conference of

Pharmacoepidemiology & Therapeutic Risk Management, August 24-28, 2019, Philadelphia, USA. *Pharmacoepi Drug Saf* 2019; 28(Suppl. 2):5-586

187. Sarayani A*, Albogami Y, Elkhider M, Hincapie-Castillo JM, Brumback BA, Winterstein AG. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24-28, 2019. *Pharmacoepidemiol Drug Saf* 2019;28(S2): 222-222 (podium presentation)
188. Sarayani A*, Pham P, Boemmel-Wegmann A, Winterstein AG. Utilization pattern and adherence to novel anti-obesity medications: A retrospective study in a privately insured population. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24-28, 2019. *Pharmacoepidemiol Drug Saf.* 2019;28(S2): 518-518
189. Sarayani A*, Albogami Y, Winterstein AG. Effectiveness of risk evaluation and mitigation strategies to prevent maternal exposure to a topiramate weight loss product. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24-28, 2019. *Pharmacoepidemiol Drug Saf* 2019;28(S2): 245-246
190. Wang X*, Brown JD, Xiao H, Zimmermann EM, Winterstein AG. Validity of low birth weight and small for gestational age in the Medicaid analytic extract database. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24-28, 2019. *Pharmacoepidemiol Drug Saf.* 2019;28(S2):156
191. Rhew K, Tran PP, Wang X, Antonelli PJ, Winterstein AG. Indications for Otic quinolone use in South Korea. American Academy of Otolaryngology Annual Meeting, New Orleans, LA, USA, September 15-18, 2019. *Otolaryngol Head Neck Surg.* 2019;161(S2): 248-249.
192. Tran PT, Rhew K, Wang X, Winterstein AG, Antonelli PJ. Appropriateness of otic quinolone use among privately insured patients in the United States. American Academy of Otolaryngology Annual Meeting, New Orleans, LA, USA, September 15-18, 2019. *Otolaryngol Head Neck Surg.* 2019;161(S2):121. (podium presentation)
193. Thai TN*, Sarayani A, Wang X, Albogami Y, Rasmussen SA, Winterstein AG. Risk of Pregnancy Loss in Patients Exposed to Mycophenolate Compared to Azathioprine: A Retrospective Cohort Study. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania, USA, August 24-28, 2019. *Pharmacoepidemiol Drug Saf.* 2019; 28(S2): 5-586. (podium presentation)
 - Second Best Abstract Submitted by Student/Postdoc Award
194. Zhu Y, Thai TN, Bateman BT, Hernandez-Diaz S, Franklin JM, Straub L, Winterstein AG, Gray KJ, Qiang Y, Hua W, Taylor LG, Huybrechts KF. Development and Validation of Algorithms to Estimate Live Birth Gestational Age in Medicaid Analytic eXtract data. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania, USA, August 24-28, 2019. *Pharmacoepidemiol Drug Saf.* 2019; 28(S2): 5– 586. (podium presentation)
195. Thai TN*, Henriksen C, Gray KJ, Bateman BT, Hernandez-Diaz S, Zhu Y, Straub L, Huybrechts KF, Winterstein AG. Determinants of Missing or Delayed Prenatal Screening in Florida, New Jersey, and Texas Medicaid Populations 1999 to 2010. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania, USA, August 24-28, 2019. *Pharmacoepidemiol Drug Saf.* 2019; 28(S2): 5– 586.

196. Hincapie-Castillo JM*, Antonelli P, Winterstein AG. Use of Joinpoint regression in drug utilization research: Post-tonsillectomy codeine use in pediatrics, United States (2005–2016). 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA, USA, August 24-28, 2019. *Pharmacoepidemiol Drug Saf.* 2019; 28(Suppl. 2):250-251
- Third Best Abstract Submitted by Student/Postdoc Award
197. Rhew K, Tran TT, Wang X, Antonelli PJ, Winterstein AG. Indications for Otic quinolone use in South Korea. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA, USA, August 24-28, 2019. *Pharmacoepidem Drug Saf.* 2019;28 (S2): 512.
198. Tran PT*, Rhew K, Wang X, Winterstein AG, Antonelli PJ. Appropriateness of otic quinolone use among privately insured patients in the United States. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA, USA, August 24-28, 2019. *Pharmacoepidem Drug Saf.* 2019;28 (S2): 536-537.
199. Goodin AJ, Squires P, Henriksen C, Jugl S, Winterstein AG, Brown JD. Prevalence of Prescription Contraceptives Following the Affordable Care Act Contraception Coverage Mandate in a Commercially Insured Population. *In Press.* Academy Health 36th Annual Research Meeting. Women's Health Session. Accepted for June 3, 2019. Washington, DC
200. Squires P, Sarayani A, Goodin AJ, Jugl S, Winterstein AG, Brown JD. Prevalence of Potential Drug-Drug Interactions involving Hormonal Contraceptive Agents among Women of Childbearing Age in a Commercially Insured Population. *Value in Health. In Press.* International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. Accepted for presentation in May, 2019
201. Hicks JK, Ong HH, Schildcrout JS, Shi Y, Tang LA, El Rouby N, Aquilante CL, Beitelshes AL, Blake KV, Empey PE, Limdi NA, Lipori GP, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley L, Williams H, Winterstein AG, Van Driest S, Ramsey L, Cavallari LH, Peterson JF. Evaluation of CPIC level A drug prescribing in IGNITE-affiliated health systems: opportunity for pharmacogenomics implementation among adult patients. Clinical Pharmacogenetics Implementation Consortium (CPIC) Open meeting. Memphis, TN. June 6-7, 2019
202. Goodin AJ*, Squires P, Henriksen C, Jugl S, Winterstein A, and JD Brown. Prevalence of Prescription Contraceptives Following the Affordable Care Act Contraception Coverage Mandate in a Commercially Insured Population. Academy Health 36th Annual Research Meeting. *Women's Health Session.* June 3, 2019. Washington, DC
203. Squires P, Sarayani A, Goodin A, Jugl S, Winterstein AG, Brown JD. Prevalence of Potential Drug-Drug Interactions involving Hormonal Contraceptive Agents among Women of Childbearing Age in a Commercially Insured Population. *Value in Health (in press).* International Society for Pharmacoeconomics and Outcomes Research Annual Research Meeting. New Orleans, LA. May 18-22, 2019
204. Muñoz MA*, Dal Pan G, Xiao H, Delcher C, Wei J, Kortepeter C, Winterstein A. An Ecological Study on Consumer Adverse Event Reporting to the US Food and Drug Administration. *Drug Saf.* 2018;41:1132
205. Muñoz MA*, Dal Pan G, Wei J, Delcher C, Xiao H, Kortepeter C, Winterstein A. Development and Validation of a Model Predictive of Case Inclusion in Pharmacovigilance Reviews. *Drug Saf.* 2018;41:1185
206. Albogami Y*, Winterstein A. Comparison of adherence and discontinuation of hypoglycemic agents among patients with asthma and diabetes: A retrospective analysis from 2005 to 2015. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):46-47

207. Jeon N*, Bussing R, Schmidt S, Albogami Y, Winterstein A. The role of mental disorders in teenage pregnancy. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):140-141
208. Sarayani A*, Winterstein AG, Chen C, Wei Y-J. Evaluation of opioid overutilization criteria suggested by Centers for Medicare and Medicaid Services among privately insured or Medigap population. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):151
209. Zhu Y*, Roussos-Ross D, Hampp C, Wei Y-J, Brumback B, Winterstein AG. Maternal use of atypical antipsychotics and gestational weight gain. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):172 (podium presentation)
210. Li Y*, Delcher C, Brown J, Reisfield GM, Wei Y-J, Wang X, Winterstein AG. Impact of schedule IV controlled substance classification on the use of carisoprodol in the United States. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):188 (podium presentation)
211. Wang X*, Chen C, Zimmermann EM, Brown JM, Xiao H, Winterstein A. Pharmacological treatment utilization and discontinuation before and during pregnancy in women with inflammatory bowel disease. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):242
212. Wang X*, Zhu Y, Xiao H, Winterstein A. The top 10 most commonly dispensed medications during pregnancy from 2005 to 2015. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):242-243
213. Wang X*, Antonelli PJ, Alrwisan A, Winterstein A. Risk of tympanic membrane perforation after quinolone ear drops for acute otitis externa: A retrospective cohort study. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):278
214. Dawwas G, Dietrich E, Winchester DE, Winterstein AG, Segal R, Park H. Comparative effectiveness of prasugrel versus ticagrelor for the prevention of cardiovascular diseases in patients with acute coronary syndrome. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):364 (podium presentation)
 - Awarded second best student abstract submission
215. Wei Y-J, Chen C, Sarayani A, Winterstein AG. Prevalence and incidence trends of opioid use disorder and prior prescription opioid utilization, 2005-2015. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):375-376 (podium presentation)
216. Li Y*, Reisfield GM, Winterstein AG. Prevalence and duration of skeletal muscle relaxant treatment among commercially insured adults in the United States: 2005 to 2015. 34th International Conference on Pharmacoepidemiology. August 22-26, 2018. Prague, Czech Republic. *Pharmacoepi Drug Saf* 2018;27(S2):417-418

217. Albogami Y*, Sarayani A, Elkhider M, Hincapie-Castillo J, Winterstein AG. Comparative Effectiveness of Risk Evaluation and Mitigation Strategies (REMSs) for Oral Acne Treatments. International Society of Pharmacoepidemiology Midyear Meeting, April 21-24, 2018, Toronto, Canada
218. Vu T*, Winterstein A, Zambrano D. Literature review of psychotropic drug-drug combinations with “severe” or “major” interactions. American Society of Health-System Pharmacists Clinical Midyear Meeting 2017, December 3-7, 2017, Orlando, FL.
219. El Rouby N*, Mosley S, Wake DT, Liu X, Weitzel KW, Elsey AR, Riva R, Langae T, Winterstein AG, Johnson JA, Cavallari L.H. Prevalence of actionable genotype and medication exposure for patients undergoing cardiac catheterization in University of Florida Personalized Medicine Program. Clinical Pharmacology & Therapeutics 2018; 103: S1. (PI-064)
220. El Rouby N*, Alrwisan A, Johnson JA, Winterstein AG, Cavallari L. Utilization of drugs with evidence for pharmacogenomic testing following percutaneous coronary intervention. 67th Annual Meeting of The American Society of Human Genetics, October 19, 2017. Orlando, FL.
221. Choi YY*, Meissner C, Park H, Brumback B, Winterstein AG. Determination of days since last active medical support for chronic lung disease associated with respiratory syncytial virus hospitalizations in infants. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. Pharmacoepi Drug Saf 2017;26(Suppl2):43 (podium presentation)
222. Bakaki PM*, Golchin N, Staley J, Horace A, Johnson H, Pestana Knight EM, Meropol SB, Dawson NV, Winterstein AG, Kleinman LC, Bolen S. Defining pediatric polypharmacy: a scoping review. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. Pharmacoepi Drug Saf 2017;26(Suppl2):196
223. Li Y*, Staley B, Henriksen C, Xu D, Lipori G, Brumback B, Johns TE, Winterstein AG. A dynamic risk prediction model for hospital-associated hypokalemia: model development and validation. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. Pharmacoepi Drug Saf 2017;26(Suppl2):208 (oral presentation)
224. Dave C*, Zhu Y, Wang X, Winterstein A, Alrwisan A, Hartzema A. Trends in opioid utilization during pregnancy and incidence of neonatal abstinence syndrome. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. Pharmacoepi Drug Saf 2017;26(Suppl2):220
225. Wei Y-J, Liu X, Rao N, McPherson M, Jones MB, Bussing R, Winterstein AG. Physical health outcomes in preschoolers with prior authorization for antipsychotics. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. Pharmacoepi Drug Saf 2017;26(Suppl2):272
226. Albogami Y*, Zhu Y, Wang X, Lyons S, Winterstein A. Agreement between Medicaid Analytic eXtract data and birth certificates on neonatal critical conditions. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. Pharmacoepi Drug Saf 2017;26(Suppl2):301
227. Li Y*, Henriksen C, Winterstein AG. Usability of Medicaid Analytic eXtract encounter data for comprehensive managed care from 2006 to 2010: an explanatory study. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. Pharmacoepi Drug Saf 2017;26(Suppl2):304

228. Liu X*, Hincapie-Castillo J, Zhuu Y, Bussing R, Winterstein A. Prevalence of concomitant use of psychotropic drugs with severe or major drug-drug interactions in children and adults with psychotropic therapy. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. *Pharmacoepi Drug Saf* 2017;26(Suppl2):334
229. Munoz MA*, Winterstein AG, Delcher C, Kortepeter CM, Wei Y-J, Xiao H, Dal Pan G. Impact of a new consumer friendly form on adverse experience reporting to the United States Food and Drug Administration. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. *Pharmacoepi Drug Saf* 2017;26(Suppl2):356
230. Zhu Y*, Hampp C, Wie Y-J, Roussos-Ross D, Brumback B, Wang X, Albogami Y, Winterstein AG. Validation of algorithms to estimate gestational age in Medicaid Analytic eXtract data. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. *Pharmacoepi Drug Saf* 2017;26(Suppl2):436-437 (oral presentation)
231. Wang X*, Zhu Y, Albogami Y, Lyons S, Winterstein A. Agreement between birth certificate and Medicaid Analytic eXtract data on major birth defects. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. *Pharmacoepi Drug Saf* 2017;26(Suppl2):504
232. Jeon N*, Staley B, Henriksen C, Lipori G, Winterstein AG. Clostridium difficile infection using hospital electronic health records. 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 26-30, 2017, Montreal, CA. *Pharmacoepi Drug Saf* 2017;26(Suppl2):610-611
233. Choi Y*, Staley B, Henriksen C, Sterner D, Lipori G, Winterstein A. Development of a Heat Map for Prioritizing Risk Factors of Hypoglycemia at Hospitals. American Diabetes Association's 77th Scientific Sessions, June 9-13, 2017 in San Diego, California. *Diabetes* 2017 Jun; 66(Supplement 1): A399-A478
234. Hincapie-Castillo JM*, Staley B, Henriksen C, Lipori G, Winterstein AG. Development of a Predictive Model for Uncontrolled Post-Operative Pain in the Inpatient Setting Using Electronic Health Record Data. 2017 International Society for Pharmacoepidemiology Mid-Year Meeting, April 1-4, 2017, London, U.K (oral presentation)
235. Dave CV*, Alwisan A, Zhu Y, Winterstein AG, Hartzema AG. Concomitant use of opioid and benzodiazepines and the risk of opioid overdose: a retrospective cohort study. 2017 International Society for Pharmacoepidemiology Mid-Year Meeting, April 1-4, 2017, London, U.K
236. Wang X*, Zhu Y, Dave CV, Alwisan AA, Voils SA, Winterstein AG. Trends of Neonatal Abstinence Syndrome Epidemic Related to Opioids Utilization and Other Risk Factors during Late Pregnancy. 2017 International Society for Pharmacoepidemiology Mid-Year Meeting, April 1-4, 2017, London, U.K
237. Choi Y*, Meissner C, Hampp C, Park H, Brumback B, Winterstein AG. Development of a predictive model for Respiratory Syncytial Virus (RSV) hospitalizations among infants. International Society for Pharmacoepidemiology Mid-Year Meeting, April 1-4, 2017, London, UK (oral presentation)
238. Zambrano D*, Winterstein AG, Bussing R, Yang S, Pace K, Campbell K. Risk factors for hospital readmission of psychiatric patients: a systematic literature review. Pharmacy Quality Alliance Annual Meeting. Arlington, VA. May 18-20, 2016. *Res Soc Admin Pharm* 2016; 12(4):e9.
239. Mosley S, Wake D, Liu X, Weitzel K, Elsey A, Winterstein A, Johnson J, Cavallari L. Potential value of preemptive panel-based pharmacogenetics testing in patients undergoing cardiac

catheterization. American College of Clinical Pharmacy Annual Meeting. Hollywood, FL October 23-26, 2016. *Pharmacotherapy* 2016;36(10):e226.

240. Soria-Saucedo R*, Liu X, Hincapie-Castillo J, Bussing R, Winterstein AG. Prevalence, Time Trends and Utilization Patterns of Psychotropic Polypharmacy: Evidence from Adult Medicaid Beneficiaries, 1999-2010. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):670
241. Soria-Saucedo R*, Liu X, Hincapie-Castillo J, Bussing R, Winterstein AG. Prevalence, Time Trends and Utilization Patterns of Psychotropic Polypharmacy: Evidence from Children and Adolescent Medicaid Beneficiaries, 1999-2010. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):669
242. Choi Y*, Staley B, Henriksen C, Lipori G, Brumback B, Winterstein AG. Development of a risk model for uncontrolled Pneumonia in Hospitalized Patients. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):597
243. Zhu Y*, Henriksen C, Winterstein AG. Validation of multiple Births in Medicaid Analytic eXtract (MAX) Data. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):341
244. Li Y*, Staley B, Henriksen C, Kubilis P, Lipori G, Brumback B, Johns TE, Winterstein AG. The Development of a dynamic Risk Model for Hospital-associated Hyperkalemia. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):301
245. Dave C*, Hartzema A, Park H, Winterstein AG. Baseline and Time-Varying Determinants of Statin Adherence. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):274
246. Jeon N*, Staley B, Klinker KP, Ghandi AB, Winterstein AG. Evaluation of the Risk of Acute Kidney Injury Associated with vancomycin plus Piperacillin-Tazobactam compared with Vancomycin plus Cefepime. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):270 (oral presentation)
247. Jeon N*, Staley B, Henriksen C, Lipori G, Winterstein AG. Development of a Risk Model to Predict Drug-Induced Acute Kidney Injury in Hospitalized Patients. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):269 (oral presentation)
 - Award for the second best conference abstract submitted by a student
248. Zhu Y*, Liu W, Li Y, Kubilis PS, Winterstein AG. Treatment Patterns in Adults with newly treated Attention Deficit/Hyperactivity Disorder. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):241
249. Dave C*, Hartzema AG, Winterstein AG. Performance of Machine Learning Algorithms in Statistical Modeling of 30 Day Heart Failure Readmissions Risks Using Automated and Investigator-specified Covariates. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):136 (oral presentation)

250. Liu X*, Carney P, Bussing R, Segal R, Cottler L, Winterstein AG. Safety of Stimulants in Children with Epilepsy: a retrospective Cohort Study. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):34
251. Hincapie-Castillo JM*, Henriksen C, Staley B, Saidi A, Lipori G, Winterstein AG. Development of a Predictive Model for Drug-induced QT Prolongation in the Inpatient Setting Using Electronic Health Record Data. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016; 25(Suppl. 3):492
252. Vogel Anderson K, Winterstein A, Rosenberg E, Farris K. IMPROVE Part 2: Evaluation of medication errors in the perioperative setting. Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA, October 18-21, 2015
253. Soria-Saucedo R*, Liu X, Hincapie-Castillo J, Bussing R, Winterstein AG. Prevalence, time trends and utilization patterns of psychotropic polypharmacy: Evidence from children and adolescent Medicaid beneficiaries, 1999-2010. Annual Research Meeting Academy Health, June 26-28, 2016, Boston, United States.
254. Zhu Y*, Liu W, Li Y, Winterstein AG. Impact of Eligibility Length on Prevalence Estimates Using Automated Healthcare Claims Data, 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:583
255. Dave C*, He J, Winterstein A, Hartzema A. The Incidence of Solid Tumors in a Healthcare Database Compared To SEER. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:540-541
256. Choi YY*, Staley B, Henriksen C, Kubilis P, Lipori G, Brumback B, Winterstein AG. Development of a Risk Model for DrugAssociated Inpatient Falls. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:514
 - Best poster award: database spotlight session
257. Liu L*, Barnicoat M, Bussing R, Winterstein AG. Psychotropic Drug–Drug Interactions in Three Most Commonly Used Drug Information Databases. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:452-453
258. Jeon N*, Winterstein AG. Addition of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Risk of Acute Kidney Injury (AKI) in Hospitalized Patients Receiving Vancomycin. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:410-411 (oral presentation)
259. Alrwisan A*, Winterstein AG, Antonelli PJ. Otic Quinolones Associated with Tympanic Membrane Perforations. American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting, Dallas, TX, September 27-30, 2015 *Otolaryngol Head Neck Surg* 2015; 153: P127 (oral presentation)
260. Li Y*, Liu W, Kubilis P, Zhu Y, Winterstein AG. Factors Associated with Pharmacological Treatment Initiation in Adult Attention-Deficit/Hyperactivity Disorder Patients: Findings from a Publicly Insured Population. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:396 (oral presentation)

261. Zhu Y*, Liu W, Li Y, Winterstein AG. Prevalence of Attention Deficit Hyperactivity Disorder in Publically Insured Adults. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:379
262. Liu X*, Kubilis P, Bussing R, Winterstein AG. State-level Variation of Psychotropic Drug Utilization in Children with ADHD in the United States Using Multiple Disparity Measures. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:277-278
263. Knox CA*, Hampp C, Brumback B, Xu X, Segal R, Winterstein AG. Risk of Cesarean Section Delivery among Live Births Exposed to Anti-Diabetic Agents during the First Trimester of Pregnancy. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:250 (oral presentation)
264. Knox CA*, Hampp C, Brumback B, Xu X, Segal R, Winterstein AG. Risk of Preeclampsia among Live Births Exposed to Anti-diabetic Agents during the First Trimester of Pregnancy. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:249-250
265. Knox CA*, Hampp C, Brumback B, Xu X, Segal R, Winterstein AG. Risk of Preterm Delivery among Live Births Exposed to Anti-diabetic Agents during the First Trimester of Pregnancy. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:249 (oral presentation)
266. Dave C*, Hartzema A, Andrade E, Winterstein A. Drug Utilization Study of Childhood Epilepsy. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:236-237
267. Winterstein AG, Staley B, Kubilis P, Henriksen C, Lipori G, Brumback B, Johns TE. Development of an Automated Risk Model for Drug-associated Inpatient Hypoglycemia. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:227 (oral presentation)
268. Liu W*, Liu X, Kubilis K, Li Y, Zhu Y, Winterstein AG. Utilization and predictors of psychotropic polypharmacy in adult patients with attention-deficit/hyperactivity disorder. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:134
269. Knox C*, Hincapie-Castillo J, Winterstein AG. Validity of Delivery Outcomes Within the Medicaid Analytic eXtract (MAX) Database. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:14
270. Alrwisan A*, Winterstein AG, Antonelli PJ. Otic quinolones after tympanostomy tubes associated with persistent tympanic membrane perforations. 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:12-13 (oral presentation)
271. Liu W*, Dahm P, Gerhard T, Antonelli P, Delaney JC, Winterstein AG. Utilization of phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction among commercially insured adults in the United States. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. *Pharmacoepi Drug Saf* 2014;23(S1):85-86

272. Winterstein AG, Cooper-DeHoff R, Kubilis P, Nichols G, Delaney JAC. Diabetogenic effects of atypical antipsychotics – exploration of measurement bias. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. Pharmacoepi Drug Saf 2014;23(S1):142-143
 - Spotlight poster winner – Methods Special Interest Group
273. Winterstein AG, Kubilis P. Measurement bias in billing data – a simulation study. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. Pharmacoepi Drug Saf 2014;23(S1):149-150
274. Winterstein AG, Gerhard T, Kubilis P, Shuster J. Stimulant effectiveness on driving citations and crashes of children with ADHD. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. Pharmacoepi Drug Saf 2014;23(S1):151-152
 - Spotlight poster winner – Pediatrics Special Interest Group
275. Knox CA*, Segal R, Winterstein AG. Epidemiology of pre-existing diabetes in pregnancy from 2000-2006 among Medicaid patients in 29 US states. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. Pharmacoepi Drug Saf 2014;23(S1):312 (oral presentation)
276. Liu X*, Kubilis P, Bussing R, Winterstein AG. Development of a novel approach to assess psychotropic polypharmacy in administrative databases. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. Pharmacoepi Drug Saf 2014;23(S1):319
277. Knox CA*, Palmsten K, Setoguchi S, Segal R, Winterstein AG. Predicting linkage within a validated algorithm that identifies mother-infant pairs within the Medicaid Analytic Extract (MAX) database. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. Pharmacoepi Drug Saf 2014;23(S1):350
278. Liu W*, Antonelli PJ, Dahm P, Gerhard T, Delaney JAC, Segal R, Crystal S, Winterstein AG. Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. Pharmacoepi Drug Saf 2014;23(S1):492-493
279. Kiskaddon A*, Johns T, Staley B, and Winterstein AG. Identifying risk factors associated with inpatient hyperglycemic events to develop a dynamic risk model. 48th Annual Meeting of the Florida Society of Health-System Pharmacists; Orlando, FL. Aug 8-10, 2014
280. Knox CA*, Palmsten K, Setoguchi S, Hernandez-Diaz S, Winterstein AG. Validation of mother-infant linkage using Medicaid Case ID variable within the Medicaid Analytic eXtract (MAX) database. Society for Epidemiologic Research 47th Annual Meeting. Seattle, WA. June 24-27, 2014
281. Wei L*, Antonelli PJ, Dahm P, Gerhard T, Delaney JAC, Winterstein AG. Comparative ototoxicity of phosphodiesterase type 5 inhibitors for erectile dysfunction. Triologic Society Annual Meeting. (oral presentation)
282. Alrwisan A*, Antonelli PJ, Winterstein AG. Epidemiology of Tympanoplasty in children following tympanostomy tube placement. American Academy of Otolaryngology Annual Meeting
 - Outstanding Poster Abstract Award

283. Ali AK*, Winterstein A, Hendeles L, Lu X, Segal R, Hartzema A. Comparison of rates of prescribing oral corticosteroids for asthma exacerbations between step-down therapy approaches among initiators of inhaled corticosteroids and long-acting beta-agonist combination therapy. *J Allergy Clin Immunology*. February 2014; 133(2S):AB177
284. Liu X*, Kubilis P, Xu D, Bussing R, Winterstein AG. Distribution and development of co-morbidities in pediatric patients with ADHD. 29th International Conference of Pharmacoepidemiology, Aug 23-28, Montreal, Canada. *Pharmacoepi Drug Saf* 2013;22:(Suppl.1):341
285. Winterstein AG, Delaney JA, Kubilis P, Crystal S, Gerhard T. Inclusion of variables associated with exposure but not outcome can compromise propensity score-based adjustments – examination of a real-life example in pediatric psychopharmacology. 29th International Conference of Pharmacoepidemiology, Aug 23-28, Montreal, Canada. *Pharmacoepi Drug Saf* 2013;22:(Suppl.1):232
286. Linden S*, Bussing R, Gerhard T, Shuster JJ, Winterstein AG. Risk of Suicide and Suicide Attempt Associated with Atomoxetine Compared to Central Nervous System Stimulant treatment. 29th International Conference of Pharmacoepidemiology, Aug 23-28, Montreal, Canada. *Pharmacoepi Drug Saf* 2013;22:(Suppl.1):175 (oral presentation)
 - Second best abstract submitted by a student
287. Knox CA*, Hampp C, Willy M, Winterstein AG, Dal Pan G. Patient Understanding of Drug Risk: Analysis of Medication Guide Assessments. 29th International Conference of Pharmacoepidemiology, Aug 23-28, Montreal, Canada. *Pharmacoepi Drug Saf* 2013;22:(Suppl.1):361 (oral presentation)
288. Winterstein AG, Eworuke E, Gerhard T. Confounding's ugly little sister: measurement bias in pharmacoepidemiology. 29th International Conference of Pharmacoepidemiology, Aug 23-28, Montreal, Canada. *Pharmacoepi Drug Saf* 2013;22:(Suppl.1):369 (workshop)
289. Bird ST, Delaney JAC, Cooper-DeHoff RM, Nichols GA, Winterstein AG. Misclassification in assessment of diabetogenic risk using laboratory-enhanced claims data. 29th International Conference of Pharmacoepidemiology, Aug 23-28, Montreal, Canada. *Pharmacoepi Drug Saf* 2013;22:(Suppl.1):3
290. Cooper-DeHoff RM, Bird ST, Nichols GA, Delaney JC, Winterstein AG. Association of antihypertensive drug classes, alone or in combination with incident diabetes: a nested case-control study. American Heart Association Scientific Sessions, Nov 3-7, 2012. Los Angeles, CA. *Circulation* 2012;126:A11073
291. Cooper-DeHoff RM, Garvan C, Delaney JA, Winterstein AG, Bavry A, Howard BV, Chen C, Manson J, Phillips LS, Liu S, Song Y, Shorr RI, Limacher M, and Women's Health Initiative Investigators. Chronic utilization of medications with metabolic effects and risk for incident diabetes in postmenopausal women. American Heart Association Scientific Sessions, Nov 3-7, 2012. Los Angeles, CA. *Circulation* 2012;126:A10050
292. Winterstein AG, Antonelli PJ, Xu D, Liu W. Sensorineural hearing loss with neomycin ear drops. Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery, Washington DC, September 9-12, 2012. *Otolaryngol Head Neck Surg* 2012;147:P103
293. Eworuke E*, Winterstein AG. Drug utilization patterns for routine therapies in patients with cystic fibrosis. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):474
294. Munoz MA, Stojanovic D, Etminan M, Winterstein AG, Delaney JAC. Trends in use of benzodiazepines, opioids, tramadol, and z-drugs from 1998 to 2008 in a managed care population. 28th International

Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):426

295. Eworuke E*, Winterstein AG. Deterministic linkage between cystic fibrosis patient registry data to Medicaid Analytical Extract Data. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):396
296. Wen X, Meador K, Winterstein AG, Hartzema AG. Utilization of antiepileptic drugs in Florida Medicaid women with epilepsy in childbearing age. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):322
297. Bird ST*, Munoz M, Winterstein A, Cooper-Dehoff R, Delaney JAC. Trends in utilization of medications with adverse metabolic effects in a managed care population between 1999 and 2008. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):300
298. Linden S*, Winterstein AG. Determinants of atomoxetine and central nervous system stimulant treatment initiation. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):183
299. Winterstein AG, Eworuke E, Xu D, Schuler P. Effectiveness of palivizumab in respiratory syncytial virus prophylaxis in children with cystic fibrosis. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):148
300. Liu X*, Kubilis P, Xu D, Winterstein AG. Psychotropic drug utilization in children with concomitant ADHD and anxiety. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):138
301. Liu W*, Antonelli PJ, Xu D, Winterstein A. Aminoglycoside eardrops and risk of sensorineural hearing loss in children with non-intact tympanic membranes. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):133
 - Received best poster award at Pediatric Special Interest Group Posterwalk
302. Knox CA*, Delaney JA, Winterstein AG. Drug utilization among pregnant diabetic women in US managed care. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26, 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012;21:(Suppl. 3):13 (oral presentation)
303. Cooper-DeHoff RM, Bird ST, Nichols GA, Delaney JC, Winterstein AG. Association of Antihypertensive Drug Classes, Alone or in Combination, with Incident Diabetes: A Nested Case-control Study. American Heart Association Scientific Sessions. November 3-7, 2012. Los Angeles, USA (oral presentation)
304. Liu W*, Kubilis P, Winterstein AG. Do physicians need both rosiglitazone and pioglitazone. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. *Pharmacoepi Drug Saf* 2011;20:S16 (oral presentation)
305. Winterstein AG, Kubilis P, Gerhard T. ADHD youths' career in psychotropic treatment. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. *Pharmacoepi Drug Saf* 2011;20:S133 (oral presentation)

306. Linden S*, Knox C, Winterstein AG. Atomoxetine utilization in youths with attention deficit/hyperactivity disorder in 29 Medicaid states. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. Pharmacoepi Drug Saf 2011;20:S134 (oral presentation)
307. Smith DJ*, Winterstein AG, Willy M, Karowski C. Generalizability of risk evaluation and mitigation (REMS) effectiveness evaluations. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. Pharmacoepi Drug Saf 2011;20:S223
308. Knox CA*, Hampp C, Kubilis P, Linden S, Winterstein AG. Appropriateness of age thresholds for palivizumab prophylaxis in preterm infants. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. Pharmacoepi Drug Saf 2011;20:S252 (oral presentation)
309. Eworuke E*, Winterstein AG. Comparing pulmonary-related outcomes for newborn-screened versus conventional-diagnosed infants with cystic fibrosis. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. Pharmacoepi Drug Saf 2011;20:S319
310. Winterstein AG, Hampp C, Kubilis P, Saidi A. Age-dependent effectiveness of RSV immunoprophylaxis. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. Pharmacoepi Drug Saf 2011;20:S322
311. He J*, Hartzema AG, Winterstein AG, Dahm P. Health-related quality of life as confounder in observational studies for localized prostate cancer. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. Pharmacoepi Drug Saf 2011;20:S324
312. Winterstein AG. Assessing Drug Safety in Concomitant Therapy for ADHD: Medicaid Data and Design Issues. NCDEU 51st Annual Meeting. June 13-16, 2011, Boca Raton, FL (oral presentation)
313. Knox C*, Delaney JA, Winterstein AG. Association of Cesarean Section Delivery among Pregnant Women with Diabetes. 3rd North American Congress of Epidemiology. June 21-24, 2011. Montreal, Canada
314. Linden S*, Knox C, Winterstein AG. Utilization of Atomoxetine and other Pharmacotherapy in youths with attention deficit / hyperactivity disorder in Medicaid patients in 29 US states. Am. J. Epidemiol. (2011) 173 (suppl 11): S1-S316.528-S
315. Hampp C*, Winterstein AG. Timing of prophylaxis relative to respiratory syncytial virus seasons. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Brighton, UK, August 19-22, 2010. Pharmacoepi Drug Saf 2010;19:S201-202
316. Chen CY*, Winterstein AG. Jointpoint regression to examine the impact of drug safety warnings on drug utilization trends when interrupted time-series analysis is not feasible. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Brighton, UK, August 19-22, 2010. Pharmacoepi Drug Saf 2010;19:S173 (oral presentation)
317. Odia E*, Hampp C, Winterstein AG. Validity of an algorithm for the identification of premature infants using Medicaid administrative data. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Brighton, UK, August 19-22, 2010. Pharmacoepi Drug Saf 2010;19:S123 (oral presentation)

318. Chen CY*, Winterstein AG. Use of stimulants following the public discussion and regulatory actions on ADHD drugs' cardiovascular safety. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Brighton, UK, August 19-22, 2010. *Pharmacoepi Drug Saf* 2010;19:S49-50
319. Hampp C*, Saidi AS, Winterstein AG. Latitude as a Factor in RSV Epidemiology in Florida. Society of Epidemiologic Research 43rd Annual Meeting, Seattle, WA, June 23-26, 2010. *Am J Epidemiol* 2010; 171(Suppl): S136
320. Hampp C*, Saidi AS, Winterstein AG. Comparison of RSV Seasonality in Four States. Society of Epidemiologic Research 43rd Annual Meeting, Seattle, WA, June 23-26, 2010. *Am J Epidemiol* 2010; 171(Suppl): S136
321. Jamison A*, Winterstein AG, Kimberlin C. Overload and Redundancy in Consumer Medication Information. American Pharmacists Association Annual Meeting. Washington DC. March 12-15, 2010. *JAPhA* 2010;50(2):301
 - Winner, APhA-Academy of Pharmacy Practice and Management Student Pharmacist Contributed Research Paper Presentation
322. Jamison A*, Linden S, Kimberlin C, Winterstein A. Oral Counseling Practices in U.S. Community Pharmacies. American Pharmacists Association Annual Meeting. Washington DC. March 12-15, 2010. *JAPhA*. 2010;50(2):300-301.
323. Rosenwasser RF*, Winterstein A, Rosenberg A, Rosenberg E, Antonelli P. Perioperative Medication Errors in Otolaryngology. The Triological Society Combined Sections Meeting. Orlando, Florida. February 4-7, 2010.
324. Hampp C*, Kauf TL, Saidi A, Winterstein AG. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab from the Perspective of a Southern US Medicaid Agency. ISPOR 12th Annual European Congress, Paris, France, 24-27 October, 2009. *Value in Health* 2009; 12 (7): A301
 - Awarded best student research poster presentation
325. Hampp C*, Winterstein AG. Seasonal versus Needs-Based Immunization Schedules – the Example of RSV. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009. *Value in Health* 2009; 12 (7): A307
 - Poster finalist, indicating top 10% of accepted abstracts
326. Chen CY*, Winterstein AG. Atomoxetine use and central nervous system stimulants use during physician office visits for attention deficit/hyperactivity disorder after the discussion on related suicidal risk. 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Providence, Rhode Island. August 16-19, 2009. *Pharmacoepidemiology and Drug Safety*, 2009;18:S176
327. Winterstein AG, Linden S, Fernandez E, Lee A, Kimberlin C. Usefulness of consumer medication information. International Conference on Pharmacoepidemiology and Therapeutic risk Management. Providence, Rhode Island. August 16-19, 2009. *Pharmacoepidemiology and Drug Safety*, 2009;18:S182
328. Hampp C*, Winterstein A. Validation of the national respiratory and enteric virus surveillance system for the detection of respiratory syncytial virus seasons. International Conference on Pharmacoepidemiology

and Therapeutic risk Management. Providence, Rhode Island. August 16-19, 2009. Pharmacoepidemiology and Drug Safety, 2009;18:S118

329. Linden S*, Kimberlin C, Winterstein AG. Counseling efforts in U.S. community pharmacies: associations to pharmacy and personnel attributes. International Conference on Pharmacoepidemiology and Therapeutic risk Management. Providence, Rhode Island. August 16-19, 2009. Pharmacoepidem Drug Saf, 2009;18:S180
330. Winterstein AG, Hampp C, Saidi A. Effectiveness of palivizumab in Medicaid infants. 25th International Conference on Pharmacoepidemiology and Therapeutic risk Management. Providence, Rhode Island. August 16-19, 2009. Pharmacoepidemiology and Drug Safety, 2009;18:S97-98 (oral presentation)
331. Gerhard T, Winterstein A, Olfson M, Saidi A, Crystal S. Effects of Preexisting Cardiovascular Risk Factors on Initiation of Stimulants in Adults Newly Diagnosed with ADHD. 25th International Conference on Pharmacoepidemiology and Therapeutic risk Management. Providence, Rhode Island. August 16-19, 2009. Pharmacoepidem Drug Saf, 2009; 18:S202 (oral presentation)
332. Lee A*, Kimberlin C, Fernandez E, Linden S, Winterstein A. Inclusion of off-label use in consumer medication leaflets. American Pharmacists Association Annual Meeting and Exposition. San Antonio, TX; April 3-6, 2009. J Am Pharm Assoc, 2009; 49(2):338.
333. Fernandez E*, Winterstein A, Lee A, Linden S, Kimberlin C. Consumer comprehension of consumer medication information leaflets. American Pharmacist Association Annual Meeting and Exposition. San Antonio, TX. April 3-6, 2009. J Am Pharm Assoc, 2009; 49(2):336.
334. Hsu CN, Kauf TL, Winterstein AG, Nelson D. Longitudinal Incidence of Liver Complications and Initiation of Antiviral Therapy among Newly HCV-infected Patients Enrolled in a Managed Care Organization (MCO). 59th Annual Meeting of American Association for The Study of Liver Disease, Oct 31-Nov 4 2008, San Francisco, CA
335. Onyenwenyi AJ*, Winterstein AG. Off-label Prescribing of Anticonvulsant Drugs – National pattern between 1992-2005. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. Pharmacoepidem Drug Saf 2008;17:S32
336. Winterstein AG, Shuster J. Fixed Effects Models May Bias Meta-Analytic Summary Estimates. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. Pharmacoepidem Drug Saf 2008;17:S133
337. Hampp C*, Winterstein AG, Saidi A. Role of Age in Respiratory Syncycial Virus Infection Risk – Recommendations for Palivizumab Utilization. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. Pharmacoepidem Drug Saf 2008;17:S186
338. He J*, Winterstein AG, Beaver TM. Predicted Impact of Nesiritide in Dialysis and All-cause Mortality in Cardiac Surgery Patients by Demonstrated Post-Operative GFR Change. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. Pharmacoepidem Drug Saf 2008;17:S241
339. Garman P, Ried LD, Hartzema A, Asal N, Winterstein AG, Daniels M. Risk of tendon Rupture after Quinolone Use in a U.S. Military Population. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. Pharmacoepidem Drug Saf 2008;17:S208

340. Hampp C*, Winterstein AG. Palivizumab utilization and compliance with recommendations in Florida. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. Pharmacoepidem Drug Saf 2008;17:S25 (oral presentation)
 - Received Student Award for Best Drug Utilization Abstract
341. Chen CY*, Winterstein AG. Treatment persistence among youths newly diagnosed with attention-deficit/hyperactivity disorder (ADHD). 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 17-20, 2008, Copenhagen, Denmark. Pharmacoepidem Drug Saf 2008;17:S199
342. Hampp C*, Schauf M, Saidi A, Winterstein AG. Changes in Respiratory Syncytial Virus Related Hospitalizations and Prevention in Infants with Cardiac Anomalies. American College of Cardiology, 57th Annual Scientific Session, March 31 2008, Chicago, IL
343. He J*, Winterstein AG, Beaver TM. Predicted Impact of Nesiritide on Dialysis and All-Cause Hospital Mortality in Patients Undergoing Cardiac Surgery by Demonstrated Improvement in Post-Operative GFR. American College of Cardiology, 57th Annual Scientific Session, March 29-April 1, 2008, Chicago, IL
344. Hampp C*, Winterstein AG, Saidi A, Schauf M. Palivizumab utilization and hospitalizations related to respiratory syncytial virus infections among Florida Medicaid recipients. 23rd International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007;16:S170
345. Kanjanarat P*, Winterstein AG, Hartzema AG, Lipowski E, Tian L. Impact of universal health care coverage in hospital drug utilization in Thailand. 23rd International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007;16:S134
346. Winterstein AG, Gerhard T, Shuster J, Zito JM, Johnson M, Saidi A. Safety of central nervous system stimulants on youths with attention-deficit/hyperactivity disorder (ADHD). 23rd International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007;16:S37 (oral presentation)
347. Winterstein AG, Gerhard T, Zito JM, Shuster J, Saidi A. Safety of methylphenidate versus amphetamine salts in the treatment of attention deficit/hyperactivity disorder (ADHD). 23rd International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007;16:S22 (oral presentation)
348. Chen CY*, Winterstein AG. Psychotropic treatment among youths newly diagnosed with attention deficit/hyperactivity disorder (ADHD). 23rd International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007;16:S21-22 (oral presentation)
349. Onyenwenyi AJ*, Winterstein AG. Rates of hypokalemia after implementation of aggressive insulin dosing in critical care patients. 23rd International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007;16:S5-6 (oral presentation)
350. Gerhard T*, Winterstein AG, Shuster, JJ, Johnson, JA, Hartzema AG, Pepine CJ. Estimating Effects of Antihypertensive Therapy on Adverse Outcomes in the Presence of Time-Dependent Confounding by Blood Pressure. 23rd International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007;16:S32 (oral presentation)

351. Gerhard T*, Winterstein AG, Shuster, JJ, Johnson, JA, Hartzema AG, Pepine CJ. Use of Average Surrogate Values Introduces Bias: A Simple Simulation. International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007; 16:S115-116
352. Gerhard T*, Winterstein AG, Shuster, JJ, Johnson, JA, Hartzema AG, Pepine CJ. Impact of Operationalization of Longitudinal Blood Pressure on Adverse Outcomes. International Conference on Pharmacoepidemiology. August 19-22, 2007. Quebec City, Canada. Pharmacoepidemiology and Drug Safety, 2007; 16:S115
353. He J*, Winterstein AG, Beaver T. Predicting Effectiveness Of Nesiritide On Dialysis And All-Cause Hospital Mortality In Patients Undergoing Cardiac Surgery By Post-Operative GFR Change. Internal Federation of Pharmacy Associations (FIP) 67th Annual Congress. September 1-6, 2007. Beijing, China
354. Chen C-Y*, Winterstein AG. Initiation of Central Nerve System Stimulants (CNSS) Treatment for Newly Diagnosed Attention-Deficit/Hyperactivity Disorder (ADHD) Children. 40th Annual Society for Epidemiologic Research Meeting, June 19-22, 2007; Boston, MA. American Journal of Epidemiology 2007;164:S136.
355. Tyler A*, Winterstein AG, LeClaire A, Staley B, Bihorac A. Quality of vancomycin use in patients with Acute Kidney Injury. American Pharmacist Association Annual Meeting. JAPhA. 2007;47(2):284
356. Graham SD*, Hartzema AG, Sketris I, Winterstein A. Effect of academic detailing on COX-2 utilisation rates in the Nova Scotia seniors population. Joint CAHSR / PHC-CHSRF Symposium, Sept 19, 2006. Vancouver, British Columbia.
357. Gerhard T*, Winterstein AG, Shuster JJ. Incidence, Prevalence, and Demographic Differences in Central Nervous System Stimulant (CNSS) Use in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD): A Study of Florida Medicaid Beneficiaries 1994-2004. Pharmacoepidem Drug Safety 2006;15:S146.
358. Winterstein AG, Gerhard T. Demographic Discrepancies in Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and Initiation of Pharmacological Treatment in Children and Adolescents: A Study of Florida Medicaid Beneficiaries 1994-2004. Pharmacoepidemiology and Drug Safety 2006;15:S299.
359. Winterstein AG, Gerhard T. Utilization of Central Nervous System Stimulants (CNSS) in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD): A Study of Florida Medicaid Beneficiaries 1994-2004. Pharmacoepidemiology and Drug Safety 2006;15:S298.
360. Winterstein AG, Gerhard T, Beaver TM. Safety of Aprotinin in Cardiac Surgery. Pharmacoepidemiology and Drug Safety 2006;15:S120.
361. Winterstein AG, Haugbolle LS, Melander A. A Systematic Review of the Nature of Preventable Adverse Drug Events in Ambulatory Care. Thomsen LA, Sondergaard B, Pharmacoepidemiology and Drug Safety 2006;15:S104.
362. Onyenwenyi A*, Winterstein AG, Hatton R. An Evaluation of the Effects of Gatifloxacin on Glucose Homeostasis. Pharmacoepidemiology and Drug Safety 2006;15:S27.
363. Snyder AM*, Klinker PK, Orrick JJ, Janelle J, Winterstein AG. Is the medication system in hospitals failing patients on HAART? American College of Clinical Pharmacy Annual Meeting, October 26-29, St. Louis, MO. Pharmacotherapy 2006;26:e104
364. Gabrielli A, Sungur M, Layon J, Bihorac A, Tyler AM, Winterstein AG, LeClaire A, Onyenwenyi A, Staley B. Inappropriate use of vancomycin in critically ill patients with AKI. Critical Care Medicine 2006;34(12):A137

365. Gerhard T*, Winterstein AG, Shuster J, Li J, Garman P, Linden S, Johnson M. Demographic Differences in Central Nervous System Stimulant (CNSS) Use in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD): A Study of Florida Medicaid Beneficiaries 1994-2004. *Am J Epidemiol* 2006;163(Suppl):S35.
366. Winterstein AG, Gerhard T, Shuster J, Li J, Garman P, Linden S, Liu H, Johnson M. Incidence and Prevalence of Central Nervous System Stimulant (CNSS) Use in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD): A Study of Florida Medicaid Beneficiaries 1994-2004. *Am J Epidemiol* 2006;163(Suppl):S36.
367. Hogan C*, Winterstein AG, Johns TE, Layon J, Russin M, Klodell CT. Weight-based heparin protocols are efficacious - but are they effective? *Critical Care Medicine* 2005;33 (12 Suppl)
 - First prize: University of Florida, College of Pharmacy, Annual Research Showcase, student division
368. Drawdy S; Allen M; Winterstein AG; Allen M; Jantz MA. Effect of hydrocortisone vs. hydrocortisone plus fludrocortisones on mortality in critically ill patients. *Critical Care Medicine* 2005;33 (12 Suppl)
369. Drawdy S*, Winterstein AG, Rosenberg A, Hatton RC, Rosenberg EI, Weiner, ID. Validation of automated alerts for the inappropriate use of non-steroidal anti-inflammatory drugs in patients with renal insufficiency. 40th Midyear Clinical Meeting of the American Society of Health Systems Pharmacists. December 4-8, 2005. Las Vegas, NV
370. Winterstein AG, Gerhard T, Shuster JJ, Hartzema AG. Exposure Propensity Scores: Concepts, Applications, and practical considerations. Workshop presented at the 8th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); Florence, Italy, November 2005.
371. Norberg J, Winterstein AG, Leclaire A, Johns TE. Insulin infusion protocols improve glycemic control, or do they? Poster presentation at the Annual College of Clinical Pharmacy Annual Meeting, October 23-26, 2005, San Francisco, CA
372. Winterstein AG, Beaver TM, Shuster JJ, Gerhard T, Alexander AA, Hartzema AG. Effectiveness of nesiritide on risk for dialysis or death after adult open heart surgery. 21st International Conference on Pharmacoepidemiology and Risk Management. Nashville, August 21-24, 2005. *Pharmacoepidemiology and Drug Safety* 2005;14(suppl 2): S65-S66
373. Kanjanarat P*, Winterstein AG, Lipowski A, Hartzema AG. Validation of Thai community hospital databases for health policy evaluations on hospital drug utilization. 21st International Conference on Pharmacoepidemiology and Risk Management. Nashville, August 21-24, 2005. *Pharmacoepidemiology and Drug Safety* 2005;14(suppl 2): S178-S179
374. Gerhard T*, Winterstein AG, Shuster JJ, Hartzema AG. Propensity-score-based analysis compared to multivariate logistic regression: implications for clinical utility. 21st International Conference on Pharmacoepidemiology and Risk Management. Nashville, August 21-24, 2005. *Pharmacoepidemiology and Drug Safety* 2005;14(suppl 2): S59
 - 3rd best student abstract award
375. Winterstein AG, Lipowski EE, Martindale R. Evidence-based Quality Improvement. American Association of College of Pharmacy Annual Meeting. June 2005, Cincinnati, OH

376. Hartzema AG, Winterstein AG, Johns TE, De Leon JM, Widmer A, Chamberlain J, Bailey W, Winkler R, Pannell R, Henshaw Z, McDonald K. Health Information for Medication Safety in Critical Access Hospitals. Patient Safety and Health Information Technology Conference, Agency for Healthcare Research and Quality, Washington, DC, June 6-10, 2005
377. Taylor MD, Winterstein AG, Hartzema AG, Segal R, Frank RG, MacLean R. The impact of glycemic control on the incidence of diabetic complications. Tenth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. May 15-18, 2005 Washington, DC. Value in Health 2005; 8(3):256 (oral presentation)
378. Winterstein AG, Johns TE, Hartzema AG. High-priority medication safety targets: two-year progress in small rural hospitals. 39th ASHP Midyear Clinical Meeting. December 5-9, 2004. Orlando, FL. (oral presentation)
379. Johns TE, Winterstein AG, Hartzema AG. Medication safety assessment in small rural hospitals: people, places, practices. 39th ASHP Midyear Clinical Meeting. December 5-9, 2004. Orlando, FL. (oral presentation)
380. Winterstein AG, Johns TE, Hatton RC, Weiner DI Incidence of acute renal failure associated with inappropriate use of NSAIDs in acute care. 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 22-25, 2004. Bordeaux. Pharmacoepidem Drug Saf 2004;13:S8 (oral presentation)
381. Winterstein AG, Johns TE, Hatton RC, Rosenber EI, Gonzalez-Rothi R, Smith WD. Screening logic to establish the incidence of preventable hypoglycemic events in acute care. 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 22-25, 2004. Bordeaux. France. Pharmacoepidem Drug Saf 2004;13:S212
382. Gerhard T*, Zineh I, Hartzema AG, Winterstein AG. Cost-effectiveness of nesiritide versus dobutamine in patients with acutely decompensated heart failure. Drug Information Association Annual Meeting 2004, June 13-16, 2004. Washington, DC. 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. August 22-25, 2004. Bordeaux, France. Pharmacoepidem Drug Saf 2004;13:S292
383. Winterstein AG, Weiner ID, Johns TE, Hatton RC. Validation of automated database algorithms to identify hospital-acquired acute renal failure. ISPOR 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 2004, Arlington, VA. Value in Health 2004;7(3):366
 - Received poster finalist award
384. Pinto S, Segal R, Winterstein AG, Annis L, Robinson D, Yates D, Pederson L, Willis M. Evaluation of pharmacist interventions in diabetic patients from rural community health centers. American Pharmacist Association Annual Meeting, March 2004. Seattle; and ISPOR 9th Annual International Meeting; May 16-19, 2004, Arlington, VA. Value in Health 2004;7(3):337
 - Received APhA-APRS Postgraduate Best Paper Award in the Clinical Sciences section at the American Pharmacist Association Annual Meeting 2004, Seattle, USA.
385. Winterstein AG, Rosenberg EI, Johns TE, Hatton RC, Smith WD 2004. Nature of Medication Errors of Omission Identified through Solicited Reports by Attending Physicians in an Academic Medical Center. J Investig Med 2003;51(s1); February 12-14, 2004, Society of General Internal Medicine Southern Regional Meeting, New Orleans

386. Annis L, Robinson D, Segal R, Pederson L, Willis M, Yates D, Winterstein A, Pinto S, Skipper A. Evaluation of pharmacist interventions in diabetic patients from rural community health centers. American Society of Health Systems Pharmacist Midyear Clinical Meeting, December 2003. New Orleans
387. Smith WD, Winterstein AG, Johns TE. Identifying Root Causes of Hyper/Hypoglycemia Episodes in Adult Medical Patients. ASHP-Midyear-Clinical-Meeting 2003; 38(DEC); FGF-03. American Society of Health-Systems Pharmacist Midyear Clinical Meeting, December 6-10, 2003. New Orleans
388. Hartzema AG, Winterstein AG, Kwon S. A Cost-benefit model for perindopril in secondary stroke prevention. International Society for Pharmaceutical Outcomes research (ISPOR) Sixth International Conference, Nov 10, 2003. Barcelona, Spain (podium presentation)
389. Hartzema AG, Winterstein AG, Kwon S. A cost-benefit model for perindopril in secondary stroke prevention. 8th International Meeting of the International Society for Pharmaceutical Outcomes Research (ISPOR) May 18-21, 2003. Arlington
 - Received poster finalist award
390. Smith WD*, Winterstein AG, Johns TE, Fitzgerald L, Kennedy L, Sauer BC. Identifying Root Causes of Hyper/Hypoglycemia Episodes in Adult Medical Patients. Southeastern Residency Conference, May 8-10, 2003, Athens, Georgia (podium presentation)
391. Correll T*, Winterstein AG, Johns TE, Lawrence T. The incidence and clinical consequence of administration of penicillin and cephalosporin antibiotics in patients who have a documented beta-lactam allergy. Southeastern Residency Conference, Athens, Georgia, May 8-10, 2003 (podium presentation)
392. Soliman G*, Winterstein AG, Kimberlin C, DeLeon J. Enhancing diabetic patients' involvement in the prevention and recognition of medication errors in an acute care setting through the use of a patient training program. Southeastern Residency Conference, Athens, Georgia, May 8-10, 2003. (podium presentation)
393. Winterstein AG, Hartzema AG Development of Community Pharmacy-Based Quality Indicators.. American Pharmacy Association Annual Meeting, March 29th, 2003, New Orleans. (podium presentation)
394. Kanjanarat P*, Winterstein AG, Johns TE, Gonzalez-Rothi R, Hatton RC. Stimulated report of in-hospital medication errors of omission and commission utilizing personal digital assistants. American Pharmacy Association Annual Meeting, March 29th, 2003, New Orleans
395. Robinson JD, Segal R, Annis LG, Pederson L, Pinto SL, Winterstein AG. Managing diabetes in Florida-based community health centers. American Society of Health-Systems Pharmacists 37th Annual Clinical Midyear Meeting, December 2002, Atlanta. (ASHP-Midyear-Clinical-Meeting); 2002; 37(DEC)
396. Pharmacists' use of automated healthcare information for medication error prevention. Presentation: Development and results of automated screens for preventable adverse drug events. American Society of Health-Systems Pharmacists 37th Annual Clinical Midyear Meeting, December 10th 2002, Atlanta. ASHP-Midyear-Clinical-Meeting (ASHP-Midyear-Clinical-Meeting); 2002; 37(DEC); PI-167 (symposium development and podium presentation)
397. Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Pharmacoepidemiologic methods to detect preventable adverse drug events. 18th International Conference on Pharmacoepidemiology. Edinburgh, UK. August 19-21, 2002. Pharmacoepidemiology and Drug Safety 2002;11(S1):S198
 - Received EuroDurg Poster Award

398. Kanjanarat P*, Winterstein AG, Johns TE, Gonzalez-Rothi R, Hatton RC, Segal R. Stimulated Report of In-hospital Medication Errors of Omission and Commission Utilizing Personal Digital Assistants (PDAs). Drug Information Association (DIA) 38th Annual Meeting, Chicago, USA. 2002, June 16-20
 - Received student poster award
399. Winterstein AG, Kanjanarat P, Johns TE. Stimulated report of in-hospital medication errors or omission and commission utilizing personal digital assistants. The Southeastern Pharmacy Health Care Administration conference. Monroe, Louisiana. June 7-9, 2002
400. Sauer BC*, Winterstein AG, Mattenklotz AM. Design and Validity of Automated Health Care Data Screens to Detect Preventable Adverse Drug Events. Annual Meeting of the International Society of Pharmaceutical Outcomes Research, May 7th, 2002. Arlington, USA. Value in Health 2002;5(3): 225
401. Segal R, Winterstein AG, Robinson D, Annis L, Yates DW, Pederson L Managing diabetes in community health centers.. Annual Meeting of the American Pharmaceutical Association, March 2002. Philadelphia, USA
402. Choy H*, Winterstein A, Lipowski E, Chiu A, Davis J. Practice Variation among warfarin clinics. 36th Annual American Society of Health-System Pharmacy Midyear Clinical Meeting. December 2001, New Orleans
403. Winterstein AG, Johns TE. Introduction of a systematic approach to detect and reduce preventable adverse events. 36th Annual American Society of Health-System Pharmacy Midyear Clinical Meeting. December 2001, New Orleans (Symposium development and podium presentation); lecture Detection, Reduction and Measurement of preventable adverse drug events. ASHP-Midyear-Clinical-Meeting; 2001; 36(Dec); PI-168
404. Kanjanarat P*, Winterstein A, Segal R, Hatton RC, Gonzalez-Rothi R, Johns TE Preventable adverse drug events in hospitals: medications, types of errors, and outcomes. American College of Clinical Pharmacy (ACCP) Annual Meeting, October 2001, Tampa (poster presentation)
405. Bastardo YM*, Winterstein AG, Schaefer M. Performance of the MOS-SF 36 Health Survey to evaluate elderly patients health outcomes. Pharmaceutical Congress of the Americas, March 2001. Orlando, FL (poster presentation)
406. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospitals admissions and morbidity in hospital inpatients – a meta-analysis of prevalence reports. American Pharmaceutical Association 148th Annual Meeting, San Francisco, March 2001 (oral presentation)
407. Winterstein AG, Bastardo Y, Schaefer M. Performance of the SF-36 Health Survey in an elderly population. 60th Congress of the International Pharmaceutical Federation, August 2000. Vienna, Austria
408. Winterstein AG, Sauer BC, Hepler CD, Poole C. The incidence of preventable drug-related hospital admissions. 16th International Conference on Pharmacoepidemiology ISPE, August 2000. Barcelona, Spain. Pharmacoepidem Drug Saf 2000;9:S147-8
409. Sauer BC, Winterstein AG, Hepler CD, Poole C. The prevalence of preventable drug-related hospital admissions: a meta-analysis. 36th Annual Drug Information Association Meeting, San Diego, June 2000
 - received 1st place student poster division
410. Winterstein AG. Indicator development to evaluate the quality of pharmacotherapy and pharmacist performance. 11th International Social Pharmacy Workshop, Kuopio, Finland. June 2000 (oral presentation)

411. Winterstein AG, Hartzema AG, Hepler CD. International development of pharmacy-based indicators to improve asthma management. 59th World Conference of the International Federation of Pharmacists, special interest group pharmacoepidemiology/ pharmaco-economics, Barcelona, Spain. September 2000 (oral presentation)
 412. Winterstein AG, Schaefer M. A trial of a community pharmacists' pharmaceutical care program to improve drug therapy and health-related quality of life for elderly patients – introduction and preliminary results from the OMA project in Germany. International Congress on Clinical Pharmacy, American College of Clinical Pharmacy, April 1999. Orlando, USA
-

Curriculum Development / Organization of Conferences

Adult Attention Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development
Scientific Program Committee and Panelist, National Academies of Science, Engineering and Medicine,
Washington, DC December 4-5, 2023

Global Gator Symposium on Research in Clinical Pharmacology and Clinical Pharmacy
Basel, Switzerland, June 3rd, 2022

Cannabis Clinical Outcomes Research Conference (CCORC)

Consortium for Medical Marijuana Clinical Outcomes Research, Orlando, FL, May 19-20, 2022

International Society of Pharmacoepidemiology Midyear Meeting, virtual, April 2022

Cannabis Clinical Outcomes Research Conference (CCORC)

Inaugural conference of the Consortium for Medical Marijuana Clinical Outcomes Research held virtual
over 2 half days April 8-9, 2021

Critical Access Hospital Patient Safety Summit

1.5-day summit in collaboration with FMQAI and the Florida Department of Health. May 14-15, 2013.

Gainesville, FL. Curriculum and selected lectures developed in collaboration with Thomas Johns, PharmD,
BCPS

Critical Access Hospital Patient Safety Summit

1.5-day summit in collaboration with FMQAI and the Florida Department of Health. June 5-6, 2012.

Gainesville, FL. Curriculum and selected lectures developed in collaboration with Thomas Johns, PharmD,
BCPS

Critical Access Hospital Patient Safety Summit

1.5-day summit in collaboration with FMQAI and the Florida Department of Health. May 2-3, 2011.

Gainesville, FL. Curriculum and selected lectures developed in collaboration with Thomas Johns, PharmD,
BCPS

Critical Access Hospital Patient Safety Summit.

1.5-day summit in collaboration with FMQAI and Florida Department of Health, March 10-11, 2010,

Gainesville, FL. Curriculum and selected lectures developed in collaboration with Thomas Johns, PharmD,
BCPS

Critical Access Hospital Patient Safety Summit

One-day summit in collaboration with FMQAI and Florida Department of Health, March 18, 2009,

Gainesville, FL. Curriculum and selected lectures developed in collaboration with Thomas Johns, PharmD,
BCPS

ASHP Bootcamp

Curriculum development (jointly with Drs. Kathy Bungay and William Kelly) for the ASHP Research Foundation aimed at facilitating a start in research for clinicians. Development of 5 online learning modules and online assignments. Faculty at the 2.5-day experiential component comprising lectures and interactive development of participant research proposals. Bethesda, MD, May 4-6, 2011, May 19-21, 2010, and May 2008.

Critical Access Hospital Patient Safety Summit

1.5-day summit in collaboration with FMQAI and Florida Department of Health, November 13-14, 2007. Gainesville, FL. Curriculum and selected lectures developed in collaboration with Thomas Johns, PharmD, BCPS

Critical Access Hospital Patient Safety Summit

1.5-day summit in collaboration with FMQAI and Florida Department of Health, November 13-14, 2006. Gainesville, FL. Curriculum and selected lectures developed in collaboration with Thomas Johns, PharmD, BCPS

Critical Access Hospital Patient Safety Summit

1.5-day summit in collaboration with FMQAI and Florida Department of Health, November 15-16, 2004. Gainesville, FL. Curriculum and lectures developed in collaboration with Thomas Johns, PharmD, BCPS and Abraham Hartzema, PharmD, MSPH, PhD.

Critical Access Hospital Patient Safety Summit

1-day summit in collaboration with FMQAI and Florida Department of Health, August 13, 2003. Gainesville, FL. Curriculum and lectures developed in collaboration with Thomas Johns, PharmD, BCPS and Abraham Hartzema, PharmD, MSPH, PhD.

Grants and Contracts

Pain, Multimorbidity, Opioid-Drug Interactions and Risk for Opioid Use Disorder or Overdose in Older Adults

R01HS029001

PD/PI: Wei

Funded for \$1,999,906 by the Agency for Healthcare Research and Quality

04/01/2023-01/31/2028

Role: co-I (5%)

The major goal of this project is to examine the associations of pain, multimorbidity, and opioid-drug interactions with risk for opioid use disorder or overdose outcomes of older adults with chronic non-cancer pain.

Characterizing efficacy and safety of hormonal contraceptives by combining pharmacometrics and RWE

INV-047564

11/1/2022 – 10/31/2024

Funded for \$1,316,795 by the Bill and Melinda Gates Foundation

Principal investigator: S Schmidt

Role: co-I (7%)

The project aims to streamline the development and regulatory evaluation of long-acting hormonal contraceptives with focus on well-known drug substances

Medical Literature and Data on Cannabis Use

FDA-RFTOP-1262928

1/27/2023 – 5/27/2023

Funded for \$328,281 by the United States Food and Drug Administration via the Sentinel Initiative

Principal investigator: AJ Goodin

Role: co-I (20%)

This project will synthesize published evidence on the harms of medical and non-medical use of cannabis and the effectiveness of medical use of cannabis for select medical conditions.

Bayesian machine learning for complex missing data and causal inference with a focus on cardiovascular and obesity studies

1R01HL166324-01

3/1/2023 – 2/28/2027

Funded for \$2,105,501 by NHLBI

Principal investigator: M Daniels

Role: co-I (10%)

This application will address important public health problems indirectly, through machine learning methods for inference in the presence of missing data and for causal mediation, and directly through constructing these methods to specifically address important research questions involving cardiovascular health in underdeveloped settings, weight management in behavioral studies, the impact of the type of bariatric surgery on weight and cancer outcomes, and pharmacoepidemiologic studies of diabetogenic risk in treatment of hypertension and mental disorders.

Evaluation of Emerging Infections during Pregnancy and their Prevention and Treatment using Enhanced and Diverse Mother-Baby Cohorts – Emerging Infections and Treatment in Pregnancy (EI-TIP)

HHS75D30122C15503

9/30/2022-9/30 2024

Funded for \$748,553 by CDC

Principal investigator: AG Winterstein (20%) MPI with Sonja Rasmussen, Johns Hopkins

This study employs linked mother-baby cohorts established from individuals enrolled in public and private insurance to conduct epidemiologic studies that address two focus areas involving the risk and benefits, and determinants of use of prevention and treatment of emerging infections during pregnancy: the impact of recommendations for universal HCV screening during pregnancy, and the safety of prenatal exposure to doxycycline on fetal and infant outcomes.

Opioid prescribing practices and health outcomes among patients with Alzheimer's disease and related dementia

R01AG073442

9/1/2022-5/31/2026

Funded for \$2,176,552 by NIA

Principal investigator: Jenny Wei

Role: co-I / PI on UF sub-award (10%)

This project proposes a longitudinal study to assess the effects of opioid prescribing practices on outcomes of patients with Alzheimer's disease and related dementia (ADRD). The objective of this project is to 1) evaluate the effects of chronic opioid therapy and of the concurrent use of opioids with antidepressants or anticonvulsants; and (2) examine the effects of moderate-to-severe pain treated with vs. without opioids on cognitive function in older adults.

Big data approaches for Safe Therapeutics in Healthy Pregnancies (BOOST-HP)

R01HD110107

8/29/2022 – 4/30/2026

Principal investigator: AG Winterstein (20%) MPI with Judy Maro, Harvard

Funded for \$2,509,682 by NICHD

In this study we will combine innovative data-mining techniques that can evaluate multiple drugs and outcomes simultaneously with formal assessments of prioritized safety signals obtained from data mining in real world populations to accelerate the generation of evidence on the safety of medications during pregnancy.

Teratogenic risk impact and mitigation (TRIM): an evidence-based decision framework

HHS75F40121C00188

9/30/2021 – 9/29/2023

Principal investigator: AG Winterstein (20%)

Funded for \$749,980 by FDA

This proposal aims to provide comprehensive evidence on the prenatal exposure to teratogenic drugs, to develop an evidence-based Teratogenic Risk Impact and Mitigation (TRIM) Decision Tool to prioritize drugs for risk mitigation (REMS programs), and, harnessing data from billing and vital records to generate new evidence, to employ TRIM to prioritize drugs for risk mitigation.

Sentinel: TreeScan in Pregnancy – Maternal Outcomes

HHSF22320140030I/HHSF22301012T

12/1/2020 – 12/31/2022

Subcontract funded for \$62,749 by FDA

Principal investigator: Richard Platt

Role: PI on subcontract (2%)

The goal of this methods project is to evaluate the performance of TreeScan to assess maternal outcomes, test signal identification methods in a pregnancy setting, and evaluate methods performance using older drugs with relatively well characterized safety profiles.

Precision antiplatelet therapy after percutaneous coronary intervention

1 R01 HL149752

7/15/20 – 6/30/25

Principal investigator: L Cavallari

Funded \$3,551,537 by NIH/NCATS

Role: co-I (5% years 1,4 and 10% year 5)

Completion of this research project will elucidate the key factors that influence outcomes with a genotype-guided precision medicine approach to antiplatelet therapy and establish optimal strategies that improve outcomes with this approach in a diverse, real-world setting.

Epidemiology and cost of RSV infections in infants and toddlers

AGR DTD 05-15-2020

05/14/2020-6/30/2022

Merck Sharpe Dohme Corp. for \$247, 758

Principal investigator: AG Winterstein (14%)

This study will estimate the number and proportion of children <5 years of age with RSV-associated inpatient admissions or outpatient visits, and estimate RSV related costs, considering relative contributions of RSV infections to the overall burden of lower-respiratory tract infections and variation in disease incidence and cost across strata defined by chronological and gestational age, key risk conditions, plan type, and RSV season and geographic region.

AGR00014988

Merck – UF collaboration on joint research to train the next generation of pharmacoepidemiologists

01/01/2020-12/31/2024

Merck Sharpe Dohme Corp. for \$375,000

Principal investigator: AG Winterstein

In collaboration with Merck epidemiologists, UF will nominate senior graduate students to conduct pharmacoepidemiologic research on specific topics identified by Merck.

Reduction of inpatient hypoglycemia rates using EHR-based risk score stratification for prioritized care by diabetes management teams

UF Health-CTSI learning health system initiative subaward from UL1TR001427 provided by NIH/NCATS for \$111,706

Principal investigator: AG Winterstein

11/21/2019-11/20/2020

This study will refine a previous EHR-based hypoglycemia prediction algorithm, implement the algorithm in the UF Health EHR system and plan clinical roll-out of diabetes management care team's response to algorithm-prioritized high-risk patients.

Together: Transforming and Translating Discovery to Improve Health

UL1TR001427

Principal investigator: D Nelson

07/01/2019-6/30/2024

Funded by NIH/NCATS for \$29,618,462

Role: co-I (10%); Director for Regulatory Science (until 6/30/2023)

The University of Florida (UF) and Florida State University (FSU) CTSI hub will work within Florida to improve human health by accelerating the translation of scientific discoveries and the implementation of evidence-based best practices for the diagnosis, treatment, prevention and cure of human diseases across the lifespan. This anticipated award represents the next phase of evolution from creating a clinical and translational science infrastructure to enhancing the local, state and national impact of CTSI-led science with a special emphasis on underserved and unique patient populations.

Consortium for Medical Marijuana Clinical Outcomes Research

Principal investigator: AG Winterstein (30%)

7/1/2019 – 6/30/2024

Funded for \$7,500,000 by the State of Florida (annual state appropriation)

This state appropriation establishes the consortium for medical marijuana clinical outcomes research, charged to generate and disseminate evidence on the outcomes of the medical use of marijuana to inform clinical and policy decisions.

Etiology and Mechanisms of Opioid Overdoses – A Pilot Study of Interactions of Pain and Substance Use in a New Era of Reduced Access to Prescription Opioids and Increasing Overdose Rates

Principal investigators: H Young and AG Winterstein

06/01/2019 – 05/31/2020

Funded for \$72,558 by the University of Florida Center for Research to Investigate Substance use and Pain (UF-CRISP)

This project will serve as pilot study for a larger initiative that will recruit a geographically dispersed group of emergency departments (EDs) to implement a surveillance system that evaluates the circumstances of opioid overdoses. Recruited cases will be evaluated in the context of a linked cohort of individuals who reside in the ED-surrounding counties, using Medicaid and Medicare billing records. In addition to the rich clinical information, including continuous updates on emerging misuse pattern, we will examine the risk models to reveal mechanistic pathways considering complex interactions between various drugs and disease conditions including pain.

Developing a Real-Time Trajectory Tool to Identify Potentially Unsafe Concurrent Opioid and Benzodiazepine Use among Older Adults

1R21AG060308

Principal investigator: J Lo Ciganic

05/01/2019-01/2021

Role: co-I (2.5%)

Funded for \$308,206 by NIA

The study aims at developing an innovative, real-time “Predicting Risky Opioid-Benzodiazepine Trajectory e-Care Tool (PROTeCT)” for efficiently identifying and predicting subgroups of older adults (aged ≥50 years) with distinct and potentially unsafe patterns of opioid and benzodiazepine use.

Drug-Drug Interactions with Hormonal Contraceptive Agents- Prevalence and Real-World Effects on Unwanted Pregnancy and Venous Thromboembolism (sub-project for: Application of Physiologically-based Pharmacokinetic Models to Inform Dosing Recommendations for Hormonal Contraceptives co-Administered with Other Medications).

Principal investigator: S Schmidt

03/01/2018-10/31/2022

Role: Co-I (7-10%)

Funded for \$2,594,662 by the Bill and Melinda Gates Foundation.

This study uses Medicaid Analytic Extract (MAX) and commercial insurer data to characterize hormonal contraceptive utilization patterns and evaluate adverse events (e.g., venous thromboembolism, unwanted pregnancy) from drug-drug interactions with a host of perpetrator medications in women.

Safety of Gadolinium-enhanced MRI Exposure during Pregnancy on Adverse Fetal Outcomes

HHSF223201810083C

Principal investigator: AG Winterstein (10%)

9/12/2018 – 3/24/2021

Funded for \$385,035 by the FDA

This proposal has the primary aim to provide robust evidence on the safety of GBCA-enhanced MRI during pregnancy regarding adverse fetal outcomes to support regulatory decision-making. It will further establish enhanced capacity to evaluate emerging safety questions in pregnancy.

Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma

R01 HL136945

PI: K Blake (UF subcontract with Nemours Children's Hospital)

5/1/2018 – 03/31/2023

Role: co-I (1%)

Funded for \$714,513 (UF portion) by NIH/ NHLBI

The goal of this study is to develop a tailored, effective, and sustainable Medication Therapy Management video telehealth care intervention plus electronic adherence self-management to improve medication adherence and health outcomes for adolescents and young adults with asthma. This 5-year study also aims to determine cost-benefit of video telehealth care intervention plus mobile electronic self-management (using CareTRx sensors and mobile application).

Sparkling Advancements in Genomic Medicine

U01 HG007269 (competitive renewal)

Principal investigator: JA Johnson

7/1/2018 – 6/30/2023

Role: co-I (10%)

Funded for \$1,825,333 by NIH, National Human Genome Research Institute

This study will evaluate the effect of genotype-guided therapy on patients with pain or depression on health outcomes, well-being, healthcare utilization and cost.

Linkage of UF Health Electronic Health Records to Medicare Claims Data as a Rich Source of Clinical Data for Collaborative Research

Principal Investigators: Cavallari and Winterstein

7/1/2018-6/30/2019

Funded for \$34,000 by the UF College of Pharmacy – PROSPER shared resource research enhancement award

This award will allow purchase of 6 years of Medicare claims data for linkage to UF Health records to build the infrastructure for outcomes research.

Safety and Effectiveness of Medical Marijuana Utilization in Florida

Principal investigator: Winterstein

7/1/2017-6/30/2018

Funded for \$1,693,525 by the State of Florida (direct appropriation)

This study will describe socio-demographic and clinical characteristics of medical marijuana users and their neighborhoods at the beginning and throughout the growth of the Florida Medical Marijuana Program; evaluate the safety and effectiveness of medical marijuana in subpopulations with specific indications considering comorbidities and concomitant medication use; and conduct research on mechanisms and outcomes of drug-drug interactions considering prevalent marijuana co-medication pattern in marijuana registry patients.

Developing the Capability of Using National Medicaid data for FDA Post-Marketing Surveillance to Assess Medication Safety During Pregnancy

HHSF223201400043I

Principal investigator for prime contract with FDA: Huybrechts

Principal investigator for UF subcontract: Winterstein (20%)

9/30/2017-3/31/2021

Funded for \$500,916 (UF portion) by the FDA

This study will develop and validate Medicaid-specific algorithms to estimate gestational age for live birth pregnancies, explore methods to identify non-live birth pregnancy outcomes (e.g., stillbirth, induced abortion, spontaneous abortion) and estimates for the gestational length of these pregnancies, if deemed feasible, and develop analytic tools to assess the impact on relative risk estimates of exposure misclassification (due to errors in estimation of gestational age and exposure measurement), outcome misclassification (due to lack of outcome validation), selection bias (due to failure to include non-live births), and residual confounding (due to missing covariates in EHD).

Genomic Medicine Implementation: The Personalized Medicine Program – administrative supplement

U01 HG007269-04S2

Principal investigator: JA Johnson

09/7/2017-04/30/2018

Role: Co-I (5%)

Funded for \$610,207 by NIH/NHGRI

The purpose of the main administrative supplement request is to seek funding to advance a variety of cross network analyses and projects that should significantly advance pharmacogenomic implementation and the IGNITE network. The other three administrative supplements are to continue our leadership in the Pharmacogenetics Working Group, the Provider Adoption, Barriers, and Education Working Group and the IGNITE website.

Improving Causal Inference via New Statistical Learning Methods with High Dimensional Data

HSRP20164102

Principal investigator: Tan

7/1/2016 - 10/2020

Role: consultant (3 days)

Funded for \$675,248 by PCORI

This study will exploit several novel ideas, based on combining inverse probability weighting and machine learning techniques, to systematically address various open issues associated with model building and estimation, learning algorithms, and parameter regularization. It will evaluate and compare the performances of new and existing methods, using both simulations and empirical data from ongoing pharmacoepidemiological studies.

Medicaid Drug Therapy Management Program for Behavioral Health – Use of antipsychotics in preschoolers

Principal investigators: Winterstein (20%) and Wei (30%)

11/1/2016 – 6/30/2017

funded for \$164,969 by the Agency for Healthcare Administration Medicaid Program via a subcontract with the University of South Florida

The purpose of this study is to (a) examine psychotropic drug utilization trajectories in preschoolers started on antipsychotic over the past 15 years in Florida (comparing time periods before and after introduction of the prior authorization program), and (b) to evaluate the effects of exposure to antipsychotics during early childhood on somatic side effects including type 2 diabetes and tardive dyskinesia.

The Child Health Quality (CHeQ) Partnership Program

U18HS025298

Principal investigator: Shenkman

Role: co-investigator 2.5% (years 1-3)

09/30/2016 – 09/29/2020

funded for \$2,638,534 by the Agency for Healthcare Research and Quality

This study will test the feasibility and usability of children quality of care measure sets through field testing and translating results into QI goals and multi-level performance improvement projects. In addition, it will implement and disseminate leading-edge methods to evaluate and compare quality of care at multiple levels, including the state, health plan, and provider levels.

Evaluating changes in Order Sets for Inpatient Pain Management

UF Health Shands Endowment Fund

Principal investigator (0%)

1/1/2016 – 6/30/2016

funded for \$27,828 by UF Health

This study will evaluate the effectiveness and safety of newly implemented explicit opioid titration protocols at UF Health Shands.

Real-time risk stratification of for hypo- and hyperglycemia to enhance glucose management outcomes in hospitals.

HHSF-223-2015-10118C [FDABAA-15-00121]

Principal investigator (PI): Winterstein (10%)

9/30/2015-9/29/2017

funded for \$296,477 by the Food and Drug Administration

This study will evaluate the effectiveness of an EHR-based algorithm that ranks patients according to hypo- and hyperglycemia risk for pharmacist intervention in two UF Health hospitals.

Real-time communication of hypoglycemic risk to prioritize pharmacy medication management services

Principal investigator (PI): Winterstein (0%)

7/1/2015-6/30/2016

funded for \$30,337 by the UF College of Pharmacy PROSPER Excellence Award

This study will pilot the feasibility and effectiveness of an EHR-based algorithm that ranks patients according to hypoglycemia risk for pharmacist intervention.

Inpatient Psychiatric Facility Outcome and Process Measure Development and Maintenance

HHSM-500-2013-13007I [HHSM-500-T0004]

Principal investigator (PI): Winterstein (20%) for UF/UF Health, Subcontract with Health Service Advisory Group

9/30/2014-9/29/2018

Funded for \$2,006,320 (UF portion) by the Centers for Medicare and Medicaid Services

This contract will support the development and validation of eight new performance measures for inpatient psychiatric facilities along with the maintenance of existing measures.

Patient-Centric, Telephonic MTM Services after Discharge to Reduce Hospital Readmissions.

Consultant (PI: McLin)

Funded for \$56,436 by the UF Health Shands Quasi Endowment Fund

Attention Deficit Disorder and Attention Deficit Disorder with Hyperactivity (ADD/ADHD) Treatment Patterns in Adult Medicaid Beneficiaries

PI: Winterstein (10%)

MED152, AHCA Contract Title: Florida Center for Medicaid and the Uninsured (FCMU) University of Florida
7/1/2013 – 6/30/2015

Funded for \$155,158 (\$357,200 with state matching funds) by the Florida Agency for Healthcare Administration (AHCA)

This will be the first study to comprehensively describe ADD/ ADHD treatment modalities in adult Medicaid beneficiaries.

Psychotropic Polypharmacy in Florida Medicaid

PI: Winterstein (7%)

MED152, AHCA Contract Title: Florida Center for Medicaid and the Uninsured (FCMU) University of Florida
7/1/2013 – 6/30/2015

Funded for \$211,266 (\$392,587 with state matching funds) by the Florida Agency for Healthcare Administration (AHCA)

This study aims to quantify potentially inappropriate psychotropic polypharmacy patterns in Medicaid children and adults. With focus on the Florida Medicaid program it will develop and present measures of polypharmacy in 29 US states and discuss variation in terms of presence of prior authorization programs or other efforts to improve psychotropic use.

Age-related Effects of Respiratory Syncytial Virus (RSV) Risk in Children with Chronic Lung Disease

PI: Winterstein (14%)

MED152, AHCA Contract Title: Florida Center for Medicaid and the Uninsured (FCMU) University of Florida
7/1/2013 – 6/30/2015

Funded for \$144,354 (\$279,100 with state matching funds) by the Florida Agency for Healthcare Administration (AHCA)

This study will expand on previous analyses in the Florida Medicaid population to evaluate at what age the RSV infection risk of children with chronic lung disease has dropped to the level of infection risk of healthy children at their first months of life to inform clinical and policy decisions regarding immunoprophylaxis.

Development and validation of a complexity score to identify hospitalized patients at high risk for preventable adverse drug events

PI: Winterstein (15%)

7/1/2013-6/30/2015 (no cost extension to 6/30/2016)

Funded for \$499,199 by the American Society for Health-Systems Pharmacy Research Foundation

PI: Winterstein

This grant uses electronic clinical data of 13 hospitals with diverse patient populations and electronic health records to develop and validate a prospective risk scoring system that can flag hospitalized patients at risk for preventable adverse drug events.

Scalable PARTnering Network for CER: Across Lifespan, Conditions, and Settings

Subcontract to ARRA Award (PI: Daley)

1R01HS019912-01

Principal investigator for subcontract: Winterstein (10%)

7/1/2012 – 9/29/2013

Funded for \$32,766 by the Agency for Healthcare Research and Quality (AHRQ)

The grant aims to design and implement an innovative, sustainable, distributed data network with enhanced capabilities to support comparative effectiveness research (CER) and to build four pairs of population-based cohorts suitable for conducting CER. The subcontract focuses on the development and evaluation of a cohort of children with attention deficit/hyperactivity disorder.

Imbalanced confounder associations between exposure versus outcomes can compromise propensity score-based adjustments – examination of a real-life example in pediatric psychopharmacology

DEcIDE-2 Subcontract: Research Consortia for Comparative Effectiveness Studies in Cancer, Cardiovascular Disease, Diabetes/ESDR, and Mental Health (PI: Crystal)

HHSA-290-2010-00010I

Principal investigator for subcontract: Winterstein (time donated)

6/12/2012-8/31/2012

Funded for \$25,379 by the Agency for Healthcare Research and Quality (AHRQ)

This subcontract utilizes a real-life example in the evaluation of central nervous system stimulant safety to evaluate the validity of propensity score-based confounding adjustments in scenarios where confounder associations with exposure and outcomes are imbalanced.

Maintenance and Development of Medication Measures

HHSM-500-2011-FL10C

PI: Winterstein (20%) for UF/UF&Shands, Subcontract with Health Service Advisory Group/FMQAI

8/1/2011-7/31/2014

Funded for \$942,207 (UF portion) by the Centers for Medicare and Medicaid Services

Objectives:

- Develop new medication measures that address the detection and prevention of adverse medication-related patient safety events that can be used in future QIO SOWs and in CMS provider reporting programs
- Maintain the previously developed medication measures that are used in the 10th SOW, and/or are NQF endorsed
- Adapt/specify existing NQF-endorsed medication measures and develop new measures for implementation in CMS reporting programs

Medication Error Prevention and Reduction in Florida Critical Access Hospitals

PI: Winterstein (5/1/2006 - 8/31/2014)

Co-Principal investigator with Abraham Hartzema from 1/1/2003 - 4/30/2006)

Subcontract with the Florida Medical Quality Assurance, Inc.

Annual renewable contract; \$326,870 total funding by the Florida Department of Health

Objectives:

- Evaluate and improve medication safety infrastructure, process and outcomes in Florida Critical Access Hospitals
- Develop a standardized medication safety assessment instrument specific to Critical Access Hospitals

Maintenance and Development of Medication Measures Special Project

HHSM-500-2008-AZ9THC

PI: Winterstein (20%), Subcontract with Health Service Advisory Group

10/1/2009-6/30/2011

Funded for \$152,247 (UF portion) by the Centers for Medicare and Medicaid Services

Objectives:

- Develop new medication measures that address medication use in ambulatory or long-term care relevant to Medicare Part D beneficiaries and that can be used in future QIO SOWs and in CMS provider reporting programs
- Maintain the previously developed medication measures that are used in the 10th SOW, and/or are NQF endorsed
- Adapt/specify existing NQF-endorsed medication measures and develop new measures for implementation in CMS reporting programs

Risk of RSV Infections and Effects on Prognosis in Children with Cystic Fibrosis

Amendment to MED054 (under CFDA 93.778)

PI: Winterstein (35%)

11/1/2009 – 6/30/2011

Funded for \$403,000 by the Florida Agency for Healthcare Administration through the Centers for Medicare and Medicaid (\$740,000 with state matching funds)

Objectives:

- Assess the impact of respiratory syncytial virus infections on CF progression
- Evaluate the effectiveness of palivizumab for RSV prophylaxis in infants and children with cystic fibrosis

Comparative Safety and Effectiveness of Stimulants in Medicaid Youth with ADHD

R01-HS0185606

PI: Winterstein (40%)

9/30/2009 – 9/29/2011

Funded for \$482,000 by the Agency for Healthcare Research and Quality (AHRQ)

Objectives:

- Evaluate the cardiovascular safety of central nervous system stimulants in the treatment of ADHD
- Evaluate synergistic effects of psychiatric polypharmacy on cardiovascular safety
- Evaluate the effectiveness of stimulant treatment on driving performance in youth with ADHD

Pharmaceutical Outcomes and Policy Research Training Program for Health Science Graduates – Cohort 1&2

PI: Winterstein (25%)

7/2/2009 – 7/31/2012

Funded for \$532,674 (cohort 1) and \$876,618 (cohort 2) by FDA/CDER

Objectives:

- Train 5 (cohort 1) and 10 (cohort 2) new FDA employees on the level of a MSc in pharmaceutical outcomes and policy research

Effectiveness of Palivizumab in Older Infants

MED054 (under CFDA 93.778)

PI: Winterstein (20%)

7/1/08 – 6/30/10

Funded for \$269,772 by the by the Florida Agency for Healthcare Administration through the Centers for Medicare and Medicaid (CMS)

Objectives:

- Evaluate the effectiveness of palivizumab in prevention of respiratory syncytial virus infections in younger (0-12 months) versus older (13-24 months) children

RSV Seasonality in Florida and Recommendations for Timing of Immunoprophylaxis

MED054 (under CFDA 93.778)

PI: Winterstein (20% in 08/09 and 10% in 09/10)

7/1/08 – 6/30-10

Funded for \$199,337 by the by the Florida Agency for Healthcare Administration through the Centers for Medicare and Medicaid (CMS)

Objectives:

- Evaluate the CDC definition of RSV seasonality against hospitalizations incidence data
- Determine RSV seasons specific to Florida geographic regions
- Describe palivizumab utilization pattern and contrast these against RSV seasonality

Risk Factors for Intraoperative Vasoplegia and Post-surgical Recovery

PI: Winterstein (time donated)

5/1/2008 - 10/31/2009,

Funded for \$73,370 by the University of Florida, Office of Research, Research Opportunity Fund

Objectives:

- Develop a database linkage between Shands at UF hospital administrative data, the Cardio-thoracic surgery registry data, and the Intraoperative anesthesia database to establish a comprehensive repository to evaluate the effect of pre- and intraoperative medication use on surgical outcomes
- Evaluate the effect of ACE-inhibitor use on intraoperative vasoplegia and post-surgical recovery

Consumer medication information evaluation project

FDA-SOL-07-00234

Co-Principal investigator (15%) (with Carole Kimberlin)

8/2007 – 7/2008

Funded for \$191,008 by the Food and Drug Administration (FDA) though a subcontract with the National Association of Boards of Pharmacy

Objectives:

- Evaluate the compliance of medication information leaflets with FDA regulatory guidance
- Evaluate consumer comprehension of medication information leaflets
- Describe the offer and extent of counseling offered in UF retail pharmacies

Clinical Predictors of Non-Use of Perioperative Beta-Blockers

Co-Principal investigator (2%) (with Eric Rosenberg, MD)

3/1/07 – 2/28/08

Funded for \$11,300 by the University of Florida College of Medicine Clinical Education Initiative grant program

Objectives: Describe patient and provider characteristics that are associated with non-use of indicated peri-operative beta-blockers.

Palivizumab utilization, effectiveness, cost among Florida Medicaid recipients

PI: Winterstein (30%)

1/1/07 – 7/37/2008

Funded for \$241,397 by the Florida Agency for Healthcare Administration through the Centers for Medicare and Medicaid

Objectives:

- Describe the compliance with palivizumab utilization guidelines

- Evaluate palivizumab effectiveness in RSV infection prevention in community-dwelling infants and children
- Assess the cost-effectiveness of palivizumab use in RSV prevention

Academic Quality Support Agreement (AQSA) Clinical queries support

PI: Winterstein 7/1/05 - 6/30/06

Funded for \$10,000 plus 2-year graduate assistantship (\$56,000) by UF&Shands and College of Medicine at the University of Florida

Objectives:

- Develop and maintain 5 quality measures to contribute to Shands at UF hospital's pay-for-performance agreement (AQSA) with the UF College of Medicine
- To provide data support for quality improvement initiatives implemented as part of the AQSA agreement

Safety of central nervous system stimulants in the treatment of attention deficit / hyperactivity disorder in children and adults

PI: Winterstein (10%)

9/10/05 – 9/30/06

Funded for \$26,450 by the Florida Agency for Healthcare Administration through the Centers for Medicare and Medicaid

Objectives:

- Describe secular stimulant utilization pattern in Florida Medicaid children
- Evaluate the cardiovascular safety of central nervous system stimulants

Prophylactic use of nesiritide (Brain Natriuretic Peptide, BNP) for the prevention of acute renal failure in thoracic aortic aneurysm patients

PI: Ejaz

Investigator (10%)

3/1/05 - 2/29/06 (extended to 2008)

Funded for \$450,582 by Johnson & Johnson

Objectives: Evaluate the efficacy of nesiritide on the prevention of acute renal failure in patients undergoing thoracic aortic aneurysm repairs

Health Information Technology (HIT) for Medication Safety in Critical Access Hospitals

P20 HS015325-01

PI: Hartzema

Investigator (10%),

10/1/04-3/31/05

Funded for \$147,559 by the Agency for Healthcare Research and Quality (AHRQ)

Objectives:

- Evaluate HIT needs in Florida Critical Access Hospitals
- Develop an HIT implementation plan for these hospitals

Evaluation of Bristol-Myers Squibb-sponsored Disease Management Program for Florida Medicaid Populations

PI: Segal

Investigator (13%)

7/1/2004 - 12/31/2005

Funded for \$120,628 by the Florida Agency for Healthcare Administration

Objectives: Evaluate the effectiveness of a faith-based disease management program for diabetes patients in Medicaid

Clinical and economic evaluation of nesiritide in the prevention of acute renal failure after cardiac surgery.

Co-Principal Investigator (7.5%) with Abraham Hartzema

5/1/2004 - 7/31/04

Funded for \$26,566 by UF&Shands Healthcare

Objectives: Evaluate the effectiveness of nesiritide in the prevention of acute renal failure after cardio-thoracic surgery

Evaluation and prediction of the long-term cost-benefit of a diabetes care program for Medicaid recipients

PI: Robert F. Frank

Investigator (40%)

3/1/2003 – 6/30/2004

Funded for \$576,944 by the Florida Agency for Healthcare Administration

Objectives:

- Develop a prediction model to quantify the impact of reduction in HbA1c on micro- and macrovascular outcomes in diabetes
- Assess Medicaid-specific cost associated with diabetes-related complications
- Develop an impact model that quantifies short- and long-term cost avoidance related to improvements in HbA1c

Nature and etiology of medication errors of omission – creating an advanced knowledge base through solicited error reporting

Co-Principal investigator (10%) with Eric I. Rosenberg,

9/1/2002 – 8/31/2003

Funded for \$24,617 by the Drug Information Association

Objectives: Quantify and describe types of medication errors of omission in general medicine wards

Clinical Pharmacy Demonstration Project in Community Health Centers

Investigator (time donated)

PI: Dan Robinson

1/1/2002 - 6/30/2004

Funded for \$250,000 by the Bureau of Primary Health Care, HRSA

Objectives: Implement and evaluate the effectiveness of a pharmacy-centered diabetes management program in community health centers

Development of a screening tool for medication errors in hospital inpatients

Principal investigator (time donated)

5/1/2001 – 4/30/2003

Funded for \$ 50,000 by the University of Florida, Research and Graduate Programs, Research Opportunity Fund

Objectives: Development and validation of quality measures for preventable drug-induced kidney injury in acute care

Development of a screening instrument for preventable drug-related morbidity in hospital inpatients

PI: Winterstein (10%)

1/1/2001 – 12/31/2003

Funded for \$22,900 by the American Society of Health-System Pharmacists Research and Education Foundation

Objectives:

- Assessment of high-priority areas of preventable adverse drug events through literature search, analysis of UF&Shands' adverse drug reaction reporting database, and a solicited error reporting study
- Development of quality measures for preventable hypo- and hyperglycemia in acute care

Qualipharm project

Co-Principal Investigator with Abraham G. Hartzema (0%)

1/1/2000 – 12/31/2000

Funded for \$22,995 by the International Federation of Pharmacy Associations (FIP)

Objectives: Development and validation of community-based quality indicators for asthma management

PICQIP performance indicators for continuous quality improvement in pharmacy.

Research fellow (100%)

PI: Charles D. Hepler

3/1/1999 – 2/28/2000

Funded by American Pharmaceutical Association for \$ 35,000

Objectives: Development and validation of quality indicators for ambulatory care pharmacy

Improving the well-being of elderly patients via community pharmacy based pharmaceutical care.

Research fellow

1996-1999

Principal investigator: James McElnay

Funded for ECU 300,000 by the Biomed-2 program of the European Union

Objectives: Develop, implement, and evaluate a community-based pharmaceutical care program for elderly patients. Included study sites in 8 European countries.

"OMA-study": pharmaceutical care for elderly patients with multi-morbidity

PI: Marion Schaefer

1996-1999

Role: Project director

Funded for DM 150,000 by the Pharmacy Association of Westfalia-Lippe, Germany

Objectives: Develop, implement, and evaluate a community-based pharmaceutical care program for elderly patients. Included 40 community pharmacies in Germany.

Berlin Study: quasi-experimental study to improve drug therapy outcomes in an elderly multi-morbid population.

PI; Marion Schaefer

1995-1997

Role: Project director

Funded for DM 20,000 by the Pharmaceutical Association of Berlin, Germany

Objectives: Feasibility study to evaluate the effectiveness of pharmaceutical care interventions in elderly patients

Fellowship / Career Award / Training Grants for Mentees

K08AG066854

Preventing the Calcium Channel Blocker – Lower Extremity Edema – Loop Diuretic Prescribing Cascade in Older Adults

Principal investigator: Scott Vouri

5/1/2021-3/31/2025

Funded for \$643,854 by National Institute on Aging

Role: Primary mentor

Major Goals: The major goals are to 1) evaluate the incidence of the calcium channel blocker-induced lower extremity edema loop diuretic prescribing cascade and 2) quantify excess adverse events that can negatively impact functionality and mobility from the calcium channel blocker-induced lower extremity edema loop diuretic prescribing cascade

Preventing and Eliminating the Calcium Channel Blocker – Lower Extremity Edema – Loop Diuretic Prescribing Cascade in Older Adults

Principal investigator: Scott Vouri

04/01/2019-3/31/2021

Funded for \$104,000 by UF Institute on Aging Pepper Junior Research Scholar Awards Program

Role: Primary mentor

Objectives:

- Develop and validate a claims-based algorithm to identify older adults with CCB→LEE→Loop PC.
- Estimate the incidence of CCB→LEE→Loop PC in older Medicare beneficiaries
- Quantify the association of excess AEs in older adults with CCB→LEE→Loop PC.

K01HL138172

Advancing Personalized Hypertension Care through Big Data Science

Principal investigator: Steven M Smith

07/15/2018-06/30/2023

Funded for \$760,778 by NHLBI

Role: Co-mentor

K01DA045618

Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations

Principal Investigator: Haesuk Park

05/01/2018 – 04/30/2023

Funded for \$648,422 by NIDA

Role: co-mentor

Research objectives:

- Understand physicians' attitudes and practices toward treating HCV-infected patients with substance use disorder and/or HIV co-infection in relation to Medicaid prior authorization policies

- Compare treatment initiation rates among patients (i) HCV mono-infected with substance use disorder, (ii) HCV mono-infected without substance use disorder; (iii) HCV/HIV co-infected with substance use disorder; and (iv) HCV/HIV co-infected without substance use disorder using two large states (Florida and Texas) Medicaid data
- For treated HCV patients, we will link the Medicaid dataset of patients with HCV-TARGET registry data to examine adherence to antiviral regimes and sustained virologic response (SVR) and investigate whether adherence and SVR are moderated by substance use disorders and/or HIV co-infection.

1K01AG054764-01A1

Pharmacological Management of Pain in Alzheimer's Disease and Related Dementia

Principal Investigator(s): Yu-Jung Wei

08/01/2017 – 05/31/2022

Funded by NIA

Role: Primary Mentor

Objectives:

- Provide preliminary data that improve our understanding of current pain medication prescribing and potential discrepancies between practices and pain guidelines
- Validating MDS-based pain, depression, and behavioral symptoms against medical records at two nursing homes
- Explore the quality of pharmacological pain management and its determinants among ADRD and non-ADRD residents with non- cancer
- Explore the extent to which pain control is associated with a decreased risk for select MH disorders, including depression, behavioral symptoms, anxiety, and sleep disorders in ADRD

UF Institute on Aging Pepper Junior Research Scholar Award

Principal Investigator(s): Yu-Jung Wei

08/01/2017 – 07/31/2019

Role: Primary Mentor

Funded for \$125,000 by UF Institute on Aging Pepper Junior Research Scholar Awards Program

UF Institute on Aging Pepper Junior Research Scholar Award

Principal Investigator: Josh Brown, PharmD, MS, PhD

08/01/2017 – 07/31/2019

Role: co-mentor

Funded for \$125,000 by UF Institute on Aging Pepper Junior Research Scholar Awards Program

CTSC KL2 – Chronic conditions, polypharmacy, and Service Utilization among children from low income families

External Mentor for Paul Bakaki, Research Scientist in Epidemiology and Biostatistics, School of Medicine at Case Western Reserve University 2015-2019

R36-HS-022384-01 - Pre-existing diabetes and pregnancy

Principal mentor/thesis advisor for grant and dissertation committee chair for Caitlin Knox, MPH

Funded for \$22,000 by the Agency for Healthcare Research and Quality (AHRQ) 2013-2014

Prevalence and incidence of nontuberculous mycobacteria in patients with cystic fibrosis

Student sponsor / dissertation committee chair, Efe Eworuke, BSpharm, MS
Funded for \$1,500 by the Cystic Fibrosis Foundation. 2012-2013

Type II Diabetes in Pregnant Women: Incidence, Drug Utilization and Outcomes of Women with Type II Diabetes during Pregnancy.

Dissertation committee chair, Caitlin Knox, MPH

Funded for \$6500 by the American Foundation for Pharmaceutical Education (AFPE) Fellowship Program. 2011-2012

Effectiveness of Palivizumab Immunoprophylaxis in Children (and Youth) with Cystic Fibrosis.

Student sponsor / dissertation committee chair, Efe Eworuke, BSPharm, MS

Funded for \$1500 by the Cystic Fibrosis Foundation. 2010-2011

Preventable kidney injury in critical care

Research mentor for Ashley Tyler, PharmD candidate

(5/22/06 - 7/4/06)

Medical Science Research Program Fellowship funded for \$5,000 by NIH T35-HL07489

Diuretic Therapy and the α -Adducin Polymorphism: Analysis of Gene-Drug Interactions in nested case-control studies

Dissertation committee chair, Tobias Gerhard, BSPharm

Funded for \$5,000 by the UF Perry A. Foote Small Grants Program. 6/1/05-5/31/06

Identifying root causes of hyper- and hypoglycemic episodes for the development and implementation of interventions to decrease their incidence.

Research advisor (residency project: Wendy D. Smith, PharmD)

12/1/2002 – 11/30/2003

Funded for \$1,900 through the American Society for Health Systems Pharmacists Research and Education Foundation Resident Medication Safety Grant Program

PROFESSIONAL SERVICE

Ad hoc reviewer for professional journals

2010 – present Acta Psychiatrica Scandinavica

2015 – present Administration and Policy in Mental Health and Mental Health Services Research

2011 – present AHRQ DEcIDe Effective Health Care Program

2017 – present American Journal of Epidemiology

2012 – present American Journal of Drug and Alcohol Abuse

2007 – present American Journal of Health Systems Pharmacy

2014 – present Annals of Pharmacotherapy

2018 – present Basic and Clinical Pharmacology and Toxicology

2011 – present BioMedCentral Pediatrics

2018 – present Birth Defects Research

2013 – present BMJ
 2017 – present Clinical Infectious Disease
 2020 – present Drugs Real World Outcomes
 2014 – present Drug Safety
 2009 – present Drugs and Aging
 2017 – present Early Human Development
 2013 – present Epidemiology
 2012 – present Expert Review of Pharmacoeconomics and Outcomes Research
 2007 – present Medical Research and Opinion
 2004 – present Clinical Pharmacology and Therapeutics
 2004 – present International Journal of Clinical Pharmacy
 2014 – present Journal of the American Heart Association
 2003 – present Journal of American Pharmaceutical Association
 2010 – present Journal of Child and Adolescents Psychopharmacology
 2007 – present Journal of the American Medical Association JAMA
 2019 – present Journal of the Pediatric Infectious Diseases Society
 2007 – present JAMA Internal Medicine
 2016 – present JAMA Pediatrics
 2003 – present Journal of Pharmaceutical Finance, Economics and Policy
 2018 – present New England Journal of Medicine
 2010 – present Pediatrics
 2019 – present Paediatric and Perinatal Epidemiology
 2011 – present Pharmacotherapy
 2004 – present Pharmacological Research
 2009 – present Pharmacoepidemiology and Drug Safety
 2022 – present PLoS Medicine
 2011 – present PLoS ONE
 2020 – present Public Health Reports
 2012 – present Reproductive Toxicology
 2008 – present Value in Health

Editorial Boards

2009 American Journal of Health System Pharmacy Research Series
 (guest editor for Research Fundamental Series – 12 papers)

2023 – present Drug Safety

Grant review panels

2023 NIH: Special Emphasis Panel/Scientific Review Group 2023/05 ZRG1 HSS-P (90) S
 2023 NIH: ZRG1 CTH-F-71 Maternal Health Research Centers Special Emphasis Panel
 2012 NIH: Special Emphasis Panel/Scientific Review Group 2012/10 ZMH1 ERB-I
 2010 Florida Department of Health, FLEX Grants
 2009 - 2012 American Society of Health Systems Pharmacist Research Foundation, Research Bootcamp applications

2009	CDC Study Section ZCD1 SXQ 02
2009	Idaho Board of Education, Center Grants
2006 - 2007	Florida Health Information Network / Governor's Advisory Board for the Implementation of Health Information Technology, Grant Program
2006, 2008	University of Florida, Division of Sponsored Research, Research Opportunity Fund
2006	American Society for Health Systems Pharmacist Research and Education Foundation, Junior Investigator Grant Program
2006	Michael Smith Foundation for Health Care Research; Senior Scholar Award Program
1999 - 2003	German Pharmaceutical Care Foundation

Tenure & Promotion and Program & Center Reviews

Wayne State University College of Pharmacy	2023
University of Pennsylvania Department of Epidemiology and Biostatistics	2023
Harvard School of Medicine Department of Medicine	2023
Robert Wood Johnson Medical School Department of Pediatrics	2022
University of Illinois in Chicago Center for Pharmacoepidemiology and Pharmacoconomics Research	2022
Brown School of Public Health	2022
University of North Carolina at Chapel Hill School of Public Health Department of Epidemiology	2021
UT Health School of Public Health	2021
Johns Hopkins School of Medicine	2021
University Regensburg, Germany	2021
Skaggs School of Pharmacy, University of California San Diego	2020
Harvard School of Medicine, Department of Population Medicine	2020, 2023
University of Illinois in Chicago College of Pharmacy	2015, 2019
John Hopkins Bloomberg School of Public Health	2014, 2018
University of Washington College of Pharmacy	2017
University of Kentucky College of Pharmacy	2017
University of North Carolina at Chapel Hill School of Pharmacy	2017
University of Colorado Skaggs School of Pharmacy	2016
University of Pittsburg, College of Pharmacy	2016
University of Pennsylvania	2016
University of Nebraska Medical Center	2016
University of North Carolina at Chapel Hill School of Public Health	2015, 2021
National University of Singapore Department of Pharmacy	2014
Northeastern School of Pharmacy	2014
Harvard School of Public Health Department of Epidemiology	2014
Oregon State University College of Pharmacy	2012, 2014, 2018, 2019
University of New Mexico College of Pharmacy	2011, 2020
University of Florida College of Medicine	2010

Memberships, Committees, Advisory Boards

International Society of Pharmacoepidemiology

2023 – 2024	Chair, Scientific Program Committee Midyear Meeting 2024
2021 – 2022	Chair, Scientific Program Committee Midyear Meeting (virtual)
2020 – 2021	Chair, Fellowship & Awards Committee
2020 – 2021	Chair, Nomination Committee
2020 – 2021	Chair, Management Oversight Committee
2020 – 2021	Immediate past president
2019 – 2020	President
2019 – 2020	Chair, Scientific Program Committee ICPE Midyear Meeting 2020
2018 – 2019	Chair, Strategic Planning Committee
2018 – 2019	Scientific Program Committee ICPE Annual Meeting 2019
2018 – 2019	President elect
2016 – 2017	Scientific Program Committee ICPE Annual Meeting 2017
2014 – 2017	Board member
2011 – present	Faculty Advisor, UF ISPE student chapter
2011 – 2012	Chair, Academic Council
2010 – 2012	Scientific Program Committee ICPE Midyear 2012
2008 – present	Education Committee
2000 – present	Member

American Society of Health Systems Pharmacists

2005 – 2010	Chair, Research Advisory Board ASHP Research Foundation
2004 – 2018	Member, Research Advisory Board ASHP Foundation
1998 – present	Member

American Association of Colleges of Pharmacy

2010 – 2011	Committee for Graduate Programs
2001 – present	Member

FDA – Center for Drug Evaluation and Research (CDER)

2015 – present	Academic partner, Sentinel
2012 – 2018	Chair, Drug Safety and Risk Management Advisory Committee (DSaRM)
2011 – 2012	Member, DSaRM
2009 – 2011	Consultant to DSaRM
2011 – 2012	Mini Sentinel Safety Science Committee, consultant

UF/UF Health

2022 – 2023	Member, search committee for UF Health chief research information officer
2022 – present	Member, Search committee for college of pharmacy dean
2021 – 2022	Organizing committee for UF College of Pharmacy Global Gator Meeting in Basel 2022
2021 – 2023	Member, UF Health Sciences AI faculty search steering committee
2021 – 2023	Chair, UF Health Sciences AI faculty search committee for AI in decision support and precision health

2020 – 2022	UF Equitable AI Working Group
2020 – 2021	Search committee for UF CTSI director
2018 – present	Co-lead, College of Pharmacy International Research Internship Program for Pharmacists
2018 – 2019	UF Office of Research, Working Group on Research Program Development
2019 – 2020	Chair, search committee for chair in epidemiology
2019 – present	T32 in Epidemiology of Substance Use, Internal Advisory Committee
2018 – 2021	CTSI KL2 Advisory Committee
2016 – 2019	UF College of Pharmacy, Graduate education task force
2016 – 2019	UF Clinical, population and data science education committee
2015 – present	College of Pharmacy, Research Committee
2015 – 2016	UF Health Power of Together (PoT) Data and Analytics implementation team
2015 – 2020	Governing Board, Medication Therapy Management Communication and Care Center, College of Pharmacy
2015	UF Health Strategic Planning Committee, work group on data analytics
2014 – 2016	College of Pharmacy Faculty Development Committee
2012 – 2018	UF Research Computing Advisory Committee
2012 – 2013	UF Academic Health Center (AHC) Advisory Committee for Research Information technology
2012 – present	Center for Pharmacometrics and Systems Pharmacology Strategic Advisory Group
2011 – 2014	College of Pharmacy Graduate Studies Committee
2009 – 2012	College of Pharmacy Tenure and Promotion Committee
2007 – 2008	Chair, Dean’s Task Force on Problem-based Learning, College of Pharmacy
2005 – 2006	PhD Epidemiology Planning Committee, College of Public Health & Health Professions
2004 – 2008	Epidemiologist, Clinical Practice Committee, UF&Health Shands
2003 – 2010	College of Pharmacy Curriculum Committee
2002 – 2004	Institute of Aging Working Group
2001 – 2012	UF Health Shands Medication Safety Committee

Other memberships & appointments

2023 - present	Organizing committee, National Academies of Sciences, Engineering, and Medicine’s (the National Academies) Workshop on Adult Attention-Deficit/Hyperactivity Disorder: Drug Development, Diagnosis, and Treatment
2022 - present	Academy of Science, Engineering and Medicine in Florida
2021 - 2023	Expert Advisor to Board, International Network for Epidemiology in Policy (INEP)
2019 - 2020	Scientific Programming Committee, Pharmaceutical Sciences World Congress (PSWC) 2020
2017 – 2019	Vice chair, Florida Medical Marijuana Research and Education Board
2012 – 2016	Federal Interagency Workgroup for Adverse Drug Events
2008 – 2014	UF Academic Health Center interdisciplinary learning community on patient safety curricula
2007 – 2008	Safety Technical Advisory Panel for the National Voluntary Consensus Standards for Therapeutic Drug Management Quality project, National Quality Forum (NQF)
2007 – 2009	Biomedical Informatics Core Committee, UF CTSA
2005 – 2007	Special advisor, Florida Governor’s Health Information Technology Advisory Board

2004 – 2008	Board Member, North Florida Foundation for Research and Education, North Florida/South Georgia Veterans Health System
1999 – 2006	Scientific Board, German National Pharmaceutical Care Foundation
2002 – 2005	Member, Drug Information Association
2001 – 2018	American Pharmacists Association (APhA)
2000 – 2020	ISPOR International Society of Pharmacoeconomics and Outcomes Research
1996 – 2003	Pharmaceutical Care Network Europe (PCNE)
1998 – 2001	Secretary, Special Interest Group Pharmacoepidemiology and Pharmacoeconomics, International Federation of Pharmacists
1997 – 1999	European Society of Clinical Pharmacy
1997 – 1999	Vice-president and Founding Member, German National Pharmaceutical Care Foundation
1997 – 2001	International Federation of Pharmacists (FIP)
1996 – 2001	German Pharmaceutical Society
1996 – 1998	Delegate for the Pharmacy Association of Westfalen-Lippe

Experience with Health-related Datasets

Florida Medicaid; MAX; HCUP; Ingenix; NCHS surveys; US hospital administrative and clinical databases (UF Health); IMS; SDI; MarketScan; OneFlorida/PCORnet; Medicare Part A,B,D

Professional Awards and Honors

Academy of Science, Engineering and Medicine in Florida	2022
UF Distinguished Professorship	2020
FDA Outstanding service award - for dedicated service to public health and exceptional leadership in the field of drug safety	2019
ASHP Foundation Literature Award for Pharmacy Practice Research	2018
UF Term Professorship	2018 – 2021
Outstanding Clinical Science Research Award, UF College of Pharmacy for best paper in pharmaceutical clinical sciences	2018
UF College of Pharmacy Teaching & Service Award	2017, 2018, 2019, 2020, 2021
UF College of Pharmacy Mentoring Award	2017
UF Doctoral Dissertation Advisor/Mentoring Award	2017
Dr. Robert & Barbara Crisafi Chair in Medication Safety	2016 – present
Fellow of the International Society of Pharmacoepidemiology	2013
APhA Wiederholt Prize for best paper (together with C. Kimberlin)	2013
	2012

Nominee by the Joint Commission of Pharmacy Practitioners for the PCORI
Methodology Committee for US GAO

University of Florida, Research Foundation Professorship Award	2010-2012 & 2017-2019
Best Practice Award in Teaching, College of Pharmacy, University of Florida	2005
Magna cum Laude, Doctoral dissertation. Humboldt University, Berlin, Germany	1999
Highest honors, Top 3 graduates, St. Angela Gymnasium, Germany	1986

REPORT ON TEACHING AND MENTORSHIP

UF COP Mentorship committees for faculty

Serena Guo, Pharmaceutical Outcomes and Policy, University of Florida
Mahmud Hasan, Pharmaceutical Outcomes and Policy, University of Florida
Tianze Jiao, Pharmaceutical Outcomes and Policy, University of Florida
Serene Guo, Pharmaceutical Outcomes and Policy, University of Florida
Valvanera Vozmediano, Pharmaceutics, University of Florida
Anna Hall, Pharmacotherapy and Translation Sciences, University of Florida
Josh Brown, Pharmaceutical Outcomes and Policy, University of Florida
Joseph Delaney, Pharmaceutical Outcomes and Policy, University of Florida
Mirjam Trame, Pharmaceutics, University of Florida
Haesuk Park, Pharmaceutical Outcomes and Policy, University of Florida

Other formal mentorship commitments

Scott Vouri, Primary mentor, NIA K08 Award, 2021-2025
Scott Vouri, Primary mentor, UF IoA Pepper Junior Scholarship Award, 2019-2020
Steve Smith, Mentoring committee member, NHLBI K01 Award, 2018-2023
Haesuk Park, Mentoring committee member, NIDA K01 Award, 2018-2023
Jenny Wei, Primary mentor, NIA K01 Award, 2017-2022
Josh Brown, Mentoring committee member, UF IoA Pepper Junior Scholarship Award, 2017-2019
Jenny Wei, Primary mentor, UF IoA Pepper Junior Scholarship Award, 2017-2019
Paul Bakaki, External mentoring committee member, KL2 CTSA, Case Western Reserve University, Cleveland, OH, 2016-2018
Katie Vogel-Anderson, Primary mentor, Mentored Research Investigator Training (MeRIT) Program, AACP Research Institute, 2016

Visiting scholars, Postdoctoral fellows, Mentored Scientists

2022 Junko Nagai, vising scholar, Meiji Pharmaceutical University, Japan (1 year)
2022 Jerry Idigo, Post-doctoral Fellow (1 year)

- First position, ORISE Fellow, CDC
- 2019 Sabina Nduaguba, Post-doctoral Fellow (2 years)
First position: Assistant Professor, West Virginia University College of Pharmacy
- 2019 Yan Li, Post-doctoral Fellow (6 months)
First position: ORISE fellow, Division of Pulmonary, Allergy and Rheumatology Products (DPARP), Food and Drug Administration (FDA)
- 2018 Kiyon Rhew, visiting scholar from Dongduk Women's University, Seoul, South Korea (1 year)
- 2017 Amie Goodin, PhD, Assistant Scientist (1.5 years)
First position: Assistant Professor, UF College of Pharmacy
- 2017 Nakyoung Jeon, Assistant Scientist (1 year)
First position: Assistant Professor, Department of Pharmacotherapy, University of Utah
- 2016 Xinyue, Liu, post-doctoral fellow (1.5 years)
First position: Associate Principal Scientist, Epidemiology, Merck
- 2015 Rene Soria-Saucedo, post-doctoral fellow (1 year)
First position: Assistant Professor, Pharmaceutical Outcomes and Policy, University of Florida
- 2015 Cathy Geason, NIHR Clinical Research Fellow, Luton and Dunstable University Hospital (2 weeks)
- 2015 Daniel Zambrano, PharmD, University of Florida, post-doctoral fellow (1 year)
First position: Director, Medical Affairs, Merck
- 2015 Amrit Cheddi, BScPharm, MS, University of Munich, visiting scholar (1 year)
- 2014 Dongxiao Wang, BScPharm, MS, Chinese PLA Hospital, Beijing, China, visiting scholar (1 year)
- 2014 Wei Liu, MD, PhD, University of Florida, postdoctoral fellow (1 year)
First position: Scientist, Center for Drug Evaluation and Research, FDA
- 2013 Omar Ibrahim, PhD, University of West-Virginia, postdoctoral fellow (3 months)
- 2009 Christian Hampp, PhD, University of Florida, postdoctoral fellow (1 year)
First position: Epidemiologist, FDA
- 2005 Linda Aagard-Thomson, University of Copenhagen, Denmark, visiting doctoral (PhD) student (6 months)

Doctoral Students (PhD) - Doctoral thesis committee chair

1. Matthew Muschett (2025)
2. Piaopiao Li (co-chair, 2024)
3. Priyanka Kulkarni (2026)

4. Hung-Kai Chen (2026)
5. Yanning Wang (2025)
6. Celeste Ewig (2025)
7. Yehua Wang (2024)
8. Nicole Smolinski, PharmD (2023)
9. Sebastian Jugl, BSP Pharm (2023)
10. Phuong Tran, BSP Pharm, MS (2023) *Advancing Evidence on Antibiotic Use, their Safety, and Methodology to Deal with Unmeasured Confounding*
First position: Associate Director in Real-world Data Analytics at Boehringer-Ingelheim
11. Thuy Thai, BSP Pharm, MS (2022) *Utilization and safety of prescription antiemetic drugs during pregnancy*
First position: Assistant scientist, Pharmaceutical Outcomes and Policy, University of Florida
12. Amir Sarayani, PharmD, MPH (2022) *Pharmacotherapy for obesity: Evaluation of drug safety and risk mitigation strategies*
First position: Manager, Global Epidemiology, Johnson & Johnson (Janssen R&D)
13. Xi Wang, MD, MPH (2020) *Utilization and Safety of Biologics for Pregnant Women with Inflammatory Bowel Diseases*
First position: ORISE fellow at the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Surveillance and Epidemiology (OSE)
14. Yasser Albogami, BSP Pharm, MS (2020) *Safety and effectiveness of pharmacological treatments in patients with chronic lower respiratory disease and type ii diabetes*
First position: Assistant Professor, King Saud University, Saudi Arabia.
15. Juan Hincapie-Castillo, PharmD, MS (2019) *Evaluating unintended consequences of strategies aimed to control the opioid crisis on acute pain management patient outcomes.*
First position: Assistant Professor, Pharmaceutical Outcomes & Policy, University of Florida
16. Yan Li, BSP Pharm, MS (2019) *Epidemiology and Safety of Skeletal Muscle Relaxants and Concomitant Opioid or Psychotropic Medication Use*
First position: ORISE fellow in the Division of Pulmonary, Allergy and Rheumatology Products (DPAAP) at the Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration (FDA)
17. Monica Munoz, PharmD, MS (2018) *Direct Reporting to the US Food and Drug Administration's Adverse Event Reporting System: An Evaluation of Reporting Patterns, Impact of Consumer Reporting Form Changes, and Pharmacovigilance Utility*
First position: Deputy Director, Division of Pharmacovigilance I, FDA
18. Yanmin Zhu, BS (2018) *Metabolic Effects of Atypical Antipsychotic Use During Pregnancy*
First position: Post-doctoral Fellow, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School

19. YoonYoung Choi, BSPHarm, MS (2018) *Calibration of chronic lung disease severity as a risk factor for respiratory syncytial virus hospitalizations merging multiple data sources*
First position: Associate Director, Outcomes Research, Merck
20. Adel Alrwisan, BSPHarm, MS (2017) *Azithromycin: an evaluation of use and safety*
First position: Special advisor to Minister of Health, Saudi-FDA
21. Nakyung Jeon, BSPHarm, MPH (2016) *Non-steroidal anti-inflammatory drugs associated acute kidney injury in hospitals*
First position: Assistant Scientist, University of Florida College of Pharmacy
22. Xinyue Liu, BSPHarm (2015) *The impact of psychotropic drugs and drug-drug combinations on seizure control in children with epilepsy*
First position: Postdoctoral fellow, Pharmaceutical Outcomes & Policy, University of Florida
23. Wei Liu, MD, MS *Phosphodiesterase Type 5 Inhibitors and Risk of Sudden Sensorineural Hearing loss: a post-marketing safety study* (2014)
First position: Epidemiologist, FDA/CDER/OSE/DEPI
24. Caitlin Knox, MPH (2014) *The comparative safety of anti-diabetic treatment in pregnant women with pre-existing diabetes*
 - AFPE pre-doctoral fellowship 2011-2013
 - AHRQ R36 HS022384 award 2013-2014
First position: Epidemiologist, Healthcore Inc.
25. Efe Odia, BSPHarm, MS (2013) *Nontuberculous Mycobacteria in Cystic Fibrosis*
 - Cystic Fibrosis Foundation Student Traineeship 2012-2013
 - Epilepsy Foundation Small Research Grants Program 2011
First position: Epidemiologist, Office for Surveillance and Epidemiology, Office of Pharmacovigilance and Epidemiology, FDA
26. Stephan Linden, BS (2013) *Risk of Suicide and Suicide Attempt Associated with Atomoxetine Compared to Central Nervous System Stimulant Treatment*
First position: Global Epidemiologist, Boehringer Ingelheim GmbH, Germany
27. Chih-Ying (Natasha) Chen, BSPHarm, MS (2010) *Use of Attention Deficit/Hyperactivity Disorder Pharmacological Treatment Following the Public Discussion on Cardiovascular Safety and the introduction of Medication Guides for Central Nervous System Stimulants and Atomoxetine*
First position: Post-doctoral Fellow at Brigham and Women's Hospital, Division of Pharmacoepidemiology, Boston MA
28. Christian Hampp, BSPHarm (2009) *Utility of Current Surveillance Systems to Detect Respiratory Syncytial Virus Seasons and Implications for Immunoprophylaxis*
First position: Epidemiologist, Office for Surveillance and Epidemiology, FDA
29. Ahunna Onyenwenyi, BSPHarm (2008) *A Pooled Analysis to Examine Trends in Off-label Prescription of Anticonvulsant Drugs*

First position: Pharmacoepidemiology Research Manager, The Degge Group, Arlington, VA

30. Tobias Gerhard, BSPHarm (2007) *Time-dependent confounding in antihypertensive drug studies*

First position: Assistant Professor, Ernest Mario School of Pharmacy, Rutgers University & Associate Director Center for Mental Health Therapeutics, Rutgers University

31. Penkarn Kanjanarat, BSPHarm, MS (2005) *Evaluation of the impact of the 30-Baht healthcare policy on drug utilization in Thailand*

First position: Lecturer Chiang Mai University, Chiang Mai, Thailand

Doctoral Students (PhD) – Doctoral thesis committee member

1. Ruba Sajdeya, MD, (2022)

2. Chuji Luo (department of statistics) (2021)

First position: Data scientist, Google

3. Phuong Pham, BSPHarm, MS (2021) *Comparative Safety of Selective Serotonin Reuptake Inhibitors among Patients with Depression*

First position: FDA/CDER/OSE ORISE fellow

4. Gabriela Ghita, MS (department of biostatistics) (2021) *Improved missing data methods: propensity score calibration and weighted GEE estimators*

5. Cheng (Alice) Chen, BSPHarm (2020) *Utilization, Safety, and Effectiveness of Prescription Gabapentinoids And Opioids Among Older Adults*

First position: post-doctoral fellow in Epidemiology & Biostatistics, University of Pennsylvania

6. Motomori Lewis, BS (2023)

7. Zhongkai Wang, MS (department of biostatistics) (2020) *Model-Based Standardization to Adjust for Confounding with Clustered Data*

First position: research scientist, Eli Lilly

8. Ghadeer Dawwas, PharmD, MPH (2018) *Safety and Effectiveness of Anti-Platelet Therapy in Acute Coronary Syndrome Patients*

First position: Post-doctoral Fellow, University of Pennsylvania

9. Vicky Osborne, MS (department of epidemiology) *Sex Differences in Risk Factors for Prescription Opioid Non-Medical Use among Youth* (2018)

First position: Principal Research Fellow, Drug Safety Research Unit, Southampton, UK

10. Shivani Rajeshwori Khan (department of epidemiology) *Predictors of daily marijuana use among a national sample of US youth* (2017)

11. Chintan Dave, PharmD, MS (2017) *Health outcomes related to statin medications*

First position: Post-doctoral fellow, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School

12. Sonam Lasopa, MPhil (department of epidemiology) *Risk factors for nonmedical use of prescription stimulants among youth 10 to 18 years.* (2016)
13. Xingdi Hu (department of epidemiology) *Alcohol treatment use in HIV-infected individuals with hazardous drinking: utilization, drinking outcomes, and survival* (2015)
First position: manager, Health economics and Outcomes Research, Baxalta Inc.
14. Ayad Ali, BSPHarm, MS (2012) *Asthma-Related Morbidity and Mortality in Patients Exposed to Inhaled Long-Acting Beta-2-Adrenoceptor Agonist Bronchodilators*
First position: Pharmacoepidemiologist, Global Patient Safety, Pharmacoepidemiology Diabetes Business Unit, Eli Lilly and Company
15. Jinghua He, BS, MS (2011) *Baseline health related quality of life as confounder in observational research for elderly men with localized prostate cancer*
First position: Epidemiologist, Merck & Co. Inc, Upper Gwynedd, PA
16. Tamara Telfair Lesperance, MPH (dropped out in 2011)
17. Chenguang Wang, MS (department of statistics) *Bayesian Nonparametric and Semi-Parametric methods for Incomplete Longitudinal Data* (2010)
18. Chien-Ning Hsu, BSPHarm, MS *Clinical Effectiveness and Cost of Antiviral Therapy in Patients with Hepatitis C Infection in a Managed Care Setting* (2010)
First position: Assistant Professor, Clinical Pharmacist, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
19. Patrick Garman, PharmD (2007) *Risk of tendon rupture after quinolone use in a U.S. military population*
First position: Deputy Director for Scientific Affairs, Military Vaccine Agency, Falls Church, VA
20. Namrata Shetty (dropped out in 2005)
21. Steven Graham, BS (2005) *The effect of academic detailing on COX-2 Utilization rates*
22. Michael Taylor, PharmD (2005) *Prostate cancer clinical practice guidelines: clinical and economic outcomes*
First position: Contract Epidemiologist Genentech, San Francisco, CA

Master Students (MSc)

1. Wen Wen (2025)
2. Rupal Aroza, BSPHarm, (2023) *Secular trends and determinants of use of gabapentin during pregnancy among publicly insured pregnant persons in the united states 2000 to 2015*
3. Juan Hincapie-Castillo, PharmD (2018) *Prevalence of Psychotherapy Surrounding Initiation of Psychotropic Polypharmacy in the Medicaid-Insured Population* (2018)
4. Yoon Young Choi, BS, MS (2017) *A Dynamic Risk Model for Inpatient Falls: Are They Predictable* (2017)
5. Yanmin Zhu (2017 non-thesis)
6. Justin Doan, MPH (2015 non-thesis)

7. Nakyoung Jeon, BS, MS (primary advisor 2013, switched to PhD program after 1 year)
8. Jessica Voqui, PharmD (2012 non-thesis)
9. Lyle Canida, PharmD (2012 non-thesis)
10. Matt Kirchhoff, PharmD (2011 non-thesis)
11. Danielle Smith, Pharm D (2011 non-thesis)
12. James Trinidad, MPH (2011 non-thesis)

Pharmacy Resident Training (UF Health Shands), research advisor

2009-10, Robyn Keen, PharmD. *Evaluation of once-daily aminoglycoside pharmacokinetics in pediatric cystic fibrosis patients*

2009-10, David Gervil, PharmD. *Effectiveness of conversion from pTT to Xa monitoring*

2005-07, Sarah Bush, PharmD. *Effect of concomitant utilization of amiodarone and haloperidol on QT prolongation*

2005-06, Laura Smith, PharmD. *Feasibility and Potential Impact of Pharmacist Intervention during Medication Reconciliation on Medication Errors in Hospitalized Patients with HIV/AIDS*

2004-05, Sherleen Drawdy, PharmD. *Effect of hydrocortisone vs. hydrocortisone plus fludrocortisones on mortality in critically ill patients*

2004-05, Ann Snyder, PharmD. *Identifying system causes of adverse drug events in hospitalized patients with HIV*

2003-04, Julie M. Whitehurst, PharmD. *Accuracy of Automated Alerts in Detecting Inappropriate Use of Non-Steroidal Anti-inflammatory Drugs*

2003-04, Jennifer Norberg, PharmD. *Evaluation of a Standardized Insulin Therapy Protocol for Critically Ill Patients*

2003-04, Ben Staley, PharmD. *Risk factors for clostridium difficile-associated diarrhea in hospitalized patients with community acquired pneumonia and COPD exacerbation*

2002-03, Todd Correll, PharmD. *The incidence and clinical consequence of administration of penicillin and cephalosporin antibiotics in patients who have a documented beta-lactam allergy*

2002-03, Gina K. Soliman, Pharm.D.: *Enhancing diabetic patients' involvement in the prevention and recognition of medication errors in an acute care setting through the use of a patient training program*

2002-03, Wendy D. Smith, Pharm.D.: *Identifying Root Causes of Hyper- and Hypoglycemic Episodes for the Development and Implementation of Intervention(s) to Decrease Their Incidence*

- received \$1,900 funding by the American Society of Health Systems Pharmacists Research and Education Foundation Residency Grant Program

2002, Kalen Porter, Pharm.D.: *Comparison of the Cost-Effectiveness of Valganciclovir vs. Ganciclovir for Cytomegalovirus Treatment in Solid Organ Transplant Patients*

Courses (professional PharmD and Pharmacy Administration PhD curriculum)

2019 – present	RPHA 5930 Seminar in Pharmacy Research (1 lecture
2008 – 2023	PHA 6717 Measurement in Pharmaceutical Outcomes Research (3 credits, annually) Co-instructor with Dr. Carole Kimberlin from 2008 to 2014; course coordinator since 2015; mandatory course in POP residential MS and PhD program taught annually
2015 - present	PHA 5226 Patient Safety & Quality; guest lecturer (2-3 lectures), 2 credit hour mandatory courses in PharmD curriculum
2015 - present	PHA 5223 Pharmacoepidemiology and Drug Safety; guest lecturer (2-3 lectures); 2 credit hour mandatory course in PharmD curriculum
2014 - present	PHC 7000 Epidemiology Seminar II: Critical evaluation, research proposals, methods; guest lecture (2h)
2002 – present	PHA 6265 Introduction to POP Co-instructor (2-6/16 weeks), 3 credit hour mandatory course in POP MS and PhD curriculum
2006 – 2011	PHA 5226 Evidence-based Pharmacy (4 credits, annually) Course coordinator from 2006 (developed as new course) to 2011, mandatory course in 3 rd year Professional PharmD Curriculum
2009 – 2011	PHA 6796 Study Design in POP research (3 credits, annually) Course coordinator from 2009-2011, core course in MS and PhD graduate curriculum
2003 – 2005	PHA 5211 Pharmaceutical Outcomes (3 credits, annually) Course coordinator from 2003-2005, mandatory 3-credit hour course in 3 rd year Professional PharmD Curriculum; was terminated in 2005 and replaced by PHA 5226
2001 - 2003	PHA 5213 Pharmaceutical Outcomes Evaluation (2 credits, annually) Co-Instructor with Dr. Earlene Lipowski from 2001 to 2003, 2-credit hour mandatory course in the 4 th year professional Pharm.D. Curriculum

Advisory responsibilities for research internships, independent study electives

Research internships (3 months or more)

2023 Darla Khouri, PharmD Candidate

2020 & 2021 Julie Al-Bahou, PharmD Candidate

2018, Victoria Reams, PharmD Candidate

2017, Trinh Nguyen, PharmD Candidate

2016, Rita Sorokina, PharmD Candidate

2015, Tracy Vu, PharmD Candidate

- funded by COP Summer Research Internship Program
- 2014, Aklil Hiruy, PharmD Candidate
- 2014, Lindsey Osterfeld, PharmD Candidate
- funded by COP Summer Research Internship Program
- 2014, Maria Barnicoat, PharmD Candidate
- funded by COP Summer Research Internship Program
- 2013, Aaron Josphe, PharmD candidate, *Epidemiology of ADHD and treatment in children with cystic fibrosis*
- funded by COP Summer Research Internship Program
- 2013, Crystal Rose, PharmD candidate, *Frequency of Nature of preventable adverse drug events in children*
- funded by COP Summer Research Internship Program
- 2012, Amy Kiskaddon, PharmD candidate, *Geographic variation of psychiatric disorders concurrently diagnosed with ADHD in Medicaid*
- funded by COP Summer Research Internship Program
- 2012, Vaishali Shah, PharmD candidate, *Treatment Patterns in Medicaid Youths with Co-morbid ADHD and ODD/CD*
- funded by COP Summer Research Internship Program
 - winner, UF/COP Research Showcase professional student poster competition
- 2011, Juan Hincapie, PharmD candidate, *Utilization and ototoxicity of external neomycine preparations in children with tympanic membrane perforation*
- funded by COP Summer Research Internship Program
- 2010, Danny Gonzalez, PharmD candidate, *Impact of EMR on medication safety in otolaryngology*
- funded by COP Summer Research Internship Program
- 2009, Allison Jamison, PharmD candidate, *Redundancy and information overload in consumer medication information leaflets*
- funded by COP Summer Research Internship Program
- 2009, Nerissa Alday, PharmD candidate, *Benchmarking Synagis reimbursement policies across Medicaid programs*
- funded by COP Summer Research Internship Program
- 2008, Abigail Lee, PharmD candidate. *Consumer medication information*
- funded by COP Summer Research Internship Program
- 2008, Rebecca Rosenwasser, PharmD candidate. *Medication errors in otolaryngology*
- funded by COP Summer Research Internship Program
- 2007, Harmony Schneider, BS, PharmD candidate. *Impact of ACE inhibitors and ARBs on perioperative vasoplegia and postsurgical morbidity and mortality*
- funded by COP Summer Research Internship Program
- 2006, Ashley Tyler, PharmD candidate (internship was NIH funded), *Acute kidney injury in critical care*
- 2005, Cristin Hogan, PharmD candidate. *Quality of anticoagulation for patients DVT/PE*

2003, Nathalie Merle, PharmD candidate. *Evaluation of the safety, effectiveness, and compliance of an insulin infusion protocol*

Research rotations or independent study courses for PharmD candidates

2016, PHA5901, 1 semester, Shannon Lyons

2016, research rotation in pharmacoepidemiology, Marie Barnicoat, PharmD candidate. *Development of a research proposal for REMS evaluations*

2014, PHA 5901, 1 semester, Marie Barnicoat, *Development of a prediction model for drug-induced liver injury*

2014, research rotation in pharmacoepidemiology, Amy Kiskaddon, PharmD candidate. *Development of an inpatient risk model for drug-induced respiratory depression*

2013, PHA 5901, 1 semester, Qian Ya Zeng, *Epidemiology of ADHD in children and adolescents with cystic fibrosis*

2012, PHA 5901, 1 semester, Rebecca Freese, *Prevalence of psychotropic medication use in children and adolescents with autism*

2007, research rotation in pharmacoepidemiology, Stephanie Ballard, PharmD candidate. *Systematic review of the efficacy of aspirin for DVT prophylaxis in orthopedic surgery.*

2006, advisor for independent research project (PHA 5901, 1 semester), Cristin Hogan, Vinay Patel, Mickala Thomson, 3rd and 4th year PharmD program. *Root causes of DVT/PE in acute care*

Internships for international pharmacy students

2023, Jaqueline Kiwitt, Ludwig Maximilian University, Munich, Germany, international exchange pharmacy internship (6 months)

2023, Laura Springer, Johann Wolfgang Goethe University, Frankfurt, Germany, international exchange pharmacy internship (6 months)

2023, Lena Froehlich, University of Marburg, Marburg, Germany, international exchange pharmacy internship (6 months)

2022, Thorben Kurzbach, Technical University of Berlin, Berlin, international exchange pharmacy internship (6 months)

2022, Carolin Arnold, Julius Maximilians University, Wuerzburg, Germany, international exchange pharmacy internship (4 months)

2021, Tansu Aydogan, Freie Universität, Berlin, Germany, international exchange pharmacy internship (6 months)

2020, Joan Gretenkord, Freie Universität Berlin, Berlin, Germany, international exchange pharmacy internship (6 months)

2018, Marie Possinger, Ludwig Maximilian University, Munich, Germany, international exchange pharmacy internship (6 months)

2018, Sebastian Jugl, Goethe University Frankfurt, Germany, international exchange pharmacy internship (6 months)

2016, Lena Bergmann, Freie Universität Berlin, Germany, international exchange pharmacy internship (6 months)

2015, Aakash Gandhi, Institute for Chemical Technology, Mumbai, international exchange pharmacy internship (5 months)

2015, Lea Charpentier, University of Limoges, France, international exchange pharmacy internship (5 months)

2015, Maud Bourzeix, University of Limoges, France, international exchange pharmacy internship (5 months)

2014, Janick Weberpals, University of Heidelberg, Germany, international exchange pharmacy internship (6 months)

2014, Emmanuelle Kaltenbach, University of Reims, France, international exchange pharmacy internship (3 months)

2013, Ariadna Auladell-Rispau, BSPPharm, University of Barcelona, Spain, international exchange pharmacy internship (1 year)

2013, Charlene Berthet, University of Limoges, France, international exchange pharmacy internship (3 months)

2012, Maria Trenkamp, Goethe Universität, Frankfurt, Germany, international exchange pharmacy internship (6 months)

2011, Shairah Djouma, University of Toulouse, France, international exchange pharmacy internship (1 month)

2011, Lea Botermann, Technische Universität Berlin, Germany, international exchange pharmacy internship (6 months)

2010, Anne Geier, Westfälische Wilhelms Universität Münster, Germany, international exchange pharmacy internship (6 months)

2010, Sebastian Wolff, Erasmus University, Frankfurt, Germany, international exchange pharmacy internship (6 months)

2008, Javier Esteban Aznarez Araiz, University of Pamplona, Spain, international exchange pharmacy internship (3 months)

2007, Katharina Woertz, Heinrich Heine University, Düsseldorf, Germany, international exchange pharmacy internship (6 months)

2007, Miriam Schauff, Heinrich Heine University, Düsseldorf, Germany, international exchange pharmacy internship (6 months)

2007, Jana Meyer, Heinrich Heine University, Düsseldorf, Germany, international exchange pharmacy internship (6 months)

2005, Stephan Linden, Carolo-Wilhelmina University, Braunschweig, Germany, international exchange pharmacy internship (6 months)

2004, advisor for international exchange internship (6 months) as part of German 4th-year Pharmacy curriculum, Christian Reidenbach, University of Saarbrücken, and Anika Krebs, University of Frankfurt, Germany

2003, advisor, international exchange internship (6 months) as part of Dutch 4th year PharmD curriculum: Anita Janssen, Groningen, The Netherlands

2002, advisor for international exchange internship (3 months) as part of German 4th-year Pharmacy curriculum, Anna Mattenklotz, Friedrich Wilhelm University of Bonn, Germany

2001, advisor for international exchange internship (4 weeks) as part of Australian 4th-year Pharmacy curriculum, Nusrat Mizra and Justin Tan, University of Sydney, Australia
